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MULTI-LEVEL REGULATION OF ENDOTHELIAL ARGININOSUCCINATE
SYNTHASE: SIGNIFICANCE FOR NITRIC OXIDE PRODUCTION

Karen Davidowitz Corbin, MS, RD

ABSTRACT

The citrulline-nitric oxide (NO) cycle, comprised of the enzymes
argininosuccinate synthase (AS), argininosuccinate lyase (AL) and endothelial nitric
oxide synthase (eNOS), is responsible for the regulated production of endothelial NO.
Although most studies have focused on eNOS to uncover important regulatory
mechanisms, we and others have determined that AS is an essential and regulated step in
endothelial NO production. AS is rate limiting for endothelial NO production and is the
primary source of arginine, the substrate for eNOS-mediated NO production, despite
saturating intracellular levels of arginine and available arginine transport systems. AS is
essential for endothelial cell viability and its expression is regulated coordinately with
eNOS by TNFα and thiazolidenediones with concomitant effects on NO production.
Given the importance of AS for endothelial health, we explored three independent
regulatory mechanisms. In Chapter One, the functional consequences of altered AS
expression due to overexpression, insulin, VEGF and ceramide were studied. We
xi

demonstrated that overexpression of AS leads to enhanced NO production and that
insulin, VEGF and ceramide coordinately regulate the expression of AS and eNOS. In
Chapter Two, the first post-translational modifications of AS in the endothelium were
characterized. We determined that AS is an endogenous phosphoprotein in the
endothelium, described several levels of biological significance of AS phosphorylation,
identified 7 sites of AS phosphorylation and began to uncover the direct impact of
phosphorylation on AS function. Finally, in Chapter Three, endothelial AS subcellular
localization was defined and important protein interactions were identified including
caveolin-1 and HSP90. The work presented in this dissertation demonstrates that multiple
mechanisms regulate the function of AS, often coordinately with eNOS, and have a direct
impact on nitric oxide production. Our findings suggest that the global understanding of
the citrulline-NO cycle as a metabolic unit will unravel new paradigms that will re-define
our understanding of the regulation of vascular function by NO.

xii

INTRODUCTION

Nitric Oxide: Historical Perspectives and Biochemistry

Nitric Oxide (abbreviation: NO; chemical formula: N═O·) is a readily diffusing
gas that can be poisonous in the environment yet powerful in biology [1, 2]. Due to its
unpaired electron, NO is a free radical, making it highly reactive. The “Molecule of the
Year” in 1992 [3, 4], the discoveries made about NO and heart function earned Robert F.
Furchgott, Louis J. Ignarro and Ferid Murad the Nobel Prize in 1998 (NobelPrize.org). In
1980, endothelium-dependent vessel relaxation was first described [5] and in 1987, it was
determined that the endothelium derived relaxing factor (EDRF) was in fact NO [6, 7].

NO moves easily in and out of cells so it cannot be stored inside producing cells
like other endogenous messengers. In the presence of oxygen, it has a half life of just a
few seconds, but its longevity in the body is not known [1, 2]. There are several nitrogenderived compounds that exert distinct biological functions including NO+ (nitrosonium),
NO· (nitric oxide) and NO- (nitroxyl anion). Most studies of nitric oxide do not
differentiate or define the specific species that is exerting biological actions [2]. From this
point forward, our discussions will be related to NO in general terms.
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NO functions via multiple mechanisms to exert biological effects. It reacts
directly or indirectly with proteins, lipids, nucleic acids, metals, other gases (such as
oxygen) and carbohydrates [1]. Like many other molecules, the effects of NO can be
either positive or negative depending on the cellular environment and amounts produced.
Both a lack of NO and an excess of NO can lead to pathological consequences such as
hypertension and septic shock, respectively [3]. NO is a signaling agent and has been
implicated in a broad number of functions including neurotransmission, memory, host
defense, vasodilation, blood flow, respiration, nutrient metabolism and apoptosis [3, 810]. Therefore, the chemical simplicity of this molecule has no bearing on its broad and
essential functions.

The Citrulline-Nitric Oxide Cycle

The citrulline-NO cycle, comprised of the enzymes argininosuccinate synthase
(AS), argininosuccinate lyase (AL) and endothelial nitric oxide synthase (eNOS), is
responsible for the regulated production of nitric oxide [11]. AS is a homotetrametic
enzyme with a molecular weight of ~47 kDa per monomer. Each monomer contains 412
amino acids. It is transcribed from a single gene on chromosome 9 and is expressed in
virtually all tissues with the highest expression in liver, kidney and brain [12-17]. AL is
also a homotetramer with a subunit molecular weight of ~50 kDa. The human AL gene is
found on chromosome 7 and has 464 amino acids per monomer. It is expressed widely,
similar to AS [13, 17, 18]. There are 3 isoforms of nitric oxide synthase (NOS): neuronal
NOS (nNOS; NOS1), inducible NOS (iNOS; NOS2) and endothelial NOS (eNOS;
2

NOS3). Each is encoded by a separate gene on chromosomes 12, 17 and 7, respectively,
and they share ~ 50-60% sequence homology [19, 20]. eNOS, the NOS isoform studied
in this work, is a homodimer with a molecular weight of 135 kDa per subunit that is
expressed in endothelium, skeletal and cardiac muscles, kidney tubules and many other
non-endothelial tissues [21, 22]. eNOS, like nNOS, is a constitutive NOS isoform that is
regulated by calcium/calmodulin. This is in contrast to iNOS which is active even at low
calcium concentrations [19]. Besides the substrates necessary to carry out its reaction (see
Table 1), eNOS requires tetrahydrobiopterin (BH4), flavin adenine dinucleotide (FAD),
flavin mononucleotide (FMN) and heme as co-factors. The amounts of NO produced by
constitutive isoforms is ~ 1000 fold less than iNOS [19, 20].

The following are the reactions catalyzed by each of the enzymes in the
endothelial citrulline-NO cycle:

Table 1: Reactions Catalyzed by Citrulline-NO-Cycle Enzymes.
eNOS (EC 1.14.13.39):
L-arginine + NADPH + H + O2 = L-citrulline + NO + NADP+
AS (EC 6.3.4.5): (rate limiting step)
ATP + L-citrulline + L-aspartate = AMP + diphosphate + argininosuccinate
AL (EC 4.3.2.1):
argininosuccinate = furmarate + L-arginine
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The function of the citrulline-NO cycle as a whole is crucial for the production of
NO. The availability of arginine is a key factor limiting NO synthesis, despite the fact
that intracellular concentrations of arginine (0.1-0.8 mM) are greatly in excess of the
reported eNOS Km (~5 µM) [11]. This phenomenon is termed “the arginine paradox”.
Although there are transport systems available that have been hypothesized to supply the
arginine utilized for NO production [23], we and others have shown that endothelial NO
production is limited by the capacity to regenerate arginine from citrulline [24-27]. In
fact, cells that express constitutive NOS isoforms, such as endothelial cells and neurons
have the capacity to regenerate arginine from citrulline [25, 28].

Dysfunction of AS and AL, which are also part of the urea cycle in ureagenic
tissues, can lead to metabolic defects termed collectively as urea cycle disorders, since
deficiency in any one of the six enzymes in the urea cycle causes disease [29]. Type I
citrullinemia is an autosomal recessive disorder caused by AS deficiency (OMIM
#215700) [30]. Some of the symptoms of this disease include severe vomiting, excess
levels of citrulline in serum, spinal fluid and urine, hyperammonemia and mental
retardation. If not treated promptly, it can lead to death. Death in the neonatal period
occurs in nearly half of cases [29]. Many mutations have been identified in the AS gene
that can lead to type I citrullinemia [31, 32].

Unlike classical citrullinemia in children that results from a mutation in the AS
gene and is associated with an overall deficiency of AS, in type II citrullinemia there is
no mutation in the AS gene (OMIM #603471) [33]. AS protein has normal kinetic
4

properties and is quantitatively deficient only in the liver. The gene that is actually
defective is SLC25A13. It encodes a mitochondrial Ca2+-dependent aspartate/glutamate
transporter called citrin [33, 34]. The loss of organization attributable to the mutated
citrin leads to reduction of AS protein, possibly through destabilization and/or
degradation. Symptoms of type II citrullinemia include enuresis, delayed menarche,
insomnia, nocturnal sweats, recurrent vomiting, diarrhea, tremors, episodes of confusion
after meals, lethargy, convulsions, delusions, hallucinations, and brief episodes of coma.
Some patients die within a few years of onset [29]. For both type I and type II
citrullinemia, a low protein diet, medications to reduce ammonia levels (examples:
sodium benzoate, sodium phenylacetate) or dialysis can be used as treatments to reduce
ammonia levels [35].

Argininosuccinic aciduria is an autosomal recessive disorder caused by multiple
possible mutations in the AL gene (OMIM 207900) [36]. Like citrullinemia,
argininosuccinic aciduria can be early onset (more severe) or late onset. Some symptoms
of early onset AL deficiency include lethargy, skin lesions, mental retardation, liver
enlargement and convulsions. Late onset disease is usually mild and symptoms tend to
occur during illness or periods of stress. Treatment for argininosuccinic aciduria is the
same as for citrullinemia [35].
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Endothelial Nitric Oxide and Vascular Health

NO regulates most normal functions of the endothelium. One primary function of
NO is vasodilation. This process occurs when NO produced in the endothelium migrates
to the adjacent smooth muscle layer, binds to the heme moiety of soluble guanylyl
cyclase (sGC) and activates it. This leads to an increase in cyclic guanosine
monophosphate (cGMP), which then activates protein kinase G (PKG) and leads to
vasodilation. Regulation of vessel dilation contributes to blood flow and blood pressure
control [37, 38].

In addition, NO regulates platelet aggregation. The health of arteries is highly
dependent on tight control over this process. During injury, platelets migrate to the site of
injury and form a plug to seal the blood vessel and minimize blood loss. On the other
hand, uncontrolled platelet aggregation diminishes the fluidity of blood, prevents the
delivery of oxygen and nutrients to tissues and can lead to thrombosis- a leading event in
myocardial infarction. During physiological conditions, the balance is tipped towards
reducing platelet aggregation. Both endothelial and platelet derived NO lead to the
activation of PKG, the inhibition of cAMP phosphodiesterase and the reduction of
cytosolic calcium. This leads to decreased platelet aggregation and adhesion and a
disaggregation of existing platelet aggregates [39, 40].

Another key vascular function regulated by NO is angiogenesis, which is defined
as the formation of new blood vessels. If unchecked, this process can be pathogenic.
6

Physiological angiogenesis is important for improving ischemic conditions and for
wound healing [41, 42]. Vasodilation is required for angiogenesis as evidenced by the
fact that many angiogenic factors, such as VEGF, possess vasodilating properties [43,
44]. NO has been demonstrated to have a direct role in angiogenesis since NO donors
promote and NO inhibitors diminish angiogenesis [45-48]. NO promotes angiogenesis
via cGMP elevation and by enhancing the expression of angiogenic factors [41, 42, 48,
49]. Enhancement of NO production in patients undergoing coronary artery bypass
grafting by administration of l-arginine in conjunction with VEGF improved
angiogenesis and surgical outcomes, thus exemplifying the tight association between NO
signaling and angiogenesis [50].

NO can be both pro-and anti apoptotic. High concentrations of NO induce cell
death in macrophages, pancreatic islet cells, tumors and other cell types. There are
several mechanisms by which NO can promote apoptosis. First, NO can activate the
mitochondrial apoptosis pathway by increasing the release of cytochrome c. This leads to
activation of the caspase-dependent apoptosis pathway. NO can also cause DNA damage
which induces p53 and leads to cell cycle arrest. Excess NO activates pro-apoptotic
kinase cascades such as c-Jun N-terminal kinase and mitogen activated protein kinases.
Finally, NO can cause an increase in the release of ceramide, a bioactive sphingolipid that
can itself induce apoptotic pathways via the death receptor pathway [51-54]. Cytokines,
high glucose lipids mediate some of the pro-angiogenic properties of NO [55-60]. NO
deficiency also leads to apoptosis [51-54].
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On the other hand, physiological concentrations of NO protect cells from
apoptosis [51-54]. One mechanism of protection is via the release of cGMP, which
subsequently diminishes cytochrome c release, caspase activation and ceramide
accumulation. In addition, NO can lead to suppression of caspase activity by reversible Snitrosylation and increase the expression of anti-apoptotic genes such as Bcl-2 and
HSP70 [54]. Shear stress is an important mechanism that protects endothelial cells from
TNFα or growth factor withdrawal-induced apoptosis [61]. One mechanism proposed for
this protective effect is via the upregulation of NOS and superoxide dismutase [62].

Considering the plethora of vascular functions regulated by NO, any
dysregulation of its bioavailability and production has far reaching consequences. In fact,
endothelial dysfunction is associated with a number of disorders including diabetes,
obesity, atherosclerosis, metabolic syndrome and hypertension [63-67]. Much of what is
known related to endothelial dysfunction and impaired NO production is related to the
expression, activation, localization, interactions and substrate/cofactor availability of
eNOS [63]. The role of other citrulline-NO cycle components remains relatively
unexplored.

Endothelial Dysfunction

There are a number of mechanisms that have been implicated as contributing
events in endothelial dysfunction, and most are related to impaired function of NO. One
hallmark of endothelial dysfunction is inflammation [68]. NO possesses anti8

inflammatory properties that are disrupted in endothelial dysfunction via mechanisms
involving increased leukocyte adhesion, increased expression of chemokines, increased
monocyte migration and infiltration of monocytes into the arterial wall [65, 69]. Another
inflammatory process disrupted in endothelial dysfunction is related to an increased level
of C-reactive protein (CRP). CRP diminishes the production of NO by reducing eNOS
expression [69]. Multiple other inflammatory molecules are elevated in endothelial
dysfunction such as TNFα. Whether elevated TNFα is a cause or consequence of
endothelial dysfunction is debatable. However, there are multiple mechanisms by which
TNFα causes endothelial dysfunction such as the inhibition of insulin signaling, an
increase in lipids such as ceramide and increased apoptosis [70-77].

In endothelial dysfunction, there is also an increase in reactive oxygen species
(ROS). This is one central mechanism by which cardiovascular disease risk factors such
as diabetes, hypercholesterolemia and hypertension lead to endothelial dysfunction [63].
One such species, superoxide, reacts with NO and leads to the production of
peroxynitrite, a toxic free radical that diminishes the bioavailability of NO and inhibits
the protective actions of NO [78]. ROS also degrade BH4, an important eNOS co-factor.
This leads to the uncoupling of NADPH oxidation from eNOS-mediated NO synthesis
and the subsequent production of superoxide instead of NO [79-81].

Another consequence of increased ROS is the inhibition of dimethylarginine
dimethylaminohydrolase (DDAH). This leads to increased levels of asymmetric
dimethylarginine (ADMA), an endogenous eNOS inhibitor [82]. ADMA inhibits eNOS
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by multiple mechanisms such as further increasing superoxide production and eNOS
uncoupling, diminishing the interaction of HSP90 with eNOS and redistributing eNOS to
the mitochondria with subsequent mitochondrial dysfunction [83-86]. ADMA has been
linked to vascular disease by contributing to reperfusion injury and increasing blood
pressure [84, 87]. Protective effects at early time points have also been shown via iNOS
mediated inhibition of intima-media thickness [88].

Elevated lipids also influence the function of the endothelium. For example,
oxidized LDL reduces eNOS activity by displacing it from the plasma membrane and
targeting to intracellular sites where it is less active [89]. Elevated ceramide levels due to
excess saturated fat in the diet or chronic inflammation diminish eNOS activation and
NO production [60, 90, 91]. Another lipid linked to endothelial dysfunction is
apolipoprotein CIII (apoCIII), a component of very low density and low density
lipoprotein that is elevated in insulin resistance and metabolic syndrome. ApoCIII
activates pro-inflammatory atherogenic pathways by directly inhibiting insulin signaling
and reducing the activation of eNOS [92]. In fact, one of the benefits of statin therapy
beyond cholesterol lowering is the improved function of eNOS and endothelial function.
One example is improved blood flow to ischemic tissues in diabetes in response to statins
due to an upregulation of eNOS [93]. There are controversies about whether statins
improve endothelial function and this is perhaps associated with other factors associated
with endothelial dysfunction. For instance, simvastatin is able to improve endotheliumdependent vasodilation in patients with low levels of ADMA but is ineffective in patients
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with high ADMA. On the other hand, arginine supplementation in combination with
statins works well with patients with high but not low ADMA [94].

Insulin resistance and diabetes are also tightly associated with endothelial
dysfunction [73]. In fact, macrovascular complications are quite common in diabetic
patients leading to the classification of diabetes as a vascular disorder [95]. Endothelial
cells express insulin receptors and many cardioprotective signaling pathways are
mediated by insulin [95]. Several derangements can occur when insulin function is
compromised including an increase in ROS, depletion of BH4, lipid abnormalities and
hypertension [96-100]. Hyperglycemia, a consequence of diminished insulin action, also
has direct impacts on eNOS expression and activity and enhances endothelial cell
apoptosis [58, 101, 102]. Collectively, these imbalances impair the ability of the
endothelium to produce adequate amounts of NO and all normal endothelial functions are
compromised leading to a striking association between insulin resistance, diabetes and
coronary artery disease.

Overall, the mechanisms that lead to endothelial dysfunction are numerous and
complex. Most of them converge and lead to one major issue- a decrease in the
production and bioavailability of NO. Therefore, a better understanding of the
mechanisms that control NO production is essential for the development of effective
prevention and treatment strategies for vascular disorders.
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Prevention of Vascular Disorders

There are multiple medical and surgical approaches to treat cardiovascular
diseases and they should be employed as early as possible to diminish long-term damage.
Considering the far reaching consequences of endothelial dysfunction and the fact that by
the time significant symptoms arise, vascular disease has already progressed
dramatically, prevention strategies are the best insurance against the development of
vascular disease [67]. Since most risk factors for heart disease mediate their deleterious
effects by impairing NO production [63], preventable risk factors need to be addressed
either with lifestyle modification of medical interventions. Healthy eating and
maintaining a normal body weight can go an extremely long way towards keeping blood
pressure within normal limits, preventing diabetes and metabolic syndrome and
maintaining a healthy level of blood lipids [103, 104]. Cigarette smoking directly impairs
NO bioavailability [105], so avoiding smoking or quitting is essential. In addition, blood
pressure and cholesterol, if inadequately responsive to lifestyle measures, should be
treated pharmacologically [106].

Argininosuccinate Synthase Functions Related to Nitric Oxide Production

AS, the focus of this dissertation, has several unique properties that are essential
for NO production and vascular health. AS is rate limiting for the production of NO
[107]. This was initially demonstrated in vascular smooth muscle cells when AS
overexpression enhanced the capacity of transfected cells to produce NO, despite non12

limiting levels of arginine [108]. In endothelial cells, we have demonstrated that
inhibition of AS activity with siRNA or the AS inhibitor α-methyl-DL-aspartic acid
diminishes NO production due to reduced AS activity [24, 109].

We also demonstrated that the co-fractionation of AS, AL and eNOS in
plasmalemmal caveolae allowed endothelial cells to effectively distinguish “bulk
intracellular arginine” from the arginine used for NO production [110]. Our substrate
utilization studies supported this view by demonstrating that the recycling of citrulline
back to arginine is an efficient, tightly coupled process [24]. The activity of AS in this
recycling process is the preferred mechanism for eNOS-mediated NO production, while
iNOS-mediated NO production in smooth muscle is dependent on arginine transport [26].

One additional and unique mechanism of regulation of NO production by AS
involves expression of endothelium-specific AS variants with different lengths of the 5’
untranslated region (5’ UTR). The shortest form of the message represents ~90% of the
total AS mRNA and encodes for full length AS. The two longer forms contain an out of
frame upstream open reading frame (uORF) that encodes a 4 kDa protein called
Argininosuccinate Synthase Regulatory Protein (ARP). Overexpression of ARP leads to
diminished NO production and siRNA knockdown of ARP leads to an increase in NO
production in endothelial cells [111].

The three dimensional structure of human AS has revealed an interesting feature
relevant to its role in NO production. It has been demonstrated that nitrosylation of AS at
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cysteine 132 (C132) leads to inactivation of the enzyme [112]. A mechanism was not
identified for this activation. The investigators who solved the human AS crystal
structure used in silico modeling to predict the effect of nitrosylation at this site on the
catalytic efficiency of AS. The authors noted that C132 is actually buried in the Nterminal domain. They suggested that a significant structural change would have to take
place for the nitrosylation to occur. Based on their in silico models, they determined that
even though C132 is not near the active site, the modification does perturb the orientation
of amino acids that are part of the active site [113]. This presents the first evidence of a
possible conformational change caused by a modification at an allosteric site which then
changes the activity of AS with subsequent effects on NO synthesis.

Regulation of Endothelial Nitric Oxide Production: Protein Expression

The functions of NO are controlled at the levels of biosynthesis and availability
because it cannot be stored. Since virtually all phenotypic properties of normally
functioning endothelial cells are related to NO, its production is tightly controlled [28,
114, 115]. This tight control requires multiple regulatory mechanisms. One such
mechanism is the regulation of the expression of the enzymes of the citrulline-NO cycle.

To assess the importance of the expression citrulline-NO cycle components on
vascular function, animal knockout models have been generated and have yielded
important information. The eNOS knockout mouse models have by far been the most
prominent in delineating the importance of the citrulline-NO cycle for vascular health.
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Deletion of the eNOS gene is not embryonic lethal, but does lead to hypertension,
impaired wound healing and angiogenesis [116]. In addition, eNOS knockout mice have
hyperinsulinemia, hyperlipidemia, diminished glucose metabolism [117] and a decrease
in skeletal muscle oxidative capacity [118]. In contrast, eNOS overexpression ameliorates
vascular dysfunction by improvements in lipids, blood pressure, myocardial contraction
and protection against ischemia-reperfusion injury [119, 120]

The lessons we have learned from eNOS knockout mice are complicated by the
fact that in some instances, a lack of eNOS has some beneficial effects and
overexpression of eNOS has deleterious effects. For example, eNOS knockout mice have
decreased formation of diet-induced fatty streaks [121] and endothelium dependent
relaxation and bradykinin-mediated blood flow are intact due to a compensatory
upregulation of nNOS [122]. Although physiological levels of NO are beneficial for
myocardial contractility, overexpression leads to a negative inotropic effect [123]. Due to
the difficulty in interpreting mouse data related to compensatory functions of the NOS
isoforms, a triple knockout mouse where eNOS, nNOS and iNOS were deleted was
recently generated. These mice had a much lower survival rate and displayed a long list
of metabolic abnormalities including metabolic syndrome, obesity, hyperlipidemia,
hypertension, and impaired glucose tolerance [124]. Taken together, animal models of
reduced or enhanced eNOS expression demonstrate the essential role of eNOS in
mediating vascular health.
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In contrast, when AS is knocked out in mice, it leads to death a few days after
birth due to the accumulation of citrulline and a severe arginine deficiency [29, 125]. A
tissue specific AS knockout mouse model is not available, but if, for example, such a
model were generated with an endothelium specific deletion of AS, we would predict
marked endothelial dysfunction based on our tissue culture work. Similarly to the AS
knockout, AL knockout mice die within 48 hours of birth and are characterized by
increased ammonia, argininosuccinic acid, glutamine and citrulline and low levels of
arginine [29, 36].

The role of the expression citrulline-NO cycle components on vascular health can
be studied at extreme levels utilizing animal models as just described. These scenarios are
rare in humans, and there are finer levels of regulation that occur in response to a number
of biological processes and signals. Shear stress is one of the most important
physiological factors that regulates the function of blood vessels [126-128].
Unidirectional, laminar shear stress exerts a protective role on the endothelium by
diminishing adhesion and platelet aggregation [129] and enhancing NO production [126,
130]. Shear stress has been shown to increase eNOS expression via a transient activation
of NfκB in bovine aortic endothelial cells. There is a shear stress responsive element
(SSRE) in the eNOS promoter that is responsible for the transcriptional regulation by
NfκB [131]. Other groups have determined that the shear stress-mediated increase in
eNOS mRNA is due to an increase in transcription and mRNA stabilization [132, 133]. In
a DNA microarray study of human umbilical vein endothelial cells, shear stress was
shown to significantly increase AS expression, but not eNOS. The authors suggested this
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might be due to the fact that shear stress-induced increases in NO synthesis depend on
arginine synthesis from citrulline via increased AS levels [134]. In a subsequent study by
a group studying the adhesion of endothelial cells in vein grafts supported the role of both
eNOS and AS in the response of the endothelium to shear stress [135]. The role of AL in
shear stress-mediated NO production has not been studied. However, it is clear that there
is a role for both AS and eNOS in mediating the response of the endothelium to shear
stress that involves multiple and perhaps overlapping mechanisms depending on the level
of shear stress and other factors.

Cytokines regulate vascular function in various ways, and tumor necrosis factor
alpha (TNFα) is well characterized in this respect. TNFα is a pro-inflammatory cytokine
with both positive and negative roles in regulating vascular function, depending on the
length of treatment and tissue type [136]. In general, conditions of chronic TNFα
elevations are deleterious to the vasculature as evidenced by the fact that humans with
diabetes, obesity and heart disease have elevated levels of TNFα [55, 71, 73, 75, 137,
138]. Often times, TNFα-mediated vascular impairment is caused by dysregulation of NO
production [70, 74, 139, 140]. One mechanism by which TNFα inhibits NO production is
by altering eNOS and AS expression. Specifically, eNOS expression has been shown to
be downregulated by TNFα via several mechanisms including decreased mRNA stability
and inhibition of transcription factor binding [141-143]. In addition, TNFα diminishes AS
expression and NO production by inhibiting the binding of SP-1 elements to the proximal
promoter [144]. AL seems to be less amenable to cytokine regulation since in vascular
smooth muscle cells, retinal endothelium or pancreatic β cells, treatment with a variety
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of different cytokines led to co-induction of AS and iNOS while AL remained static
[145-147].

Peroxisome proliferator-activated receptor gamma (PPARγ) is a member of the
nuclear receptor superfamily of ligand-activated transcription factors. PPARγ regulates
the transcription of genes involved in lipid and glucose metabolism [148], differentiation
[148-150] and cell growth [148]. Thiazolidinediones (TZDs) are a group of synthetic
PPARγ agonists that provide cardiovascular benefits such as reduction of blood pressure
and improvement in insulin-sensitivity [151-153]. In addition, TZDs reduce lesion
formation in animal models of atherosclerosis [154-156], improve flow-mediated
vasodilation and decrease vascular smooth muscle cell migration by stimulating
endothelial NO production [157, 158]. These anti-diabetic compounds also counter the
effects of the inflammatory response associated with elevated serum levels of TNFα and
ceramide. For instance, rosiglitazone impairs TNFα-induced activation of MAPK,
restoring insulin signaling and leading to normalization of glucose uptake in brown
adipocytes [159]. In humans with type 2 diabetes, pioglitazone was protective against
TNF-mediated endothelial dysfunction [76]. In hepatocytes made insulin resistant via
TNFα treatment, troglitazone is able to restore insulin sensitivity, partially via blocking
the downstream actions of ceramide [160].

Another mechanism by which TZD’s improve endothelial function is by inducing
the expression of components of the citrulline-NO cycle. For example, eNOS expression
and NO production are enhanced by troglitazone by a mechanism that seems to be PPAR
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independent [161]. Telmisartan, an angiotensin II receptor blocker, has recently been
identified as a partial PPARγ agonist. Its cardioprotective mechanism is mediated
partially by the upregulation of eNOS [153]. In addition, troglitazone enhances NO
production and AS expression by activating a PPAR responsive element in the distal AS
promoter [162]. There have been no studies on the effects of PPAR agonists on AL.
Taken together, the positive benefits of TZD’s are multifactorial and lead to improved
vascular parameters by mechanisms that include the upregulation of eNOS and AS.

Insulin is an important regulator of vascular function. Insulin mediates its effects
on vasodilation by stimulating NO release [163, 164]. One mechanism by which insulin
increases NO production is by increasing the expression of eNOS. Kuboki et al.
demonstrated that insulin increases eNOS mRNA within 1 hour of treatment. This
increase was mediated by activation of the PI3-kinase pathway [165]. In another study,
the mechanism of insulin transcriptional regulation of eNOS was found to involve
increased binding of SP-1 and AP-1 transcription factors [166]. The link between insulin
and NO has another important feature. NO itself leads to the secretion of insulin in
pancreatic islet β-cells [167]. This process is dependent on the recycling of arginine to
citrulline [168]. This suggests an involvement of both AS and AL. In addition, eNOS
expression and function is diminished in diabetes. For example, high glucose diminishes
the expression of eNOS [102]. In addition, insulin enhances the expression of eNOS in
diabetic rats [169]. The impact of insulin or diabetes on endothelial AS and AL
expression has not been studied, but one group did note that in the early phases of
streptozotocin (STZ)-induced type 1 diabetes in rats, AS and eNOS mRNA and protein
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expression was induced in aorta. This increase then diminished as diabetes progressed.
There was very little effect on AL mRNA, and possibly a slight induction after 4 weeks,
but the effects on AL were not studied any further [170]. Thus, glucose, insulin and NO
metabolism are tightly associated processes that involve both AS and eNOS (and possibly
AL) expression.

VEGF is an important mediator of vascular health by regulating vasodilation and
angiogenesis [171]. VEGF exerts its cardioprotective functions, in part, by increasing the
expression of eNOS. In human umbilical vein endothelial cells (HUVECs), VEGF
augments the expression of eNOS in a time and dose-dependent manner. This was linked
to increased basal and stimulated NO production [172]. Another group obtained similar
results when using rat aortic rings [173]. In addition, insulin increases the expression of
both eNOS and VEGF in diabetic rats leading to increased NO production and vascular
relaxation [169]. The role of VEGF in regulating AS or AL has not been studied.
Therefore, VEGF and NO signaling pathways are linked by direct effects on eNOS
expression.

Ceramide, a bioactive sphingolipid, has been implicated in the development of
insulin resistance and atherosclerosis [57, 61, 77, 174]. In general, supraphysioloical
levels of ceramide contribute to endothelial dysfunction [60, 91, 175] and most of what is
known involves impairment of eNOS activation (which is discussed in the next section).
However, Li and colleagues demonstrated that ceramide decreases NO production in
human endothelial cells via a mechanism that involves ROS generation. They found that
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eNOS expression is enhanced as a compensatory mechanism. This enhanced expression
was not sufficient to ameliorate the diminished NO synthesis caused by the generation of
ROS [90]. The direct effects of ceramide on AS and AL expression have not been
studied.

The intricate and diverse mechanisms regulating the expression of AS and eNOS
in the endothelium and other tissues suggests that this is an important mechanism
mediating vascular biology and warrants continued investigation. For this reason, the
regulation of AS expression in endothelial cells encompasses Specific Aim 1 of this
dissertation and is described in Chapter One.

Regulation of Endothelial Nitric Oxide Production: Post-Translational Modifications

Although controlling the expression levels of AS, AL and eNOS is an important
mechanism for regulating the levels of NO produced, this mode of regulation seldom
occurs quickly enough to acutely increase or decrease NO production. Since NO is
constantly being produced and its levels are frequently adjusted to meet cellular demands,
post-translational modifications (PTM) have been described as a prominent mechanism in
regulating NO production.

The acute regulation of eNOS by reversible phosphorylation is well described.
Although eNOS is regulated by tyrosine phosphorylation [176, 177], serine/threonine
phosphorylation is a much more prominent mechanism. There are 5 well characterized
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sites of eNOS phosphorylation: serine 116 (S116), threonine 497 (T497), S617, S635 and
S1179 (bovine; these sites are equivalent to S114, T495, S633 and S1177 in human)
[178-180].

S116 is located in the oxygenase domain of the enzyme [179]. There is
controversy as to whether this site activates or inactivates eNOS. A recent paper
demonstrated that mutation of this site to an alanine increased NO production while
mutation to an aspartic acid diminished NO production. In addition, phosphorylation at
this site increased the inhibitory interaction of eNOS with caveolin-1 and diminished
vascular reactivity. Hence, this site seems to be inhibitory for the function of eNOS
[181]. On the other hand, Drew et al. found that HDL and Apo A1 led to increased NO
release due to eNOS phosphorylation at several sites, most profoundly at S116. This
suggested a positive role for S116 [182]. It is possible that there are tissue and stimulusspecific functions for S116.

There is a great deal of consensus regarding the inhibitory role of T497, which is
located in the eNOS calmodulin binding domain [179]. In fact, in the study mentioned
above where they found that S116 does activate eNOS, they also found that HDL and
Apo A1 diminish phosphorylation at T497 [182]. Many other studies have confirmed
this inhibitory regulation [81, 183-185]. In particular, several different groups have
demonstrated that mutation of T497 to aspartic acid (phospho-mimetic) greatly
diminishes eNOS activity and NO production while the alanine mutation (phospho-null)
has opposite effects [79, 184]. When this site is phosphorylated, calmodulin cannot bind
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to and activate eNOS [184]. T497 is constitutively phosphorylated and upon stimulation
with agents that increase intracellular calcium, such as bradykinin or VEGF, the site is
dephosphorylated by protein phosphatase 1 (PP1) leading to calmodulin binding [184]. In
addition, the dephosphorylation of T497 has to occur before the activating
phosphorylation at S1179 can take place [185]. Protein kinase C has been shown to
increase phosphorylation at this site [183], thereby diminishing eNOS function. Certain
PKC isoforms, such as PKCα and PKCε can activate eNOS by leading to
phosphorylation at S1179 [186, 187].

Serines 617 and 635 are both in the eNOS autoinhibitory domain, which is part of
the reductase domain [179]. This domain is reported to keep eNOS in an inhibited state
that is reversed upon calmodulin binding [19, 188]. These sites are phosphorylated in
response to bradykinin, ATP and VEGF [179, 182, 189]. Shear stress has also been found
to lead to the phosphorylation of S635 [190]. The phosphorylation at S617 is transient in
nature while S635 phosphorylation is more persistent. Akt phosphorylates S617 while
PKA phosphorylates S635. The mechanism of regulation of eNOS activation by these
two sites is suggested to involve a two step process. During initial agonist-induced
activation of eNOS, S617 is phosphorylated and increases eNOS sensitivity to calcium.
Then, S635 phosphorylation increases eNOS specific activity to levels similar to what
occurs when S1179 is phosphorylated [189].

The most studied site of eNOS phosphorylation is S1179, located near the Cterminus in the reductase domain [179]. Phosphorylation at this site leads to an
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approximately 2-fold activation of eNOS specific activity [189]. This activation is due to
a decrease in the calcium-dependence of eNOS and an increase in electron flux from the
reductase domain to the oxygenase domain, which leads to increased NO output [191].
This site is phosphorylated by a number of kinases including Akt, AMPK, PKA, PKG
and calmodulin II protein kinase in response to a variety of stimuli including insulin,
adiponectin, bradykinin, VEGF, HDL and Apo A1 [127, 130, 182, 183, 185, 186, 192202]. For example, fluid shear stress, VEGF and bradykinin lead to the activation of PKA
and subsequent phosphorylation of eNOS at S1179 [183, 203].

Although the regulation of eNOS by a complex pattern of stimulus-specific
phosphorylation and dephosphorylation events has been studied extensively, there have
been no reports of such studies for AS and AL. Evidence supporting post-translational
regulation of AS is beginning to accumulate. First, in a proteomic study to identify novel
phosphoproteins in HeLa cells, AS was found to be phosphorylated at S352 [204]. This is
the first and only indication of this type of modification of AS. The authors did not
investigate the biological relevance of this modification. In addition, in vascular smooth
muscle, AS is reversibly inactivated by nitrosylation in conditions of high NO output by
iNOS. Their work suggests that AS is at least partially responsible for sensing cellular
NO levels and adjusting output accordingly in an effort to maintain homeostasis [112].
Nitrosylation of cysteine residues has emerged as an extremely important, reversible
modification that regulates the activity of a number of proteins such as caspase-3, the
ryanodine receptor and actin [205]. Importantly, eNOS is basally nitrosylated in
endothelial cells and is then rapidly denitrosylated in response to VEGF stimulation
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[206]. The nitrosylation of AS in the endothelium has not been studied, but may represent
an important additional mechanism of regulation.

Another important PTM that regulates NO production is the acylation of eNOS by
the irreversible N-myristoylation at glycine 2 (G2) and the reversible thiopalmitoylation
at cysteine 15 (C15) and C26 [207]. These modifications are crucial for the targeting and
anchoring of eNOS to the plasma membrane, which is an essential location for the
production of NO [207-210]. These modifications have not been studied for AS or AL.
However, we have demonstrated that AS and AL and eNOS co-fractionate with caveolin1 in caveolar membrane fractions, which indicates that mechanisms must exist to target
these enzymes to the plasma membrane in conjunction with eNOS.

Glycosylation is an additional type of PTM that regulates NO production. Olinked glycosylation occurs at serine and threonine residues, typically in response to the
flux of excess glucose into the hexosamine biosynthesis pathway. Glycosylation often
competes with phosphorylation at the same or adjacent sites leading to a ying-yang type
of regulatory scheme [211, 212]. In endothelial cells, glycosylation of eNOS decreases its
activity and diminishes phosphorylation at S1179 [213]. The functional relevance of this
modification was illustrated in diabetes-related erectile dysfunction, where glycosylation
reduced S1179 phosphorylation at baseline and in response to VEGF and shear stress
[214]. In this study, it was determined that glycosylation only affects S1179 and not
T497, S617 or S635. Although glycosylation of AS in endothelial cells has not been
studied, in Caco-2 cells the expression of AS is stimulated by glutamine via glycosylation
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of the transcription factor SP-1 [215]. This modification leads to nuclear import of SP-1
and a subsequent increase in AS transcription. The regulation of AL by glycosylation has
not been studied.

Taken together, the extensive studies of eNOS PTM by phosphorylation,
nitrosylation, glycosylation and acylation have a prominent role in regulating the ability
of the endothelium to produce NO. Due to the few papers in the literature that suggest
that AS is also regulated by PTM and to the prominent role of serine/threonine
phosphorylation in regulating eNOS function, Specific Aim 2 is dedicated to the
thorough investigation of endothelial AS serine/threonine phosphorylation. The findings
are presented in Chapter Two.

Regulation of Endothelial Nitric Oxide Production: Subcellular Localization and Protein
Interactions

The precise location of a protein within the cell is critical for its function.
Compartmentalization of proteins that are in the same metabolic or signaling pathway
allows for efficient communication, channeling of substrates and accessibility to
important regulatory factors. In addition, the regulation of subcellular transport to
localize these proteins involves several mechanisms including vesicles, cytoskeletal
components and protein interactions. Furthermore, protein interactions often mediate the
functions of their interacting partners via mechanisms that do not involve transport such
as post-translational modification or conformational change [216]. There is a complex
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network of interacting proteins that are known to regulate NO production via eNOS [180]
and the scientific community is just beginning to describe similar mechanisms for AS and
AL.

The regulation of eNOS is dependent its localization within the cell [217, 218].
There are two regions in the cell that have been found to independently produce NO, the
Golgi and the plasma membrane [219, 220]. Within the plasma membrane, eNOS is
localized to caveolae [217]. Caveolae are invaginations of the plasma membrane that are
rich in glycosphingolipids and cholesterol and serve as platforms for the integration of
signaling pathways. Caveolae are also involved in endocytosis and transcytosis. Caveolin
is an integral membrane protein that is an important structural component of caveolae
[218, 221]. Although activation of eNOS by phosphorylation at S1179 does not cause
translocation from the Golgi to the plasma membrane, the proper localization of eNOS is
necessary for this phosphorylation to occur [208, 220]. Mistargeting of eNOS also
attenuates NO release [222, 223]. In the plasma membrane, eNOS is constitutively
phosphorylated at S1179 and is highly active. In the Golgi, phosphorylation at S1179 is
diminished and less NO is produced in response to calcium signaling [224]. Furthermore,
plasma membrane eNOS is more responsive to agonists such as insulin and angiopoietin
and demonstrates increased binding to HSP90 as compared to Golgi-eNOS [219]. Despite
this understanding, there is still some doubt as to whether Golgi versus plasma membrane
NO production is of more or less significance or whether the distinct functions of these
pools require further study to define their specific purpose in the cell.
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The targeting of eNOS to Golgi versus plasma membrane is controlled by several
mechanisms. One key mechanism involves myristoylation and palmitoylation [209].
Myristoylation is necessary for eNOS to associate with the membrane, essential for
optimal eNOS activity, important for compartmentalization in the Golgi and is a
prerequisite for palmitoylation. Palmitoylation is essential for eNOS targeting to the
membrane and specifically to caveolae [210]. In a study by Jagnandan and colleagues,
organelle-specific eNOS constructs were generated in an attempt to determine the
compartment-specific function of eNOS. The authors found that the nucleus,
mitochondria cytoplasm and trans-Golgi network are inefficient for NO production as
compared to the plasma membrane and cis-Golgi network. This is apparently not due to
insufficient substrate availability since iNOS targeted to the same regions functions
normally. The relative lack of calcium/calmodulin in these regions may responsible for
the inefficiency of eNOS, which unlike iNOS is dependent on calcium and calmodulin
for function [224]. A subsequent study determined that calcium and calmodulin are not
the reason for disparate function in different organelles. The study found it is actually
phosphorylation that regulates organelle-specific eNOS function since Golgi localized
eNOS had reduced phosphorylation at S1179, S635 and S617 [225].

In addition to acylation as a targeting mechanism, there is an intricate network of
cytoskeletal components that regulate eNOS function and likely also its translocation.
Actin is a prominent regulator of eNOS. For example, F-actin is required for shear stress
mediated eNOS upregulation due to its role in mechanotransduction [226]. In general, the
interaction of eNOS with actin increases its activity. One mechanism is due to increased
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interaction with HSP90 [227]. On the other hand, the interaction of eNOS with actinin-4,
an actin-associated protein, inhibits eNOS activity by preventing calmodulin from
interacting with and activating eNOS [228]. Vimentin is another important cytoskeletal
component that regulates eNOS function. Vimentin is an intermediate filament that is
essential for flow-mediated dilatation [226]. Although the eNOS activity per se has not
been related to vimentin, the importance of this cytoskeletal component in mediating
vessel relaxation implies the involvement of eNOS. Vimentin is also an essential
structural component of caveolae [229]. In addition, the inhibition of microtubules
(tubulin and microtubule associated proteins) leads to decreased eNOS activity and NO
production [230]. Furthermore, it has been demonstrated that HSP90 and calmodulin both
interact with tubulin. The interaction of tubulin with HSP90 is important for eNOS
activity since disruption of microtubule assembly diminishes the eNOS-HSP90
interaction and reduces NO output The specific role of the calmodulin-tubulin interaction
on the function of the citrulline-NO cycle is unclear [230]. As discussed in a latter
section, both HSP90 and calmodulin are important binding partners of eNOS that
stimulate its function. This suggests that microtubules also play a role in eNOS function.
Whether the mechanism is structural or involves eNOS transport is not clear.

Finally, several protein interactions are essential for eNOS cellular transport. One
well studied interaction is with caveolin-1. AS discussed previously, caveolin-1 is an
important component of caveolae. It is believed that caveolae function as vesicles that
regulate eNOS transcytosis and caveolin-1 is required in this process [222]. More
importantly, caveolin-1 and eNOS both interact with NOSTRIN (eNOS trafficking
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inducer), which also recruits dynamin, a Golgi localized GTP-ase, and facilitates caveolar
transport [231]. NOSTRIN transport of eNOS is dependent on the actin cytoskeleton
[232]. Although NOSTRIN is important for eNOS translocation, it inhibits eNOS activity
regardless of localization in the cell and overexpression of NOSTRIN leads to
redistribution of eNOS from the plasma membrane to intracellular vesicular structures
[232]. The specific regulation of this complex and its trafficking is still unclear. NOSIP
(eNOS interacting protein) is another important protein that regulates eNOS
translocation. NOSIP interacts directly with eNOS and inhibits its activity [233].
Furthermore, NOSIP is important for the subcellular redistribution of eNOS between the
caveolae and intracellular compartments [234]. Much like NOSTRIN, NOSIP
overexpression leads diminished plasma membrane localization of eNOS [233].

To date, there have been no studies delineating the regulation of AS or AL
intracellular targeting. The localization of AS and AL has been understudied in
endothelial cells. However, we have demonstrated that AS, AL eNOS and caveolin-1 cofractionate in caveolar membrane preparations [110]. In vascular smooth muscle, AS
demonstrates both cytoplasmic and membrane localization along with a punctuate pattern
of distribution that suggests mitochondrial localization [108]. Otherwise, no other studies
have addressed the subcellular localization of AS or AL as part of the citrulline-NO
cycle. Much more is known about their localization in tissues that produce urea. For
example, in liver, these enzymes are localized in mitochondria.
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In addition to the role protein interactions play in the targeting of eNOS, there are
several proteins that regulate eNOS functions in other ways. Aside from the role of
caveolin in AS localization, it has direct effects on inhibiting eNOS activity [235]. The
interaction of caveolin with eNOS is direct and occurs in a region of eNOS that contains
a caveolin binding motif [235]. The interaction of eNOS with caveolin is disrupted upon
stimulation with calcium ionophores, bradykinin or fluid shear stress [236, 237]. Another
interaction that negatively regulates eNOS function is the bradykinin receptor. This
interaction is similar to that with caveolin in that it represents a membrane docking
interaction that is relieved upon treatment with agonists such as bradykinin and calcium
ionophores [238].

There are a multitude of proteins that interact with eNOS and enhance its
function. One prominent interaction is with heat shock protein-90 (HSP90). This
molecular chaperone activates eNOS via a mechanism that involves phosphorylation at
S1179 [239]. HSP90 delivers the kinase Akt to eNOS and promotes its phosphorylation
[240]. Calmodulin is an important positive regulator of eNOS that also interacts with
HSP90 and is responsible for displacing the eNOS-caveolin interaction [241]. In fact,
caveolin and calmodulin are involved in the reciprocal regulation of eNOS. Upon agonist
stimulation and an increase in intracellular calcium, calmodulin binds to eNOS and
displaces caveolin [242]. In addition, eNOS interacts with the CAT-1 arginine transporter
and this increases its activation via phosphorylation at S1179 and 635. The mechanism of
enhanced NO release does not involve arginine transport [243].
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In contrast to eNOS, very little is known about protein interactions involving AS
and AL as part of the citrulline-NO cycle. Recently, the interaction of an NADPH sensor
protein (HSCARG) with AS was shown to down regulate AS activity in epithelial cells.
Their results implied that HSCARG regulation of AS activity is crucial for maintaining
the intracellular balance between redox state and NO levels [244]. This is the first study
to define a protein interaction with AS that is essential for NO production.

Given the prominence of regulation of NO production by eNOS subcellular
localization and protein interactions, we hypothesize similar mechanisms exist to regulate
the role of AS in endothelial NO production. Therefore, Specific Aim 3 of this
dissertation will explore both the subcellular localization and protein interactions of AS.
Our findings are described in Chapter Three.
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SPECIFIC AIMS

Purpose

Heart disease is the number one killer of Americans. As the incidence of obesity,
diabetes and metabolic syndrome continues rising at an alarming rate, so will the
prevalence of endothelial dysfunction [1] . Since endothelial dysfunction is often
accompanied by diminished or excessive nitric oxide (NO) production [2], it is essential
to continue our efforts to gain a better understanding of the regulation of NO synthesis.
Our studies were designed to expand our global understanding of vascular biology by
assessing the regulation of the citrulline-NO cycle from a different perspective. Since
much of the focus has been on the regulation of endothelial nitric oxide synthase (eNOS),
our research is targeted at a better understanding of another equally important component
of the citrulline-NO cycle, argininosuccinate synthase (AS).

Central Question and Hypothesis

AS is an enzyme that is important for the production of nitric oxide. The central
question we are addressing with the work described is: How does AS regulate endothelial
NO production? Due to the fundamental role of AS for vascular biology, we hypothesize
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that multiple mechanisms regulate AS function to control NO production and support
endothelial function.

Specific Aim 1

The role of eNOS in the control of NO production is well studied [2]. Much less
is known about the regulatory role of AS. We and others have demonstrated the
importance of AS expression for the production of NO [3-14]. We hypothesize that a
multitude of stimuli alter AS expression to enhance NO production in a manner
consistent with the substrate needs of eNOS. In Specific Aim 1, described in Chapter
One, we will first examine the role of AS overexpression in regulating NO production.
We will then determine whether insulin, vascular endothelial growth factor (VEGF) and
ceramide impact AS expression coordinately with eNOS.

Specific Aim 2

Although regulation at the level of transcription and translation is an important
mechanism controlling the level of function of an enzyme, this type of regulation seldom
accounts for acute changes in enzymatic activity. NO synthesis is a constant and dynamic
process. It is well documented that eNOS is regulated by a complex set of reversible posttranslational modifications [15-17]. Since AS is the source of substrate for eNOS [9, 11],
we hypothesize that a similar pattern of post-translational modifications exists for the
acute regulation of AS function. In Specific Aim 2, described in Chapter Two, we will
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determine whether AS is an endogenous phosphoprotein, define the biological
significance of AS phosphorylation, and uncover the possible mechanisms by which AS
phosphorylation regulates its function.

Specific Aim 3

Post-translational regulation of protein function often involves subcellular
localization and dynamic protein interactions. There is a complex literature surrounding
the regulation of eNOS trafficking, activation and function that is driven by protein
interactions [17-19]. However, very little is known about such regulatory mechanisms
controlling AS function. In Specific Aim 3, described in Chapter Three, we will define
the subcellular localization of AS and identify key interacting partners.

Working Model

It is our belief that the regulation of caveolae-localized AS, in conjunction with
eNOS, is mediated by an interrelated set of mechanisms that controls the expression, post
translational modifications and protein interactions that are so critical for the overall
function of the system. As demonstrated in Figure 1, we hypothesize that agonists and
antagonists will coordinately regulate the expression, activation and protein interactions
of AS and eNOS so that the level of NO produced is adequate to meet the current needs
of the cell. In addition, it is our belief that the multiple mechanisms that regulate AS and
eNOS are inter-related, yet specific to environmental signals. Although there might be
57

instances where there is some discoordinate regulation of AS and eNOS, such instances
are necessary in scenarios where an initial change in regulation of one of these two
enzymes would signal a need for a change in NO production which would then be
followed by a coordinate regulation of the other enzyme for the express purpose of
restoring homeostasis. We also believe that there are specific mechanisms that control the
regulation of the caveolae-localized citrulline-NO complex in comparison to other
locations within the cell. Importantly, the coordinate, multi-level regulation of AS and
eNOS is designed specifically to regulate the synthesis of NO in an attempt to support the
health of the endothelium and ultimately of the cardiovascular system. Any derangements
of the physiological regulation of this complex, even if minor, would have a great impact
on vascular health and explains the prominence of vascular disorders seen with a variety
of metabolic imbalances.
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Figure 1: Working Model of the Regulation of the Citrulline-NO Cycle Under
Physiological Conditions. Figure depicts the central components of our study of the
citrulline-NO cycle, AS and eNOS, as a caveolae-localized complex that is coordinately
regulated by agonists and antagonists via expression, phosphorylation and protein
interactions in an effort to produce adequate amounts of NO to promote vascular health.
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CHAPTER ONE
ARGININOSUCCINATE SYNTHASE FUNCTION AND EXPRESSION

Overview

Argininosuccinate synthase (AS) is a key, regulated step of the citrulline-nitric
oxide (NO) cycle. We have previously demonstrated several levels of regulation of AS
expression that impact NO production. First, when AS expression is reduced utilizing
siRNA, NO production, AS enzymatic activity and endothelial cell viability is
diminished. The loss of endothelial cells is via apoptosis and can be rescued with an NO
donor, demonstrating the direct role of AS activity and NO production in maintaining
endothelial cell viability. In addition, TNFα, a cytokine associated with vascular disease,
leads to decreased expression of AS under conditions of chronic inflammation. This
decreased expression occurs via a reduction in the ability of SP-1 elements to activate the
AS proximal promoter, similar to the effects of chronic TNFα treatment on the eNOS
promoter. Finally, we have demonstrated that AS expression is increased by the PPARγ
agonist drug, troglitazone, due to enhanced activity at a distal AS PPAR responsive
element (PPRE). To expand our understanding of AS transcriptional regulation, we
explored several pathways. First, we tested whether AS overexpression in endothelial
cells enhances NO production. Our data demonstrates that AS overexpression
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significantly increased basal NO production within 6 hours of transfection. Since insulin
is a key regulator of vasodilation and vascular function, the hypothesis that insulin
enhances AS expression and NO production was tested. Western blot and real time PCR
experiments showed that AS protein and mRNA expression were up-regulated by
physiological doses of insulin. Insulin coordinately regulated eNOS expression.
Luciferase assay data also suggested that insulin may be activating a distal AS promoter
element. Nitric oxide assays demonstrated that insulin alone can increase NO production
and that it also acts synergistically with bradykinin and the calcium ionophore A23187 to
increase NO production. This suggests that insulin up-regulation of AS is part of the
mechanism by which it increases NO production. Since VEGF mediates important
endothelium-specific functions such as angiogenesis and vasodilation, the hypothesis that
VEGF enhances AS expression and NO production was examined. Western blot analysis
demonstrated that VEGF increases AS expression. We also demonstrated a timedependent increase in NO production in response to VEGF. Finally, we investigated the
effects of ceramide on AS and eNOS expression. Ceramide is a bioactive sphingolipid
with roles in cell signaling and apoptosis. Often times, the pathogenic effects of TNFα
are mediated by ceramide. This prompted the hypothesis that ceramide would diminish
AS expression under pathogenic conditions. Western blot analyses demonstrated that
ceramide decreased AS and eNOS expression. In addition, ceramide diminished eNOS
activation. Collectively, the data in this Chapter suggests that AS expression is highly
regulated in a manner that is consistent with its role in supporting the catalytic activity of
eNOS.
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Materials and Methods

Bovine Endothelial Cell Culture: Bovine aortic endothelial cells (BAEC) were
isolated by our laboratory from bovine aorta following the procedure of Gospodarowicz
et al [1], and were used from passages 4-10. The study of bovine AS is supported by the
extensive use of BAEC in research and the fact that AS shares a high sequence identity
between human [2], bovine [3], rat [4] and mouse [5]. BAEC were cultured at 37°C
under an atmosphere of 5% CO2 in complete Dulbecco’s Modified Eagle’s Medium
(DMEM) (1 g/L glucose, Mediatech) that contained 10% fetal bovine serum (Hyclone
Laboratories), 100 units/ml penicillin and 100 μg/ml streptomycin (Mediatech). Cells
were treated once they reached confluence.

AS Expression Vector: The AS plasmid contains both a V5 and 6X-His tag at its
C-terminus. The vector map and sequence are below:
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Figure 2: AS Expression Vector Map
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Figure 3: AS Expression Vector Sequence. Green = AS start; Red = AS stop; Turquoise =
codons mutated to make T131, S180 and S189 variants in Chapter Two.
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AAAATCAACG
GTAGGCGTGT
CTGCTTACTG
TAAGCTTGGT
CCGTCACGAT
CCTGCATCCT
TCGGCCAGAA
AGGTGTTCAT
AGTCCAGCGC
TCGCCCGCAA
CCACAGGAAA
AGATCAAGGT
ACGATCTGAT
CGTGGAGCAT
CCAAGAACCA
ACAGCCCGGA
TCGGGGATGG
CTGGCAAGCA
CCCGGGGTAT
AGGCCTTCAC
CCGAGCTGGT
TTGCCAAGTC
TGTACATCCT
ACGTGCAGGG
GGCTGAAGGA
TCCAGCACAG
CTAACCCTCT
TTTAAACCCG
CCTCCCCCGT
ATGAGGAAAT
GGCAGGACAG
GCTCTATGGC
CCTGTAGCGG
TTGCCAGCGC
CCGGCTTTCC
TACGGCACCT
CCTGATAGAC
TGTTCCAAAC
TTTTGCCGAT
ATTAATTCTG
CAGAAGTATG
CTCCCCAGCA
GCCCCTAACT
TGGCTGACTA
CCAGAAGTAG
TTGTATATCC
ACAAGATGGA
CTGGGCACAA

GAGATCTCCC
AAGCCAGTAT
TTAAGCTACA
GCGTTTTGCG
TAGTTATTAA
CGTTACATAA
GACGTCAATA
ATGGGTGGAG
AAGTACGCCC
CATGACCTTA
CATGGTGATG
ATTTCCAAGT
GGACTTTCCA
ACGGTGGGAG
GCTTATCGAA
ACCGAGCTCG
GTCCGGCAAA
CGTGTGGCTG
AGAAGACTTT
TGAGGACATC
ACTGTACGAG
GCAGGTGGAG
GGGGAACGAC
CATCGCTCCC
GGAGTATGCG
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CATGCTCGAG
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CGGCGTGGGC
CTACGAGACC
CATGGACCGG
CTACACGGGT
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TGGCCGGGAG
AGACTACGAG
ATATCATCGC
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CCTCGGTCTC
CTGATCAGCC
GCCTTCCTTG
TGCATCGCAT
CAAGGGGGAG
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CGCATTAAGC
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CCGTCAAGCT
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GGTTTTTCGC
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TGGAATGTGT
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GGCAGAAGTA
CCGCCCATCC
ATTTTTTTTA
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ATTTTCGGAT
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GATCCCCTAT
CTGCTCCCTG
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CTTACGGTAA
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TATTTACGGT
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GTCTATATAA
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TGGAGGATGC
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GGCCTCTACA
ATCGAGTTCA
AGCACAGCGT
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TTCTGGCACA
GTGGAAGGGA
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CCTTTGACGT
CTCAACCCTA
TGGTTAAAAA
GTCAGTTAGG
ATCTCAATTA
TGCAAAGCAT
CGCCCCTAAC
TTTATGCAGA
TTTTTGGAGG
CTGATCAAGA
GTTCTCCGGC
GCTGCTCTGA
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GGTGCACTCT
CTTGTGTGTT
GCTTGACCGA
ATGTACGGGC
TTACGGGGTC
ATGGCCCGCC
TTCCCATAGT
AAACTGCCCA
TCAATGACGG
CTACTTGGCA
AGTACATCAA
TTGACGTCAA
ACAACTCCGC
GCAGAGCTCT
CTCACTATAG
GCTCCGCCGA
TTCTGGCCTA
GCTATGACGT
GGAAGAAGGC
TTGTGGAGGA
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CATTGCCTAC
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CTCTCTCGCC
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CTGCTACTCG
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GGCTGGAATC
GGACCCGGCC
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CCTGTACCTG
CCGCTTCATC
CCACGCTCAT
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TCATCACCAT
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TAGGGGGTAT
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TTCACGTAGT
GTTCTTTAAT
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GGATCGTTTC
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AGTCCCCAGG
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CTTCTGAGCG
CACGAGATTT
GGGACGCCGG
CCAACTTGTT
CAAATAAAGC
CTTATCATGT
TGTTTCCTGT
TAAAGTGTAA
CACTGCCCGC
GCGCGGGGAG
TGCGCTCGGT
TATCCACAGA
CCAGGAACCG
AGCATCACAA
ACCAGGCGTT
CCGGATACCT
GTAGGTATCT
CCGTTCAGCC
GACACGACTT
TAGGCGGTGC
TATTTGGTAT
GATCCGGCAA
CGCGCAGAAA
AGTGGAACGA
CCTAGATCCT
CTTGGTCTGA
TTCGTTCATC
TACCATCTGG
TATCAGCAAT
CCGCCTCCAT
ATAGTTTGCG
GTATGGCTTC
TGTGCAAAAA
CAGTGTTATC
TAAGATGCTT
GGCGACCGAG
CTTTAAAAGT
CGCTGTTGAG
TTACTTTCAC
GAATAAGGGC
GCATTTATCA
AACAAATAGG

CTTTTTGTCA
CTATCGTGGC
GCGGGAAGGG
CTTGCTCCTG
GATCCGGCTA
CGGATGGAAG
CCAGCCGAAC
ACCCATGGCG
ATCGACTGTG
GATATTGCTG
GCCGCTCCCG
GGACTCTGGG
CGATTCCACC
CTGGATGATC
TATTGCAGCT
ATTTTTTTCA
CTGTATACCG
GTGAAATTGT
AGCCTGGGGT
TTTCCAGTCG
AGGCGGTTTG
CGTTCGGCTG
ATCAGGGGAT
TAAAAAGGCC
AAATCGACGC
TCCCCCTGGA
GTCCGCCTTT
CAGTTCGGTG
CGACCGCTGC
ATCGCCACTG
TACAGAGTTC
CTGCGCTCTG
ACAAACCACC
AAAAGGATCT
AAACTCACGT
TTTAAATTAA
CAGTTACCAA
CATAGTTGCC
CCCCAGTGCT
AAACCAGCCA
CCAGTCTATT
CAACGTTGTT
ATTCAGCTCC
AGCGGTTAGC
ACTCATGGTT
TTCTGTGACT
TTGCTCTTGC
GCTCATCATT
ATCCAGTTCG
CAGCGTTTCT
GACACGGAAA
GGGTTATTGT
GGTTCCGCGC

AGACCGACCT
TGGCCACGAC
ACTGGCTGCT
CCGAGAAAGT
CCTGCCCATT
CCGGTCTTGT
TGTTCGCCAG
ATGCCTGCTT
GCCGGCTGGG
AAGAGCTTGG
ATTCGCAGCG
GTTCGCGAAA
GCCGCCTTCT
CTCCAGCGCG
TATAATGGTT
CTGCATTCTA
TCGACCTCTA
TATCCGCTCA
GCCTAATGAG
GGAAACCTGT
CGTATTGGGC
CGGCGAGCGG
AACGCAGGAA
GCGTTGCTGG
TCAAGTCAGA
AGCTCCCTCG
CTCCCTTCGG
TAGGTCGTTC
GCCTTATCCG
GCAGCAGCCA
TTGAAGTGGT
CTGAAGCCAG
GCTGGTAGCG
CAAGAAGATC
TAAGGGATTT
AAATGAAGTT
TGCTTAATCA
TGACTCCCCG
GCAATGATAC
GCCGGAAGGG
AATTGTTGCC
GCCATTGCTA
GGTTCCCAAC
TCCTTCGGTC
ATGGCAGCAC
GGTGAGTACT
CCGGCGTCAA
GGAAAACGTT
ATGTAACCCA
GGGTGAGCAA
TGTTGAATAC
CTCATGAGCG
ACATTTCCCC

GTCCGGTGCC
GGGCGTTCCT
ATTGGGCGAA
ATCCATCATG
CGACCACCAA
CGATCAGGAT
GCTCAAGGCG
GCCGAATATC
TGTGGCGGAC
CGGCGAATGG
CATCGCCTTC
TGACCGACCA
ATGAAAGGTT
GGGATCTCAT
ACAAATAAAG
GTTGTGGTTT
GCTAGAGCTT
CAATTCCACA
TGAGCTAACT
CGTGCCAGCT
GCTCTTCCGC
TATCAGCTCA
AGAACATGTG
CGTTTTTCCA
GGTGGCGAAA
TGCGCTCTCC
GAAGCGTGGC
GCTCCAAGCT
GTAACTATCG
CTGGTAACAG
GGCCTAACTA
TTACCTTCGG
GTGGTTTTTT
CTTTGATCTT
TGGTCATGAG
TTAAATCAAT
GTGAGGCACC
TCGTGTAGAT
CGCGAGACCC
CCGAGCGCAG
GGGAAGCTAG
CAGGCATCGT
GATCAAGGCG
CTCCGATCGT
TGCATAATTC
CAACCAAGTC
TACGGGATAA
CTTCGGGGCG
CTCGTGCACC
AAACAGGAAG
TCATACTCTT
GATACATATT
GAAAAGTGCC

CTGAATGAAC
TGCGCAGCTG
GTGCCGGGGC
GCTGATGCAA
GCGAAACATC
GATCTGGACG
CGCATGCCCG
ATGGTGGAAA
CGCTATCAGG
GCTGACCGCT
TATCGCCTTC
AGCGACGCCC
GGGCTTCGGA
GCTGGAGTTC
CAATAGCATC
GTCCAAACTC
GGCGTAATCA
CAACATACGA
CACATTAATT
GCATTAATGA
TTCCTCGCTC
CTCAAAGGCG
AGCAAAAGGC
TAGGCTCCGC
CCCGACAGGA
TGTTCCGACC
GCTTTCTCAT
GGGCTGTGTG
TCTTGAGTCC
GATTAGCAGA
CGGCTACACT
AAAAAGAGTT
TGTTTGCAAG
TTCTACGGGG
ATTATCAAAA
CTAAAGTATA
TATCTCAGCG
AACTACGATA
ACGCTCACCG
AAGTGGTCCT
AGTAAGTAGT
GGTGTCACGC
AGTTACATGA
TGTCAGAAGT
TCTTACTGTC
ATTCTGAGAA
TACCGCGCCA
AAAACTCTCA
CAACTGATCT
GCAAAATGCC
CCTTTTTCAA
TGAATGTATT
ACCTGACGTC

TGCAGGACGA
TGCTCGACGT
AGGATCTCCT
TGCGGCGGCT
GCATCGAGCG
AAGAGCATCA
ACGGCGAGGA
ATGGCCGCTT
ACATAGCGTT
TCCTCGTGCT
TTGACGAGTT
AACCTGCCAT
ATCGTTTTCC
TTCGCCCACC
ACAAATTTCA
ATCAATGTAT
TGGTCATAGC
GCCGGAAGCA
GCGTTGCGCT
ATCGGCCAAC
ACTGACTCGC
GTAATACGGT
CAGCAAAAGG
CCCCCTGACG
CTATAAAGAT
CTGCCGCTTA
AGCTCACGCT
CACGAACCCC
AACCCGGTAA
GCGAGGTATG
AGAAGAACAG
GGTAGCTCTT
CAGCAGATTA
TCTGACGCTC
AGGATCTTCA
TATGAGTAAA
ATCTGTCTAT
CGGGAGGGCT
GCTCCAGATT
GCAACTTTAT
TCGCCAGTTA
TCGTCGTTTG
TCCCCCATGT
AAGTTGGCCG
ATGCCATCCG
TAGTGTATGC
CATAGCAGAA
AGGATCTTAC
TCAGCATCTT
GCAAAAAAGG
TATTATTGAA
TAGAAAAATA

AS Overexpression: Experimental plasmids (2 μg/well of a 6 well dish) were
transiently transfected into BAEC using either Lipofectamine 2000 (Invitrogen) or
Fugene (Roche) in serum free Opti-MEM I (Invitrogen) as indicated. After 4 h, media
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was replaced with Dulbecco’s modified Eagle’s medium containing 10% serum and cells
were cultured for 6 or 24 h.

Western Blot: For western blots, equal amounts of protein (measured via BCA
assay, Pierce) from clarified lysates were separated on polyacrylamide gels (BioRad),
transferred onto polyvinylidene fluoride membranes (PVDF, Millipore) and blotted with
indicated antibodies [AS, eNOS, phospho-eNOS (S1177) (BD Biosciences)]. Where
appropriate, GAPDH (Novus Biologicals) was used as a loading control.

RNA Isolation and Real Time PCR: Total RNA was isolated using Tri Reagent
following the manufacturer’s instructions (Sigma). RNA was treated with DNase
(Ambion DNA-free). Two μg of RNA was reverse transcribed using the High Capacity
cDNA Reverse Transcription Kit per the manufacturer’s instructions (Applied
Biosystems). A 20 μl reaction was prepared with 10 μl 2X reaction mix (10X RT buffer,
dNTP’s, 10X RT random primers, 10 X MultiScribe Reverse Transcriptase, RNase
inhibitor and nuclease-free water) and 10 μl RNA. The following thermal cycler
parameters were utilized for the reverse transcription: 25°C for 10 min, 37°C for 120
min, 85°C for 5 sec and hold at 4°C. Real time quantitative PCR was performed using the
AS specific primers ASL200 and ASR352 utilizing a taq-man probe and with the eNOS
specific primers eNOSL1075 and eNOSR1226 utilizing SYBR green as described
previously by our laboratory [6, 7]. Results were normalized to GAPDH utilizing the
primers GAPDHL351 and GAPDHR508. Primer sequences are below:
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Table 2: Primers Used for Real Time PCR.
ASL200
ASR352
eNOSL1075
eNOSR1226
GAPDHL351
GAPDHR508

5’-TCA
5’-ACA
5’-TAC
5’-AGC
5’-CAT
5’-TGA

GCA
CAT
ATG
ACA
GTT
TGG

AGG
ACT
AGC
GCC
TGT
CGT

AGT
TGG
ACG
AGG
GAT
GGA

TTG
CTC
GAG
TTG
GGG
CAG

TGG
CTT
ATT
ATC
CGT
TGG

AGG AGT-3’
CTC GCT-3’
GG-3’
TC-3’
GAA CCA-3’
TCA TAA-3’

Luciferase Vector Construction: For the luciferase vector, the 189 and 3075 base
pair (bp) regions of the AS promoter were constructed as described previously [6, 8].
Briefly, luciferase reporter constructs were designed to include the AS promoter and 5’UTR up to the AUG start codon cloned upstream of the luciferase gene. The left primers
ASL189 (5’-GCACTCGAGATCTGCAGGTGGCTGTGAA) and ASL-3075 (5’GTACCTCCACTGAAATTGAA) and were combined with ASRluc, (5’ATAGAATGGCGCCGGGCGTTTCTTTATGTTTTTGGCGTCTTCCATCGTGACGT
GACCAGCGGC) to amplify the AS promoter with an XhoI site on the 5’ end and an
NcoI site on the 3’ end which were used to clone into the vector pGL3Basic (Promega).
This strategy took advantage of an NcoI site within the luciferase gene, close to the start
codon, to allow for the AS 5’-UTR to be cloned adjacent to the start codon.

Luciferase Assays: BAEC were cultured as described above and plated in a 24
well plate prior to transfection. Experimental plasmids (200 ng each) and renilla control
plasmid pRL-TK (50 ng) were transiently transfected into BAEC using Transit-LT1
(Mirus) in serum free media. After 4 hours liposomes were removed and incubation
continued for 24 hours. Cells were treated with insulin (10 nM, 2 hours). Cells were lysed
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using passive lysis buffer (Promega). Ten μl lysate was assayed for luciferase and renilla
activity using a Dual-Luciferase Reporter Assay System (Promega) according to the
manufacturer’s instructions. Luciferase and renilla activity were measured as relative
light units (RLUs) using a luminometer (Turner Designs). All results were normalized to
renilla expression.

AS Promoter Analysis: The AS promoter elements that are identified in the
discussion were found by doing a promoter search with 2 KB of the AS promoter. The
promoter sequence for human AS mRNA with accession number NM_000050 was found
utilizing the Transcriptional Regulatory Element Database (TRED)
(http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?process=home). The promoter sequence was
then analyzed utilizing the Transcription Element Search System (TESS) database
(http://www.cbil.upenn.edu/cgi-bin/tess/tess).

Nitric Oxide Assays: Nitric oxide released into tissue culture medium was
measured utilizing the fluorescent probe 2,3-diaminonaphthalene (DAN) as described
previously [9]. BAEC’s were serum starved overnight prior to all treatments except in the
A23187 experiments. Briefly, at the indicated time points after treatment with insulin,
A23187 (calcium ionophore), ionomycin (calcium ionophore), bradykinin or VEGF as
indicated, aliquots of tissue culture medium were collected. Then, freshly prepared DAN
reagent in 0.62 M HCl was added to culture supernatant, mixed immediately and
incubated for 15 minutes. The reaction was stopped with a final concentration of 2.8 M
NaOH and the samples were read on a BMG Fluostar Galaxy Spectrofluorometer
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exciting at 360 nm and emitting at 405 nm. Total protein was measured via the BCA
assay, and data are presented as pmol nitrite produced per mg protein or as fold change
over control.

To measure intracellular NO production in fixed cells, the NO-specific
fluorescent dye, 4,5-diaminofluorescein diacetate (DAF-2 DA), was utilized as described
by Montagnani et al [10]. Briefly, BAEC’s grown to confluence were loaded with DAF-2
DA (final concentration 1 µM, 20 min, 37 C) and then rinsed three times, kept in the
dark, and maintained at 37 C. Cells were treated as indicated. Fluorescence intensity was
imaged utilizing a Nikon Eclipse E1000 Fluorescence Microscope.

Statistical Analyses: Statistical analysis was conducted with a Student’s T-test of
at least 3 independent experiments. Data is presented as the average +/- the standard error
of the mean.

Results

AS Overexpression Enhances Endothelial NO Production: We hypothesized that
since AS is an important mediator of the ability of eNOS to produce NO, its
overexpression would enhance basal NO production. As seen in Figure 4A, transient
overexpression of AS utilizing constant amounts of AS plasmid with increasing amounts
of transfection reagent led to the generation of BAEC’s that expressed increasing
amounts of AS. This led to enhanced production of NO that reached a plateau at the mid71

range of AS overexpression, likely due to the inability of eNOS to process the excess
substrate without any additional stimulation of its activity. In a similar experiment, the
empty vector was also transfected with constant plasmid DNA and increasing amounts of
transfection reagent (Figure 4B). The results confirmed that it is the overexpression of AS
per se that leads to the increase in NO production. These experiments were carried out
after 24 hours of AS overexpression and significant cell loss was visually noted. To
determine whether the cell loss was due to some condition associated with
overexpression or to the enhanced NO production, the experiment was repeated but the
NO measurement was conducted after only 6 hours of AS overexpression since no
significant cell loss was noted at that time point. As shown in Figure 4C, NO production
was enhanced at the 6 hour time point and this corresponded with a small but detectable
overexpression of AS. This suggested that the cell loss was caused by the AS-mediated
increase in NO production. Figure 4D demonstrates that AS overexpression does not
have a consistent effect eNOS expression which suggests the effects on NO production
are directly associated with the overexpression of AS.
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Figure 4: AS Overexpression Enhances Nitric Oxide Production. (A) BAEC were serum
starved overnight then transfected with 2 μg AS plasmid DNA with increasing amounts of
Fugene transfection reagent (4, 5, 6, and 8 μl which correspond to AS0, AS1, AS2, AS3 and
AS4, respectively). Graph demonstrates a nitric oxide assay with data presented as fold NO
produced compared to control. Blot demonstrates expression levels of AS that correspond to
the NO values. * p < 0.007 (n = 3). (B) Nitric oxide assay of BAEC overexpressing AS or an
empty vector conducted as in A, except Fugene amounts were 3, 4, 5, 6, 7 and 8 µl and this
time the empty vector was transfected with all conditions. (F3:D2 = 3 μl Fugene and 2 μg
plasmid DNA, etc.). Data is presented as pmol nitrite/mg protein (n = 1). (C) NO assay in cells
transiently transfected with the AS expression vector for 6 hours. This time, Lipofectamine
2000 was the transfection reagent used. Graph demonstrates a nitric oxide assay with data
presented as fold NO produced as compared to control. Blot demonstrates expression levels of
AS that correspond to the NO values (n = 2). (D) Representative blot demonstrating the lack of
effect of AS expression on eNOS expression (n = 2).
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AS Expression and Function are Enhanced by Insulin: Insulin is known to
enhance NO production and is a key mediator of vascular health. Part of its
atheroprotective properties stem from direct effects on eNOS expression. We
hypothesized that AS expression would also be enhanced by insulin. To test this, time
course experiments were carried out and it was determined that insulin enhances AS
expression most consistently after 2-4 hours of treatment (Figure 5A). We then conducted
dose response experiments to test the impact of 1-1000 nM insulin (2 hours) on AS and
eNOS expression. Insulin enhanced AS and eNOS expression coordinately. The highest
expression was seen at the 100 nM dose, but 10 nM still led to a significant increase in
expression (Figure 5 B & C). Additional experiments were conducted with the 2 hour
time and 10 nM dose and the effects of insulin on AS expression were confirmed (Figure
5 D & E).
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Figure 5: Insulin Increases AS and eNOS Protein Expression. (A) BAEC were serum starved
ON and cells were treated with insulin (100 nM) for the indicated times (n = 3). (B) BAEC were
serum starved overnight then treated with insulin (1-1000 nM) for 2 hours. Representative western
blot demonstrating expression of AS and eNOS. GAPDH was used as a loading control. Data is
represented as fold change over control. (C). Densitometry of 2 independent experiments
normalized to GAPDH. (D) Representative blot demonstrating expression of AS and eNOS in
response to 10 nM insulin treatment for 2 hours. (E) Densitometry of C normalized to GAPDH

I6h

I4h

I2h

I1h

A

I 30 min

Control

demonstrating fold change over control (n = 5). * p < 0.004

AS
GAPDH

B
Insulin
AS
eNOS
GAPDH

76

C

4

AS

3.5

eNOS

Relative Expression

3
2.5
2
1.5
1
0.5
0

D

Insulin
1nM

Insulin
10nM

Insulin

Control

Control

AS
eNOS
GAPDH

E

3

Relative Expression

2.5
2

Control

*

Ins 10nM

*

1.5
1
0.5
0
AS

eNOS

77

Insulin
100nM

Insulin
1000nM

To determine whether the increase in AS protein expression was related to an
increase in mRNA, real time PCR experiments were carried out. The data demonstrated
that insulin also increases AS mRNA (Figure 6A). A similar trend was noted for insulin
effects on eNOS mRNA. (Figure 6B).

Figure 6: Insulin Increases AS and eNOS mRNA Expression. BAEC were serum starved
overnight then treated with insulin (10 nM) for 2 hours. (A) Real time PCR results demonstrating
AS in control (gray bar) versus insulin treated cells (black bar). * p < 0.02 (n = 4). (B) Real time
PCR demonstrating increase in eNOS expression with insulin treatment. (n = 2)
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To determine whether insulin mediates the expression of AS by enhancing
activity at specific AS promoter regions, we tested the effect of insulin on a proximal
promoter construct (189 bp) versus a full length promoter construct (3075 bp). Luciferase
assay data suggested that there may be distal AS promoter elements regulated by insulin
(Figure 7).

Figure 7: Insulin Enhances AS Promoter Activity at a Distal Element. BAEC were
serum starved overnight then treated with insulin (10 nM) for 2 hours. Luciferase assay
results comparing 189 versus 3075 base pair promoter constructs. Gray bars represent
vehicle treated cells and black bars represent insulin treated cells. Data is presented as
relative luciferase units normalized to renilla expression. (n = 1)
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Insulin is known to enhance NO production. To assess whether insulin was
leading to an increase in NO production in our system and to correlate increased AS
expression to a functional enhancement of the citrulline-NO cycle, we utilized two
methods. First, we treated the cells with insulin, bradykinin, A23187 (calcium ionophore)
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or a combination of treatments and measured NO released into the medium. Although
this assay was not sensitive enough to reliably measure the effect of insulin alone, we
were able to detect an increase with bradykinin that was enhanced by insulin (Figure 8A).
Insulin also demonstrated the ability to enhance NO production above what the calcium
ionophore A23187 can do alone (Figure 8B). We then utilized a probe that can measure
intracellular NO levels in fixed cells. With this assay, we did see an increase in NO
production with insulin treatment alone as evidenced by a visually determined increase in
green fluorescence (Figure 8C). As expected, this increase was less than what was seen
with the calcium ionophore ionomycin.
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Figure 8: Insulin Enhances Stimulated and Basal NO Production. (A) BAEC were
serum starved overnight then treated with insulin (100 nM), bradykinin (10 µM) or both
for 4 hours. NO assay was conducted by measuring nitrite released into the medium
before and after treatment (n = 3). (B) BAEC were treated with insulin (100 nM),
A23187 (1 μM) or both for 4 hours. NO assay was conducted as in A (n = 1). (C) BAEC
were serum starved overnight then loaded with 1.0 μM DAF2-DA for 20 minutes. Cells
were then treated with insulin (100 nM) or ionomycin (2 μM) for 10 minutes. Cells were
fixed and imaged utilizing fluorescent microscopy (ex 480 nM; em 510 nM).
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VEGF Regulates AS Expression and Enhances Endothelial NO Production:
VEGF is an important mediator of endothelial function. We tested the hypothesis that
part of the mechanism of VEGF-mediated vascular protection is associated with an
increase in AS expression. First, we measured the time dependency of NO production in
response to VEGF. As seen in Figure 9A, after 10 minutes of VEGF treatment, there was
a statistically significant increase in NO production over untreated cells that continued to
increase up to our final time point of 2 hours. Then, western blot analyses were
conducted. The results demonstrated that VEGF increases AS and eNOS expression
within 2 hours of treatment (Figure 9B). Importantly, as demonstrated and discussed
further in Chapter Three, AS activity is required for maximum effects of VEGF on NO
production (Figure 16, Page 122).
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Figure 9: VEGF Increases Endothelial Nitric Oxide Production and Upregulates AS
and eNOS Expression. (A) Nitric oxide assay measuring NO release into tissue culture
medium (pmol nitrite/mg protein) by BAEC’s treated with VEGF (100 ng/ml) from 5
minutes to 2 hours. Diamonds represent control samples and squares represent VEGF treated
samples. * p < 0.02; ** p < 0.0003 (n = 3). (B) Representative western blot of BAEC’s
treated with VEGF (100 ng/ml) for 2 hours. Blot demonstrates expression of AS and eNOS.
GAPDH was used as a loading control. (n = 2 for AS and n = 1 for eNOS)

**

10500
9450
pmol nitrite/mg protein

A

Control

8400

VEGF

7350

**

6300
5250

**

4200

*

3150
2100
1050
0
5

Control

B

10
30
T ime

AS
eNOS
GAPDH

83

VEGF

0

60

120

Ceramide Diminishes AS and eNOS Expression and Suppresses eNOS Activation:
Chronic elevations in ceramide impair vascular function and diminish eNOS expression.
Often times, ceramide mediates the pathogenic effects of TNFα on insulin signaling and
other pathways. To test whether chronic ceramide elevations impact AS and eNOS
expression, western blot analyses were conducted. When BAEC were treated with
ceramide (10 µM) for 16 or 24 hours, AS and eNOS expression was diminished in a time
dependent manner (Figure 10A). In addition, the increase in eNOS phosphorylation seen
with insulin treatment was diminished when BAEC were pre-treated with ceramide
(Figure 10B).
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Figure 10: Ceramide Diminishes AS and eNOS Expression and Suppresses eNOS
Signaling. (A) Representative western blot of BAEC’s treated with ceramide (10 μM) for
indicated times after overnight serum starvation. Blot demonstrates expression of AS and
eNOS. GAPDH was used as a loading control (n = 1). (B) Representative blot of BAEC
that were serum starved for 2.5 hours prior to pre-treatment with ceramide (cer; 10 μM)
for 5 minutes followed by insulin treatment for 30 minutes (ins; 100 nM). Blot depicts
eNOS phosphorylation (peNOS S1177) and total eNOS. GAPDH was used as a loading
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Discussion

In this Chapter, we made several important observations. First, we demonstrated
that transient overexpression of AS leads to enhanced NO production. This increase was
above the basal contribution of the endogenous citrulline-NO cycle. These findings are
supported by the work of Xie et. al [11] which demonstrates that overexpression of AS in
vascular smooth muscle cells (VSMC) increases NO production when cells are
stimulated with lipopolysaccharide (LPS) and interferon gamma (IFNγ). Under those
conditions, the effects they noted were related to inducible nitric oxide synthase (iNOS)
and not eNOS. Even with stimulation, they saw about a 3-4 fold increase in NO
production in stably transfected VSMC. In our case, we were monitoring basal effects
and noted ~2 fold increase in NO production when AS was transiently overexpressed
compared to untransfected or empty vector transfected controls. Our results implied that
the effects we saw involved the AS-eNOS axis and not the AS-iNOS axis since a
stimulant was not provided to induce iNOS. The fact that we saw the effects by 6 hours
also suggested that iNOS is not involved since such as short time period of time without
any stimulation would preclude iNOS induction. Further, the expression of eNOS was not
consistently affected by AS overexpression nor did any small variations in eNOS
expression correlate with the increases in NO production. This suggests the increase in
NO production was a direct result of AS overexpression.

Furthermore, our studies support our previous work that demonstrates a
significant loss of NO production and endothelial cell viability when AS is knocked
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down with siRNA [12]. In those studies, reducing AS expression was directly linked to
reduced expression of Bcl-2 and increased caspase activity. Thus, the cell loss was
attributed to apoptosis. Further, it was demonstrated that apoptosis could be rescued with
an NO donor. Therefore, apoptosis was mediated by the diminished production of NO as
a direct consequence of decreased AS expression and activity. The work presented here
alludes to the converse scenario. An increase in AS expression led to a significant
increase in NO production, despite saturating levels of NO in the medium and without a
change in eNOS activity or expression. In addition, the increase in NO production caused
a significant cell loss, likely due to apoptosis. The fact that alterations of AS expression
by overexpression or via treatment with various stimulants was associated with enhanced
nitric oxide production also supports the body of evidence that demonstrates that AS is
rate limiting for NO production. In addition, it is known that the recycling of arginine
from citrulline is the preferred source of substrate for eNOS-mediated NO production,
despite available transport systems and excess intracellular arginine levels [13, 14].
Therefore, our work also supports the mounting evidence that in endothelial cells, the
citrulline-NO cycle is a tightly coupled system that generates a dedicated source of
arginine for eNOS-mediated NO production [15, 16].

A second set of findings that are collectively important to note is that physiologic
(insulin, VEGF) or pathogenic (ceramide) biological molecules affect AS expression
coordinately with eNOS. This coordinate regulation is essential for the appropriate level
of NO to be produced. Since AS is rate limiting for the production of NO by eNOS [11,
13, 14, 17], it is logical that its expression and function must be controlled in a manner
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consistent with the substrate needs of eNOS. A possible exception to this would be in
cases where NO levels have gone beyond physiological concentrations, which might lead
to a decrease in AS function in order for NO production to be reduced. Although
ultimately, this would lead to a coordinate downregulation of eNOS function, the initial
response might be one of discoordinate regulation.

Several important biological treatments were explored in this Chapter and each
one has important implications. We noted modest, yet significant increases in AS and
eNOS expression in response to insulin. This work is supported by the work of
Oyadomari et al. [18] who demonstrated that in rats with type 1 diabetes due to
streptozotocin (STZ) treatment, AS and eNOS expression in whole aorta is enhanced
initially and then decreases with longer duration of diabetes. The regulation is coordinate,
much like what we see in cell culture models, and suggests the initial increase is a
compensatory response while the end result is dysregulation of the citrulline-NO cycle.
There is some controversy related to whether eNOS expression is diminished in animal
models of diabetes or vascular disease [19]. This is likely due to differences in the animal
models themselves and the treatment protocols utilized. In addition, mechanisms other
than expression levels may underlie some forms of vascular disorders. Despite the
controversy, it is clear that eNOS dysfunction is a hallmark of vascular disorders. Our
work certainly demonstrates that AS is also a very important player and more research is
needed to delineate the role of AS in diabetic animals and humans.
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The role of insulin in regulating AS expression may be due to the direct effects of
insulin in regulating the AS promoter. Although the results presented regarding enhanced
AS promoter activity at a distal site in response to insulin are preliminary, there are
several AS promoter elements that are known to be insulin responsive such as SP-1, USF
and HIF1α [20-22]. Therefore, it is possible that there are several regions in the AS
promoter that might regulate the insulin-mediated upregulation of AS mRNA and protein
seen in our studies. In addition, we saw similar increases in eNOS expression and it has
already been demonstrated that eNOS has at least two insulin responsive elements: SP-1
and AP-1 [23].

Our work suggests that the functional consequence of insulin up-regulation of AS
expression is an increase in NO production. The increases we noted with insulin were
generally modest and were most prominent when other stimulants, such as bradykinin,
were used. This leads to our hypothesis that insulin is not necessarily a “stimulant” for
NO production. Rather, we believe that the function of normal insulin signaling is to
allow for NO stimulating pathways to be basally activated and ready for additional
stimulation by vasodilators. Without insulin signaling, the optimal function of stimulants
would be blunted. One key deficiency in our understanding of the upregulation of AS
expression by insulin and the concomitant increase in NO production is whether these
effects are direct or simply due to known effects on eNOS. To fill in this gap, future work
is needed to determine whether insulin increases AS enzymatic activity.
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Despite some of the gaps in our understanding of how insulin directly affects AS
activity, our work with VEGF, another important mediator of vascular health with direct
effects on the endothelium [24], supports the hypothesis that AS plays a direct role. Like
insulin, we found that VEGF leads to a coordinate upregulation of AS and eNOS protein
expression with a concomitant and significant increase in NO production. Our first hint
that AS activity is directly involved comes from experiments that demonstrate that the
maximal increase in VEGF-mediated NO production is blunted by a specific AS
inhibitor. This data is presented and further discussed in Chapter Three, Figure 16, Page
122. Whether the effect of VEGF on AS protein expression is due to an increase on
mRNA expression or stability is yet to be determined. However, there is some evidence
in the literature that VEGF regulates the expression of some genes such as tissue factor
and metallothionein via promoter activation [25]. It is possible there is a similar
mechanism in place for AS. Another important finding from this work is the novel link
between AS and angiogenic pathways. Although the function of AS in arginine
regeneration has been associated with tumor survival and angiogenesis [26], a link
between AS activity per se and angiogenic factors has not previously been described.
Additionally, the AS-VEGF axis has not been defined in endothelium.

Our finding that chronic ceramide treatment diminishes AS and eNOS expression
demonstrated that pathogenic environments lead to a dysfunction of the citrulline-NO
cycle as a whole and not just eNOS. The effects of ceramide on AS expression have not
been studied and most studies related to eNOS have determined that ceramide causes
inhibition of eNOS activation, not expression. In fact, the only study that assessed eNOS
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expression in response to ceramide in human endothelial cells found that although NO
production was diminished due to elevations in ROS, eNOS expression was enhanced in
an ineffective compensatory mechanism when treated for 10 or 16 hours [27]. In our
study, both AS and eNOS expression were diminished in a time dependent manner at 16
or 24 hours when using the same dose used by the previous study [27]. The discordance
of results may be due to the cell type used or the differences in ceramide preparations
from different manufacturers. More likely, the issue is related to the fact that ceramide
can have both beneficial and inhibitory effects [28] and this might explain the disparity.
Overall, this implies that multiple mechanisms are disrupted in disease states that
ultimately lead to the inability of the endothelium to produce adequate amounts of NO
with downstream consequences such as atherosclerosis or myocardial infarctions.

The pathways we have studied related to the regulation of AS expression: TNFα,
PPARγ agonists, insulin, VEGF and ceramide are relevant not just individually but also
due to the fact that there is a great deal of cross talk between these pathways. One
example is that ceramide mediates the pathogenic effects of chronic elevations of TNFα
by inhibiting insulin actions [29]. Also, one mechanism by which PPAR agonists
improve insulin sensitivity and improve NO function is by reducing the damaging effects
of TNFα [30]. VEGF signaling, NO production and angiogenesis are all impaired in
insulin resistant conditions [31-34]. These associations and the pivotal role of AS
function in all these pathways improve our global understanding of vascular biology.
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Another important observation about AS expression is that in tissues where its
function is in the urea cycle, such as liver, expression is very high [35]. On the other
hand, in tissues where AS functions with iNOS to produce NO (such as vascular smooth
muscle and glial cells), its expression tends to be very low or even undetectable basally
but is highly inducible by cytokines leading to iNOS induction and high output NO
production [36-38]. Our findings suggest that in the endothelium, AS expression is
basally repressed and this repression is removed in response to stimuli to increase NO
output. This proposed de-repression mechanism leads to a modest change in AS
expression in response to the multiple mechanisms we have explored up to this point (~
2-3 fold). It turns out that eNOS transcriptional regulation in general also changes on the
order of about 2-3 fold [39]. Although this might seem insignificant, the modest increases
in NO associated with this change in expression can lead to pronounced changes in
vascular tone. Since in the endothelium, eNOS functions to produce constant yet
relatively low levels of NO, our model of modest changes in AS expression fits well with
this functional paradigm.

Thus far, we have found an important pattern of coordinate regulation of AS and
eNOS expression. It is important to note in this discussion that the studies led by Laura
Pendleton in our lab have uncovered a unique translational regulatory mechanism that
involves the expression of different lengths of AS message due to increasing lengths of
the 5’ UTR [40]. The longer forms of message are endothelium specific and encode for a
unique, small protein called Argininosuccinate Synthase Regulatory Protein (ARP). This
protein regulates AS translation in trans since it suppresses the translation of the short
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form of message that actually encodes for full length AS [7]. So far, this mechanism is
unique to AS and seems to allow regulation of tissue-specific AS function. Thus, this is
one example of regulation of AS that may be completely distinct from eNOS regulation.
On the other hand, this may turn out to be a novel global paradigm that allows for the
vast complexity of human biology despite a relatively small genome.

Overall, the studies presented in this Chapter further define the central role of AS
for NO production and vascular health by uncovering several mechanisms that regulate
its expression and lead to concomitant changes in endothelial NO production. These
findings are significant since vascular disorders are sometimes characterized by reduced
levels of eNOS expression [41-45]. Thus, we predict an important role of AS expression
in health and disease.
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CHAPTER TWO
ARGININOSUCCINATE SYNTHASE PHOSPHORYLATION

Overview

Argininosuccinate synthase (AS) is essential for endothelial nitric oxide (NO)
production and its regulation in this capacity has been studied primarily at the
transcriptional level. The dynamics of vascular function suggest that an acute regulation
system may mediate AS function. This premise underlies our hypothesis that AS is
phosphorylated in vascular endothelium. Since serine/threonine phosphorylation has been
identified as the key mechanism mediating acute nitric oxide production, we focused on
these modifications. We began our studies by conducting a bioinformatic analysis of the
AS protein sequence utilizing 4 different databases. We identified 31 putative sites of AS
serine/threonine phosphorylation that were positive hits in at least 2 of the 4 databases.
Immunoprecipitation and immobilized metal affinity chromatography demonstrated that
AS is an endogenous phosphoprotein. An in vitro kinase screen revealed that protein
kinase A (PKA) and protein kinase c alpha (PKCα), kinases that enhance NO production
via eNOS activation, phosphorylate AS. Vascular endothelial growth factor (VEGF) was
identified as a candidate pathway for regulating AS phosphorylation since it activated
PKA, PKCα and eNOS. In addition, α-methyl-DL-aspartic acid (MDLA), an AS
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inhibitor, diminished maximal VEGF-mediated NO production. Immunoprecipitation
studies suggested that VEGF enhances AS phosphorylation. We then focused our studies
on identifying specific sites of AS phosphorylation utilizing proteomics. Thus far, we
have been able to identify the following sites of AS serine/threonine phosphorylation:
T131, S134, S180, S189, S328. Analysis of the AS 3-dimensional structure revealed
important structure-function hypotheses related to the identified sites. Site directed
mutagenesis of T131, S180 and S189 to generate phospho-null (alanine substitution) and
phospho-mimetic (aspartic acid substitution) variants revealed a decrease and partial
recovery of NO production compared to wild type, respectively. In silico modeling of
phosphorylation sites utilizing the human AS crystal structure revealed that T131, S134
and S328 are the most accessible sites for modification by phosphorylation. Overall, our
data demonstrates that regulation of AS by serine/threonine phosphorylation is an
important mechanism for ensuring NO homeostasis. Our work suggests that targeting the
kinases that lead to AS phosphorylation is one avenue to normalize AS function and
offers an attractive therapeutic option for vascular disorders.

Materials and Methods

Bioinformatics: The following bioinformatic databases were utilized to identify
putative AS phosphorylation sites and kinases: NetworKIN
(http://networkin.info/search.php), Phospho-Motif
(http://www.hprd.org/PhosphoMotif_finder), NetPhosK
(http://www.cbs.dtu.dk/services/NetPhosK/) and Group Based Prediction System
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(http://bioinformatics.lcd-ustc.org/gps2/). Additionally, kinase motifs were identified by
searching for specific motifs in the AS sequence utilizing Expasy Prosite (Scan Prosite
Tool: http://www.expasy.ch/tools/scanprosite/). Multiple sequence alignments were
conducted utilizing ClustalW (http://www.ebi.ac.uk/Tools/clustalw2/index.html). The 3dimensional human AS crystal structure was generated utilizing ViewerLite software
version 5.0 (Accelrys Corporation, San Diego, California) or iSee software from the
Structural Genomics Consortium (http://www.sgc.ox.ac.uk/iSee/).

Bovine Aortic Endothelial Cell Culture: See Chapter One, Page 64
In Vivo 32P Orthophosphate Labeling: BAEC were serum starved for 4 hours in
phosphate-free DMEM. Cells were transfected with V5-His tagged AS for 24 hours (see
Chapter One, Page 64 for a full description of this vector) and then biosynthetically
labeled with [32Pi] according to the procedure of Michel et al [1]. Labeled cells were
treated with 10 μM bradykinin for 1 hour. Cell lysates were prepared and
immunoprecipitations were carried out using antibodies directed against the V5-tag of
overexpressed AS. Following the isolation of immune complexes with protein G-agarose
(Santa Cruz), the complex was eluted by heating in SDS-PAGE sample buffer. The
samples were fractionated via SDS-PAGE (4-20% gradient gels; Bio-Rad). After drying
the gel, detection of phosphorylated AS was via Phosphor Imaging (GE Healthcare).

Immunoprecipitation and Western Blot: To determine whether AS is an
endogenous phosphoprotein, immunoprecipitations (IP) were carried out utilizing a
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phospho-serine/threonine antibody (BD Biosciences) and an AS antibody (Everest
Biotech). To assess regulation of AS phosphorylation by VEGF, IP were carried out
utilizing an AS antibody (Everest Biotech). After serum starvation overnight, complete
medium with serum was replenished for 2 hours to restore maximal basal
phosphorylation levels or cells were treated with VEGF (100 ng/ml) as indicated in figure
legends. BAEC lysates were prepared from 150 mm dishes by adding 1 ml NP-40 buffer
(50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1% NP-40) plus protease and phosphatase
inhibitors (Calbiochem and Pierce, respectively) and scraping. Lysates were centrifuged
at 12,000 x g at 4°C for 10 minutes. Equal amount of total protein (measured by BCA
assay, Pierce) from clarified lysates was incubated with 200 µl Dynabeads protein G
(Invitrogen) per ml lysate at 4°C for 1 hour for pre-clearing. Supernatants were collected
and incubated with corresponding antibodies at 4°C for 4 hours. The antibody-antigen
complex was then incubated with 200 µl/ml Dynabeads Protein G for 1 hour at 4°C. IP’s
with same species normal IgG antibodies (Santa Cruz) were conducted in parallel as
negative controls. Whole cell lysate (WCL) was utilized as a positive control for antibody
reactivity. For western blotting methods, refer to Chapter One, Page 68. Membranes were
blotted with indicated antibodies [eNOS, phospho-eNOS (S1177) (BD Biosciences);
PKA, phospho-PKA (T497), phospho-PKA substrate, phospho-PKC substrate, phosphoserine/threonine-phenylalanine (Cell Signaling Technologies); phospho-serine
(Millipore)]. Where appropriate, GAPDH (Novus Biologicals) was used as a loading
control.
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Affinity Chromatography: Two different methods were utilized to separate
phosphorylated and non-phosphorylated protein. First, the Phosphoprotein Enrichment
Kit from Pierce was utilized. Procedures were conducted according to supplied
instructions. In brief, cells were washed in HEPES buffered saline and lysed in included
lysis buffer + 0.25% CHAPS and protease/phosphatase inhibitors (HALT Protease and
Phosphatase inhibitor cocktails, Pierce). An equal amount of protein (measured with the
Coomassie Plus Protein Assay; Pierce) diluted to 0.5 mg/ml was placed in supplied
columns and incubated on a platform rocker for 30 minutes at 4°C. The flow through was
collected and after washing, phosphoproteins were eluted with supplied elution buffer.
Flow through and eluted fractions were concentrated using iCON Concentrators (Pierce).
Total protein was measured and western blots were conducted as above. The presence of
AS in the phosphoprotein fraction was monitored using a total AS antibody (BD
Biosciences). To demonstrate effectiveness of separation and enrichment of
phosphoproteins, membranes were probed with [phospho-Akt (S473) (Cell Signaling
Technologies)]. Additionally, cytochrome C (Cell Signaling Technologies), a nonphosphorylated protein, was used as a negative control. For the λ-phosphatase
experiments, once cell lysates were collected, cells were treated 700 μg of λ-phosphatase
per 100 μg protein for 20 minutes at 37°C. The IMAC procedure then was continued as
above.

The second method involved the Qiagen PhosphoProtein Purification Kit.
Procedures were according to supplied directions. In brief, after collecting cells by
trypsinization and washing cell pellet in HEPES buffered saline, cellular proteins were
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extracted in lysis buffer containing 0.25% (w/v) CHAPS, protease/phosphatase inhibitors,
and benzonase for 30 min at 4°C and centrifuged at 10,000g at 4°C for 30 min to remove
insoluble material. Total protein was diluted to a concentration of 0.1 mg/ml in a total of
25 ml of lysis buffer and was applied to a lysis buffer-equilibrated PhosphoProtein
purification column at room temperature. The column was washed with lysis buffer and
the phosphoproteins were eluted with 2 ml of PhosphoProtein Elution Buffer. The yield
of phosphorylated protein was determined by the BCA assay. The flow-through samples
were passed through two additional columns to ensure complete removal of
phosphoproteins from the sample. The eluted and flow-through fractions were then
concentrated by ultrafiltration in a 10-kDa cutoff Amicon Ultra column (Millipore
Corporation) and equal amount of protein from each sample was subjected to SDSPAGE. The presence of AS in the phosphoprotein fraction was monitored using a total
AS antibody (BD Biosciences). To demonstrate effectiveness of separation and
enrichment of phosphoproteins, membranes were probed with phospho-eNOS (S1177)
(BD Biosciences). α-tubulin was utilized as a loading control.

Purification of Bovine Argininosuccinate Synthase: Bovine AS (NP_776317)
was subcloned into the pET-28(c)+ vector (Novagen) and expressed in E. coli. The
protein was subsequently purified via the fused His tag by affinity chromatography
utilizing Ni-NTA His-bind resin per the manufacturer’s instructions (Novagen).
Successful purification was verified via SDS-PAGE. Purity was ~90% as determined by
densitometry as shown below:
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Figure 11: SDS-PAGE Demonstrating AS purification

AS

In Vitro Kinase Screen: Purified AS was utilized to run in vitro kinase reactions
according to the manufacturer’s instructions (SignalChem, Vancouver, BC). Kinases
were selected by conducting a bioinformatic search for putative AS kinases and then
choosing a subset of those kinases for the screen based on their known role in regulating
NO production. The following kinases were screened: AMP-activated protein kinase
(AMPK; subunits A1/B1/G1 and A1/B1/G2), casein kinase II (CKII; subtype α1),
glycogen synthase kinase 3 beta (GSK3β), protein kinase A (PKA- catalytic unit cα),
protein kinase C alpha (PKCα) and protein kinase G (PKG- subtype 1). In brief, reactions
contained the following components: active protein kinase, 10X reaction buffer, protein
kinase activator, 33P-ATP and 5-10 µg recombinant, His-tag purified AS. A positive
control to test for kinase activity was carried out with the appropriate peptide substrate
and a blank reaction was carried out with all assay components except substrate. The
assays were initiated by the addition of 33P-ATP and the reaction mixtures were
incubated at 30°C for 45 minutes. The assays were terminated by spotting the reaction
mixture onto a phosphocellulose P81 plate. After 3 15-minute washes in 1% phosphoric
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acid, the radioactivity on the P81 plates was counted via scintillation counting. For
imaging, in vitro kinase reactions were carried out essentially as above except they were
terminated upon addition of SDS-PAGE sample buffer. Reactions were fractionated on
10% SDS-PAGE gels (BioRad) and exposed to film. For the dose response experiments,
the reactions were carried out as above, with the exception that AS protein (substrate)
concentration was varied from 2.5-12.5 µg. To determine if pre-phosphorylation of AS
was required for CKII or GSK3β to phosphorylate AS, an in vitro phosphorylation
reaction was carried out with AS and PKC using cold ATP followed by the in vitro
reaction with CKII or GSK3β utilizing radiolabeled ATP.

Nitric Oxide Assays: See Chapter 1, Page 70 for the methodology employed to
measure NO released into the medium utilizing the DAN assay. For the VEGF
experiments, cells were treated with VEGF +/- an AS inhibitor, α-methyl-DL-aspartic
acid (MDLA; Sigma) as indicated. The experiments with wild type and mutant AS were
carried out by overexpressing AS (see below).

Generation of AS Variants and Transient Transfections: The AS expression
vector, fully described in Chapter One, Page 64, was utilized to mutate identified
phosphorylation sites to determine their role in NO production utilizing procedures
routinely conducted by our laboratory [2]. Briefly, phosphorylated residues were mutated
to alanines to mimic a non-phosphorylated state and to aspartic acid to mimic a
constitutively phosphorylated state following the “Quick Change” protocol utilizing Pfu
Turbo DNA Polymerase (Stratagene). We compared the NO production of wild type
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versus phospho-mutant AS in BAEC’s since we have demonstrated a consistent and
reproducible increase in NO production when wild type AS is overexpressed in BAEC’s
(See Chapter One, Figure 4, Page 73).

Primers were designed according to the guidelines from Strategene for the
successful use of their “Quick Change” protocol. For the S180A/S189A, the S189A
variant was used as the template and the S180A primers were used to introduce the
additional mutation. All variants were verified by sequencing. The following primers
were utilized:

Table 3: Primers Used for Site Directed Mutagenesis

Variant
T131A

Wild Type Sequence
C CGG TTT GAG
CTC ACC TGC TAC
TCG CTG G

T131D
S180A

CAA GAA CCC GTG
GAG CAT GGA CGA
GAA CCT G

S180D
S189A
S189D

AGA ACC TGA TGC
ATA TCA GCT ACG
AGG CTG GAA TCC

Sense Primer
C CGG TTT GAG CTC
GCC TGC TAC TCG CTG
G
C CGG TTT GAG CTC
GAC TGC TAC TCG CTG
G
CAA GAA CCC GTG GGC
CAT GGA CGA GAA CCT
G
CAA GAA CCC GTG GGA
CAT GGA CGA GAA CCT
G
AGA ACC TGA TGC ATA
TCG CCT ACG AGG CTG
GAA TCC
GGA TTC CAG CCT CGT
AGG CGA TAT GCA TCA
GGT TCT

Antisense Primer
C CAG CGA GTA GCA
GGC GAG CTC AAA
CCG G
C CAG CGA GTA GCA
GTC GAG CTC AAA
CCG G
C AGG TTC TCG TCC
ATG GCC CAC GGG
TTC TTG
C AGG TTC TCG TCC
ATG TCC CAC GGG
TTC TTG
AGA ACC TGA TGC
ATA TCG ACT ACG
AGG CTG GAA TCC
GGA TTC CAG CCT
CGT AGT CGA TAT
GCA TCA GGT TCT

Experimental plasmids were transiently transfected into BAEC using
Lipofectamine 2000 (Invitrogen) in serum free Opti-MEM I (Invitrogen). Two μg AS
plasmid DNA was used per well of a 6-well dish or 10 μg per 100 mm dish. After 4 h, the
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medium was replaced with Dulbecco’s modified Eagle’s medium containing 10% serum
and cells were cultured for 24 h.

Purification of Overexpressed AS: Two methods were utilized to partially purify
the AS expression vector. In order to obtain sufficient material for mass spectrometry
analysis, at least 3 100-mm dishes were transfected per treatment group as described
above and lysates were pooled. Cells were treated with either 20 or 100 nM okadaic acid,
a serine/threonine phosphatase inhibitor, in an attempt to enhance phosphorylation signal
for the experiments to characterize the AS expression vector.

The first method involved immunoprecipitation of overexpressed AS with a V5
antibody. Lysates were prepared utilizing NP-40 lysis buffer (50 mM Tris HCl, pH 7.4,
150 mM NaCl, 1% NP-40) plus protease and phosphatase inhibitors (Calbiochem and
Pierce, respectively) and scraping. Clarified lysates were pre-cleared with a protein G
bead slurry (Protein G Plus Agarose, Santa Cruz) for 1 hour. Immunoprecipitation was
conducted with an antibody against the V5 tag of the AS expression construct
(Invitrogen) by incubating the pre-cleared lysate with antibody for 2 hours at 4°C. The
protein G bead slurry was added to samples and incubated overnight at 4°C. Purified AS
and associated proteins were eluted with 2X SDS-PAGE sample buffer.

The second method involved purification via the 6X-his tag of the AS expression
vector. Magnetic Ni-NTA agarose beads (Qiagen) were utilized according to the
manufacturer’s instructions. Briefly, cells were lysed in Buffer B-Tween + 1% NP-40
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(100 mM NaH2PO4, 10 mM Tris·Cl, 8 M urea and 0.05% tween, pH 8.0). Lysates were
cleared by centrifugation. Ni-NTA agarose beads were added (20 μl/ml) to the lysates
and incubated with end-over-end rotation for 2 hours at 4°C. Cells were washed in Buffer
C-Tween (same as buffer B, pH 6.3) and eluted with Buffer E-Tween (same as buffer B,
pH 4.5).

To monitor expression levels, western blots were conducted as described
previously (purified samples and whole cell lysates were compared) and membranes were
probed with an AS antibody. To assess whether the purified vector was phosphorylated,
membranes were probed with a phospho-serine antibody (Zymed). To visualize
effectiveness of purification, duplicate gels were run, coomassie stained, dried by vacuum
and photographed.

Liquid Chromatography and Tandem Mass Spectrometry: AS was transiently
overexpressed in BAEC’s. Twenty four hours after transfection, cells were deprived of
serum overnight. Cells were treated with insulin, bradykinin, insulin + bradykinin and
okadaic acid. Overexpressed AS was purified by its fused 6X-His tag using Ni-NTA
agarose magnetic beads (Qiagen) as described above. Proteins were separated by SDSPAGE to identify the AS band (51 kD). A duplicate gel was run to confirm expression of
the AS plasmid by western blot. Gel bands of interest were excised and destained. The
protein disufides were reduced with triscarboxyethylphosphine and then the cysteines
were alkylated with iodoacetamide. In-gel trypsin digestion was used for proteolysis.
The resulting peptides were extracted and concentrated prior to liquid chromatography
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coupled to tandem mass spectrometry (LC-MS/MS) analysis. Nanoflow reverse phase
liquid chromatography was used to separate the peptides by hydrophobicity (LC
Packings, Dionex, Sunnyvale, CA). Online detection was accomplished with an
electrospray linear ion trap mass spectrometer (LTQ, Thermo, San Jose, CA). Peptide
molecular weight measurements preceded ion selection, fragmentation, and fragment ion
detection in MS/MS. Tandem mass spectra were assigned to peptide sequences using
Mascot and Sequest database search algorithms. Sequence assignments were validated
by manual inspection of the data.

In-Silico Modeling of AS Three Dimensional Structure: In silico models of AS
with identified phosphorylation sites were generated by the University of South Florida
Department of Chemistry by Dr. Wayne Guida and Daniel Santiago utilizing a Molecular
Dynamics approach. Modeling was dependent on the original X-ray structure (PDB ID:
2NZ2). Substrate binding affinity was measured when sites were not phosphorylated
versus phosphorylated (comparative docking). The methodology is composed of four
phases:
I. Substrates were docked to original enzyme structure.
II. Phosphorylation models were created for each possible serine/threonine residue.
III. Low energy conformer for each phosphorylation model was identified.
IV. Substrates were docked into phosphorylation models and docking scores were
compared.
Statistical Analyses: See Chapter One, Page 71.
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Results

AS is an Endogenous Phosphoprotein: Since serine/threonine phosphorylation is a
prominent mechanism that regulates acute eNOS function, we focused on these
modifications. To assess whether endogenous AS is phosphorylated, several approaches
were taken. First, a bioinformatic search for AS serine/threonine phosphorylation
utilizing four different databases was conducted. The benefit of utilizing multiple
databases is that they each utilize slightly different approaches. For example, NetPhos 2.0
utilizes trained neural networks for predictions [3]. On the other hand, NetworKin
predicts in vivo kinase-substrate relationships by augmenting the information gained from
kinase substrate motifs with context for kinases and phosphoproteins [4]. Phospho-Motif
predictions are based on known consensus kinase motifs as well as additional motifs that
are curated from the literature [5]. Finally, Group Based Prediction System improves on
the methods of standard prediction systems by grouping kinases into hierarchical
structures and developing and approach to minimize false positives [6]. By cross
referencing results from the 4 databases, the number of false positives should be reduced.
Through these in silico experiments, 31 sites were identified that were positive hits in at
least 2 of the 4 databases (Table 4).
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Table 4: Predicted AS serine/threonine phosphorylation sites. Data was generated by
cross-referencing results from 4 different databases and choosing only sites that were
positive hits in at least 2 of 4 databases.

Position Peptide

Position Peptide

Position Peptide

2
6
17
65
80
91
92
115
119
131
174

180
189
208
210
219
242
243
246
278
284
288

301
328
341
352
365
368
376
396
410

--MSGKG
GKGSVVL
GLDTSCI
EDISKEF
IQSSALY
LLGTSLA
LGTSLAR
KYVSHGA
HGATGKG
FELSCYS
VPVTPKN

NPWSMDE
MHISYEA
GLYTKTQ
YTKTQDP
APNSPDM
GDGTTHS
DGTTHST
THSTALE
GMKSRGI
IYETPAG
PAGTILY

EAFTMDR
FWHSPEC
IAKSQER
VQVSVFK
GRESPLS
SPLSLYN
ELVSMNV
NINSLRL
NKVTAK-

To evaluate whether the in silico identification of AS phosphorylation was
occurring endogenously, immunoprecipitation of BAEC lysates was carried out with a
phospho-serine/threonine antibody followed by immunoblotting with an AS antibody. As
seen in Figure 12, AS co-immunoprecipitates when cellular proteins that are
phosphorylated at serine and/or threonine residues are enriched. Similar results were
obtained with the reverse immunoprecipitation, but in this case, the best results were
obtained when probing with a phospho-serine and a phospho-serine/threonine/tyrosine
antibody (Figure 12). In addition, in vivo 32P orthophosphate labeling was utilized to
determine if AS is phosphorylated. AS was overexpressed, labeled with 32P then treated
with bradykinin. Lysates were prepared and overexpressed AS was purified via
immunoprecipitation. As shown in Figure 12, AS is phosphorylated basally and this
increased upon bradykinin treatment.
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Figure 12: AS is an Endogenous Phosphoprotein, Part I. (A) Representative blot (n = 3)
of immunoprecipitation of BAEC lysates utilizing a phospho-serine/threonine antibody (IP
pS/T) or a same-species normal IgG (IP IgG). The membrane was probed with an AS
antibody (IB AS). WCL; whole cell lysate. (B) Representative blot (n = 3) of
immunoprecipitation of BAEC lysates utilizing an AS antibody (IP AS) or a same-species
normal IgG (IP IgG). The membrane was probed with a phospho-serine or a phosphoserine/threonine/tyrosine antibody (IB pS and IB pS/T/Y, respectively); pAS = phospho-AS.
(C) Phosphor-image demonstrating the level of

32

P incorporation in response to bradykinin

stimulation (10µM) in BAEC’s where either AS (AS-V5-His) or an empty vector were

IP IgG

IPAS

B

WCL

IP IgG

A

IP pS/T

overexpressed and immunoprecipitated (n = 1).

IgG

IB pS

pAS

IB AS

C

pAS

Bradykinin

Control

IB pS/T/Y

AS-V5-His

pAS

Empty Vector

To further validate that AS is indeed an endogenous phosphoprotein in the
endothelium, we utilized immobilized metal affinity chromatography (IMAC) to separate
and enrich phosphorylated protein from total protein. This was done with two different
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methods since the different resins utilized to bind phosphorylated proteins have affinity
for some phosphoproteins and not others [7]. With the first method, the western blot
analysis in Figure 13A demonstrated that a fraction of AS eluted from the column as a
phosphorylated protein. As a control, membranes were re-probed with a phospho-Akt
antibody. Phospho-Akt was observed in the eluted phosphoprotein fraction with a relative
absence in the flow-through fraction (Figure 13A). As a negative control, membranes
were re-probed with a cytochrome c antibody (cytochrome c is not phosphorylated) and
no cytochrome c was observed in the eluted phosphoprotein fraction (Figure 13A).

Figure 13B demonstrates the similar results that were obtained with the second
method. A fraction of AS eluted as a phospho-protein. This time, phospho-eNOS was
utilized as a positive control to demonstrate the effectiveness of the separation of
phosphoprotein from total protein (Figure 13B). In addition, these experiments were
conducted with various treatments in an attempt to monitor changes in AS
phosphorylation. There were no obvious changes in the amount of AS eluted in the
phosphoprotein fraction. Because of the high affinity of these resins for phosphorylated
proteins, it is nearly impossible to detect changes in binding to the column with a total
protein antibody since a treatment may cause a change in phosphorylation sites rather
than a net increase or decrease in phosphorylation. It became evident that this technique
could not be used to monitor changes in phosphorylated AS without having a phosphoAS antibody. This was demonstrated in subsequent experiments where dephosphorylation
reactions were carried out with λ-phosphatase prior to the IMAC experiments. While
decreases in phosphorylation were noted when using a site specific phospho-Akt
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antibody, there was little to no change in the amount of AS eluted when a total AS
antibody was used. In order for these experiments to have worked, AS needed to be
completely dephosphorylated prior to IMAC in order to see a significant change.

Finally, to make sure that the IMAC data was not an artifact, IMAC was
conducted and then AS was immunoprecipitated from the eluted phosphoprotein fraction.
As shown in Figure 13C, AS was successfully immunoprecipitated from the eluted
fraction suggesting that the signal noted with IMAC is indeed a fraction of AS that elutes
as a phosphoprotein and not simply a non-specific band at the AS molecular weight.
Taken together, the immunoprecipitation, 32P labeling and phosphoprotein affinity
chromatography strongly suggest that AS is an endogenous phosphoprotein in vascular
endothelium.
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Figure 13: AS is an Endogenous Phosphoprotein, Part II. (A) Representative blot (n = 3)
demonstrating separation of phosphorylated protein from total protein utilizing immobilized metal
affinity chromatography (IMAC). The top panel shows the membrane was probed with AS.
Phospho-Akt was utilized as a positive control and cytochrome c was used as a negative control.
(B) Representative blot of IMAC conducted as in (A) but with a different resin (n = 3). The blot
shows the level of AS, phospho-eNOS or α-tubulin in the eluted (E) or flow through (FT)
fractions in response to treatment with insulin (100 nM), okadaic acid (50 nM; OA) or H89 (n =
3). (C) Representative blot of the eluted phospho protein fraction of BAEC’s treated without
(vehicle) or with λ-phosphatase (λ-pptase) prior to IMAC conducted as in (A) (n = 2). (D)
Representative blot demonstrating IMAC conducted as in (B). The data represents AS expression
in the whole cell lysate (WCL), the eluted IMAC fraction (IMAC) or from the IMAC fraction
after immunoprecipitation with an AS antibody (IMAC + IP) in cells treated with okadaic acid
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Biological Relevance of AS Phosphorylation: In order to establish the biological
significance of AS phosphorylation, we conducted a targeted in vitro kinase screen. First,
we identified putative AS kinases utilizing four bioinformatic databases. From that list of
kinases, the following were selected for the screen due to their known role in nitric oxide
biology: AMP-activated protein kinase (AMPK), casein kinase II (CKII), glycogen
synthase kinase 3 beta (GSK3β), protein kinase A (PKA) and protein kinase C alpha
(PKCα). Akt1 was used as a negative control due to the lack of the consensus Akt
phosphorylation motif in the AS protein sequence (R-X-R-X-X-S/T). The kinase screens
were carried out with purified recombinant bovine AS and as shown in Figure 14A,
PKCα and PKA were identified as AS kinases due to their ability to phosphorylate AS in
vitro. Although there was an increase in counts above the blank reaction with AMPK and
Akt1, this was below the threshold considered significant (Figure 14A). SDS-PAGE
fractionation of in vitro kinase reaction products and visualization by film exposure
confirmed that PKCα and PKA, but not Akt1, phosphorylate AS (Figure 14B). Repeat in
vitro kinase reactions for GSK3β and CKII were carried out, but AS was pre-
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phosphorylated with PKCα. CKII and GSK still were unable to phosphorylate AS in
vitro (Figure 14C).

Figure 14: AS is Phosphorylated by PKCα and PKA. (A) In vitro kinase assays. Gray bars
represent the incubation of purified AS minus kinase (Blank). Black bars represent the incubation
of purified AS with the indicated kinase (Kinase). Kinase activity is represented as counts per
minute (CPM). * p < 0.0002; ** p < 0.00003; (n = 3 for PKC, PKA and Akt; n = 1 or 2 for
remaining kinases). (B) Representative image of in vitro kinase reactions as described in (A) but
only showing PKCα, PKA and Akt. pAS; phosphorylated AS (n = 2). (C) AS was prephosphorylated with PKC (using cold ATP) then in vitro kinase reactions were carried out with
GSK3β and CKII as in (A) (n = 1).
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To test the dose-dependence of PKCα and PKA phosphorylation of AS, in vitro
kinase reactions were conducted with a constant level of PKCα or PKA and varying AS
concentrations (2.5 µg to 12.5 µg). The results demonstrate dose-dependent
phosphorylation of AS by PKCα that plateaus at 5 µg of AS (Figure 15A). With PKA,
the level of phosphorylation was linear up to 7.5 µg AS (Figure 15B). In addition, there
are numerous PKA and PKC motifs in the AS protein sequence, and this supports the in
vitro data generated (Table 5).
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Figure 15: Dose Dependence of AS Phosphorylation. (A) In vitro kinase reactions carried
out with a constant concentration of PKCα and increasing concentrations of AS (2.5-12.5
μg). Activity is represented as corrected CPM after subtracting blank (n = 1). (B) In vitro
kinase reactions carried out with a constant concentration of PKA and increasing
concentrations of AS (2.5-12.5 μg). Activity is represented as corrected CPM after
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Table 5: Possible Sites Phosphorylated by PKA or PKCα. Data generated with
bioinformatics databases. Only sites that were positive hits in at least 2 of 4 databases are
shown.

Kinase
PKA
PKCα

Possible Sites
S2, S6, S115, T119, T174, S180, S219, S278, S352, S365,
S396, T410
S2, S6, T91, S115, T119, T174, T208, S219, T242, S352,
S365, S396, T410

To further support the biological significance of AS phosphorylation, we
considered several candidate pathways that could regulate AS phosphorylation. Insulin,
VEGF and bradykinin pathways were all tested. Preliminary data looked positive for all
three pathways since all demonstrated the ability to enhance AS phosphorylation. The
data was strongest with vascular endothelial growth factor (VEGF). Since both PKA and
PKCα have been linked to VEGF and NO production, this pathway was investigated
further. In Chapter One, Figure 9A, we demonstrated that VEGF significantly enhances
NO production starting at 10 minutes and continuing up to 2 hours. In order to assess
whether PKA, PKCα and eNOS were activated during acute stimulation of NO
production by VEGF, we measured their phosphorylation after treatment with VEGF for
10 minutes. Indeed, PKA, PKCα and eNOS had increased levels of phosphorylation in
response to VEGF, suggesting that these are key events that contributed to the enhanced
production of NO (Figure 16A).
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Although eNOS is known to be activated during VEGF stimulation to enhance
NO production, it is not known whether AS activity is also enhanced and necessary for
increased NO production during VEGF stimulation. To study this, the 2 hour time point
was used in order to clearly distinguish VEGF-stimulated NO production under ASinhibited and uninhibited conditions. BAEC’s were pre-treated for 1 hour with the AS
inhibitor α-methyl-DL-aspartic acid (MDLA, 10 mM), an aspartic acid analogue that
competitively inhibits AS [8]. The cells were then treated with VEGF (100 ng/ml) for 2
hours. As shown in Figure 16B, the VEGF-mediated increase in NO production was
substantially diminished when endothelial cells were pre-treated with MDLA. When this
experiment was repeated with a 10 minute treatment with VEGF, the AS inhibitor MDLA
essentially abolished both basal and VEGF-stimulated NO production (Figure 16C).

To determine whether the requirement for AS activity for maximal VEGFmediated NO production was related to AS phosphorylation, BAEC’s were treated with
100 ng/ml VEGF for 10 minutes. Lysates were prepared and immunoprecipitations were
carried out utilizing an AS antibody. Subsequent western blotting with phosphoserine/threonine, phospho-PKC substrate and a phospho-PKA substrate antibody revealed
that AS phosphorylation was enhanced by VEGF treatment (Figure 16D).
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Figure 16: VEGF is a Candidate Pathway for Regulating AS Phosphorylation. (A)
Representative western blot (n = 3) of BAEC treated with VEGF (100 ng/ml, 10 minutes).
Membranes were immunoblotted with phospho-PKCα (pPKCα), total PKCα, phospho-PKA
(pPKA), total PKA, phospho eNOS (peNOS), total eNOS and GAPDH (GAPDH). (B) NO
assay of cells treated with MDLA alone (pre-treated for 1 hour), VEGF alone (2 hours) or
VEGF + MDLA. *** p < 0.00005; * p < 0.05; n = 3 (C) Experiment conducted as in (B) with
the exception that treatment with VEGF was for 10 minutes (n = 1). (D) Immunoprecipitation
of cell lysates that were treated +/- VEGF (100 ng/ml, 10 min) with an AS antibody (IP AS)
or a same-species normal IgG (IP IgG) followed by probing with phospho-serine/threonine
(pS/T), phospho-PKC substrate (pPKC Substrate) and phospho-PKA substrate
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Identification of Specific Sites of AS Phosphorylation: In order to assess the best
methodology to pursue mass spectrometry identification of AS phosphorylation, two
approaches were taken to purify sufficient amounts of AS. For these experiments, we
decided to utilize overexpression. Although this scenario is somewhat artificial, the low
stoichiometry of phosphorylation prompted us to take measures to maximize the
possibility of detecting phosphorylated-AS peptides. The first purification method
involved immunoprecipitating overexpressed AS utilizing a V5 antibody to pull it down
via its V5 tag. The expression levels of AS with his method were excellent and
overexpressed AS was sufficiently purified (Figure 17A and B, respectively). In addition,
AS, but not the empty vector control demonstrated phosphorylation at serine residues
both basally and in response to okadaic acid treatment (a phosphatase inhibitor). There
was no apparent increase in phosphorylation with treatment (Figure 17A). One possible
problem with this methodology involves the fact that the heavy chain IgG (~55 kD) is
inevitably pulled down (Figure 17B). Since it is close to the overexpressed AS molecular
weight (~51 kD), IgG might interfere with the identification of AS.
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Figure 17: Overexpression and Purification of AS Utilizing Immunoprecipitation. (A)
Immunoprecipitation was utilized to purify overexpressed AS-V5-His utilizing a V5 antibody. Blot
compares samples that were treated with increasing concentrations of okadaic acid (OA) as indicated.
Left side of blot shows immunoprecipitated samples (IP V5) and right side shows whole cell lysate
(WCL) of samples expressing AS (AS-V5-His) or an empty vector. Top blot was probed with AS
antibody and both overexpressed (AS: OE) and endogenous AS (AS: E) can be detected. Bottom blot
was probed with a phospho-serine (pS) antibody. (B) Image of duplicate gel that was coomassie stained.
Red box indicates AS (51 kD). Black box indicates non-specific heavy chain IgG band (~50-55 kD).
Protein marker is indicated by arrow.

AS OE
AS E

pS

B

Protein marker

125

Oa 100 nM

Control

Empty Vector

Oa 100 nM

OA 20 nM

AS-V5-His

Control

Oa 100 nM

OA 20 nM

Empty Vector

Oa 100 nM

OA 20 nM

Control

IgG Control

Post-IP Sup

AS-V5-His

Control

A

WCL

OA 20 nM

IP V5

This prompted us to test a second method that involved utilizing Ni-NTA
magnetic beads to affinity purify overexpressed AS via its 6X-His tag. This method
allowed for excellent enrichment and purification of the overexpressed AS (Figure 18A
and B). It also allowed for a significant amount of endogenous AS to co-purify (Figure
18A). Considering the effectiveness of this method and the lack of IgG interference, it
was chosen for downstream mass spectrometry experiments. In addition, as shown in
Chapter One, Figure 4, AS overexpression leads to enhanced NO production, suggesting
that overexpressed AS functions similarly to the endogenous enzyme. Overall, this data
supports the use of the overexpression system to identify specific sites of AS
phosphorylation.
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Figure 18: Overexpression and Purification of AS Utilizing Ni-NTA. (A) Ni-NTA agarose was
utilized to purify overexpressed AS-V5-His. Blot compares samples that were treated with increasing
concentrations of okadaic acid (OA) as indicated. Left side of blot shows purified samples (NI-NTA
Purified) and right side shows whole cell lysate (WCL) of samples expressing AS (AS-V5-His) or an
empty vector. Top blot was probed with AS antibody and both overexpressed (AS: OE) and
endogenous AS (AS: E) can be detected. Bottom blot was probed with a phospho-serine (pS) antibody.
(B) Image of duplicate gel that was coomassie stained. Red box indicates AS (51 kD). Protein markers
are indicated by arrows.
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In order to identify specific sites of AS phosphorylation, AS was overexpressed
and cells were treated with okadaic acid, insulin, bradykinin, and insulin + bradykinin.
AS was purified utilizing Ni-NTA agarose magnetic beads and cellular protein was
separated utilizing SDS-PAGE. The band corresponding to overexpressed AS was
excised and prepared for liquid chromatography-tandem mass spectrometry (LC-MS/MS)
analysis. We have thus far identified the following sites of AS phosphorylation: T131,
Y133, S134, S180, S189, Y207 and S328. The sites that have been identified on several
occasions are T131, S180 and S189 while the remaining sites have not yet been
confirmed. Assessment of the cumulative data did not provide clear determination as to
whether any particular treatment enhanced phosphorylation at a specific site. We did note
that the patterns of AS phosphorylation are indeed dynamic. Attempts were made to
relatively quantitate the phosphorylation of AS +/- different treatments utilizing data
from the liquid chromatography phase to enhance peptide identification via mass
spectrometry. This data was also inconclusive. However, there were trends noted that
suggested changes in phosphorylation patterns. In addition, the peptide 131-TCYS-134
contains multiple possible modifications. Their close proximity makes it impossible to
determine which site is actually modified (i.e. T131 vs. S134). Figure 19 is an example of
the data generated via LC-MS/MS. The spectrum at the top shows that under control
conditions, T131 is not phosphorylated. The spectrum below it indicated that upon
okadaic acid treatment, T131 becomes phosphorylated. The mass to charge ratio (m/z)
difference of a peptide phosphorylated by a serine or threonine modification is ~80. The
m/z difference of 11 between the non-phosphorylated vs. phosphorylated T131 was
derived by the fact that the non-phosphorylated peptide was alkylated (m/z = 57). The
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m/z difference between the non-phosphorylated and phosphorylated peptide with a
charge of +2 was calculated as follows: (80-57)/2 = 11.
Figure 19: Identification of AS Phosphorylation Sites Utilizing Liquid ChromatographyTandem Mass Spectrometry. AS was overexpressed and cells were treated with okadaic acid (100
nM) for 30 min. After purification and SDS-PAGE, the band corresponding to overexpressed AS
was excised digested, and subjected to liquid chromatography-tandem mass spectrometry. Figure
shows mass spectra of control (top) and okadaic acid (bottom) treated samples. In the control
samples, T131 is not phosphorylated while in the okadaic acid samples, T131 is phosphorylated.

Control

Okadaic Acid
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Although AS is the focus of this work, we did identify some novel eNOS
phosphorylation sites that are worth noting. These experiments were carried out by
immunoprecipitating eNOS as described in Chapter Three, Page 166, and subjecting the
eNOS band to LC-MS/MS to identify phosphorylation sites. The novel sites of bovine
eNOS phosphorylation were: T60, T62, T389, and S485.

Since the focus of this work is serine/threonine phosphorylation, further
investigation into biological significance was conducted for only those modifications.
First, to determine the evolutionary relevance of the sites, a multiple sequence alignment
was conducted. As seen in Figure 20, T131, S134, S180, S189 and S328 are 100%
conserved among mammals with the exception that humans have a serine at position 131
while other mammals have a threonine. The sites that were completely conserved even
down to insects and E. coli were S180 and S189. The only minor substitution was a
threonine at position 189 in E. coli. Overall, the mammalian AS sequences depicted in
the figure are about 95% identical. Sequence identity then declines with the lowest being
25% for the E. coli sequence compared to human or bovine (per ClustalW analysis). With
such a low level of conservation among some of the non-mammalian species, the
persistence of phosphorylatable residues at some of the positions strongly suggests
biological importance.
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Figure 20: Multiple sequence alignment of AS Phosphorylation Sites. Panels show the peptide
containing T131 and S134 (A), S180 and S189 (B) or S328 (C). Sites are highlighted in blue.
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143
143
143
143
143
144
142
142
142
155

Human
Bovine
Rat
Mouse
Dog
Frog
Zebrafish
Fruit Fly
Yeast
E. coli

KNPWSMDENLMHISYE
KNPWSMDENLMHISYE
KSPWSMDENLMHISYE
KSPWSMDENLMHISYE
KNPWSMDENLMHISYE
KDPWSMDENIMHISYE
KAPWSMDANLMHISYE
ATPWSTDANILHISYE
AKPWSTDENQAHISYE
EKAYSTDSNMLGATHE

191
191
191
191
191
192
190
190
190
203

Human
Bovine
Rat
Mouse
Dog
Frog
Zebrafish
Fruit Fly
Yeast
E. coli

LKFAELVYTGFWHSPE
LKFAELVYTGFWHSPE
LKFAELVYTGFWHSPE
LKFAELVYTGFWHSPE
LKFAELVYTGFWHSPE
QRFAEQIYNGFWYSPE
IKFSELIYNGFWFSPE
DRMADYVYNGFWFSPE
PNYSRLIYNGFLLHPE
RQLGRLLYQGRWFDSQ

330
330
330
330
330
331
329
330
334
340
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To further elucidate the biological role of these sites, an in silico experiment was
conducted to identify putative kinases. As seen in Table 6, several important kinases were
identified as possible kinases for the identified sites including PKA, AMPK, CKII and
GSK3β. Interestingly, PKC motifs were not found at any of the AS phosphorylation sites
identified so far.

Table 6: Putative Kinases for Identified AS Serine/Threonine Phosphorylation Sites.
Data was generated based on motif searches with Prosite or via bioinformatic databases.

RESIDUE

PUTATIVE KINASES

T131

AMPK
CKI & CKII
MAPK

S134
S180

CKI
PKA
CKII
PKG
CKII
MAPK
GSK3
CKII
MAPK

S189
S328

Another methodology to explore biological significance involves utilizing the 3dimensional structure of an enzyme to assess possible structure-function relationships. As
indicated in Table 7, each of the identified AS serine/threonine phosphorylation sites is
linked to physiologically relevant pathways. T131 and S134 are located in the Nterminal, nucleotide binding domain of AS, which has been shown to be involved in
conformational change during catalysis in the E. coli enzyme. T131/S134 are also
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adjacent to cysteine 132, a site that is reversibly nitrosylated in vascular smooth muscle
and functions as a negative regulator of AS enzyme activity under conditions of
excessive NO production. S180 is in the N-terminal domain but is part of the catalytic
cleft. It is hypothesized to interact with ATP {per e-mail conversation with Dr. Jonas
Uppenberg [9]}. Interestingly, S180 is mutated in citrullinemia (S180 Æ N), a disease
characterized by diminished AS function. S189 is also in the N-terminal domain as part
of the catalytic cleft and hydrogen bonds with citrulline. S328 is located in the catalytic
domain. Additionally, it is adjacent to the AS caveolin-1 binding motif (discussed in
Chapter Three), suggesting a role in regulating the interaction between AS and caveolin.

Table 7: Hypothesized Biological Significance of AS Phosphorylation. Identified AS
serine/threonine phosphorylation sites, their hypothesized relevance based on the literature and
3D structure analysis and the number of times that each site was identified in bioinformatic
databases.

RESIDUE

HYPOTHESIZED BIOLOGICAL ROLE

DATABASE
FREQUENCY

T131/S134

Located in the nucleotide domain which is hypothesized to be
involved in conformational change upon catalysis. Near cysteine
132, a site known to be nitrosylated under conditions of excess
NO production. This site inhibits AS activity. It is possible that
the phosphorylation and nitrosylation serve as “on-off” switches
in response to cellular NO needs.
Located in the catalytic cleft and putatively binds ATP. This site
is known to be mutated in citrullinemia, suggesting that it is
important for AS activity.

3/1

S189

Also located in the catalytic cleft. Forms a hydrogen bond with
citrulline so it is important for AS activity.

2

S328

This site is located in the catalytic domain. It is in close
proximity to T131. Additionally, it is adjacent to the AS caveolin
binding motif, suggesting a role in regulating this putative
interaction.

2

S180
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Figure 21 shows the 3-dimensional structure of an AS monomer, dimer and
tetramer and illustrates its intricate complexity. The location of the identified
phosphorylation sites with respect to the 3-dimensional structure of AS is depicted in
Figure 22.
Figure 21: The AS 3-Dimensional Structure. AS monomer (A), homo-dimer (B) and
homo-tetramer (C) as illustrated by the Structural Genomics Consortium iSEE software (A)
or generated by the USF Department of Chemistry (B, C).

A

B

C
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Figure 22: Structure-Function Relationships of AS Phosphorylation Sites. (A) AS 3D structure
(monomer) with location of identified phosphorylation sites in relation to domains (modified from
Structural Genomics Consortium iSee software). The N-terminal domain is in green, the catalytic
domain is in orange, the C-terminal domain is in gray and the protruding loop that links the Nterminal and catalytic domains is in purple. (B) AS 3D structure (monomer) with location of
identified phosphorylation sites in relation to substrates (citrulline and aspartate) (modified from
ViewerLite-generated structure). Arrows point to the residues and substrates. Phosphorylated
residues are identified in ball and stick form in black. Aspartate and citrulline are in CPK form (gray
and purple, respectively).

A
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T134

B

S131

S328

Aspartate

S180
S189
Citrulline

Mechanism of AS Regulation by Phosphorylation: To understand the role of
specific AS phosphorylation sites on enzyme activity, phospho-null (S/T Æ A) and
phospho-mimetic (S/T Æ D) variants were generated for T131, S180 and S189, the 3
sites that were confirmed several times by mass spectrometry. First, the effect of alanine
mutations was tested. As shown in Figure 23A, preventing phosphorylation at any of
these sites significantly reduced the ability of endothelial cells to produce NO.
Mimicking constitutive phosphorylation at those sites yielded some recovery of NO
production, especially with the S180D variant, but NO levels did not reach those of the
wild-type enzyme (Figure 23B). A repeat experiment where the phospho-null and
phospho-mimetic variants were compared head-to-head confirmed the observations made
when the variants were tested individually (Figure 23C). Since the S180 and S189 have
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such essential catalytic functions, a double variant was created where both sites were
mutated to alanine. As shown in Figure 23D, the double mutation did not further diminish
NO production as compared to the single mutation.

Figure 23: Role of T131, S180 and S189 on Endothelial Nitric Oxide Production.
BAEC’s were transiently transfected with wild type (WT) empty vector (EV) or variants
(T131A, T131D, S180A, S180D, S189A, S189D, S180A189A). (A) Comparison of WT AS
to phospho-null alanine variants (n = 2). (B) Comparison of control (C- untransfected), EV
and WT AS to phospho-mimetic (aspartic acid) variants (n = 1). (C) Head to head
comparison of EV and WT versus phospho-null and phospho mimetic variants (n = 2). (D)
Comparison of control, empty vector and wild type AS to single and double alanine mutants
at positions 180 and 189 (n = 3). * p < 0.02; ** p < 0.007
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The work with the AS phospho-null and phospho-mimetic variants led to an
important observation. Consistently, when BAEC’s were transiently transfected with
wild-type AS, there was a high degree of cell loss that increased over time. Theoretically,
this was due to the role of AS in maintaining endothelial cell viability by maintaining
appropriate amounts of NO as demonstrated in Chapter One. The phospho-null variants
of AS never demonstrated any significant cell loss or even visible cell stress. This highly
suggested that all 3 sites have a role in AS function.

Another approach that was utilized to assess biological significance of AS
serine/threonine phosphorylation involved the use of computational modeling. Since the
human crystal structure of AS was solved recently, we now have an invaluable tool to
study structure-function relationships. The theory behind this line of experiments was that
certain amino acids may enhance or interfere with substrate binding while others might
be more accessible to modification by phosphorylation. To test these theories, all the
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identified serine or threonine phosphorylation sites [T131 (S131 in human structure),
S134, S180, S189 and S328] were modeled plus or minus the phosphate modification and
plus or minus substrates. The Molecular Dynamics method was then utilized to measure
substrate binding affinity. Serines 180 and 189 were found to flank citrulline.
Phosphorylation at either of these sites led to significantly diminished affinity for
substrates. In addition, in the tetrameric structure those sites are completely buried in the
active site (Figure 24). S131, S134 and S328 lie in close proximity in the 3-dimensional
structure (Figure 25). In the dimer, these 3 serines are partially covered by the "free" Cterminal helix that is part of the dimer-dimer interface. Although this region is partially
buried, there is surface exposure. S328 has its oxygen facing away from solvent. The
oxygen of S131 is hydrogen bonded to H327. S134 has its proton hydrogen-bonded to
the backbone carbonyl of H327 leaving its oxygen exposed to solvent and ready for
nucleophilic attack. In Figure 26, a close up view of these sites is shown that
demonstrates that S134 and S328 are more accessible than S131. S131 has its hydroxyl
group buried by the loop where S328 is located. In this figure it is also evident that S131
and S134 are in the outer portion of an alpha helix. In summary, the in silico modeling of
AS plus or minus phosphorylation at identified sites revealed that the most likely
candidates for modification by phosphorylation are S131, S134 and S328.
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Figure 24: Close Up of Human AS Active Site. Serines 180 (left) and 189 (right) are shown
in yellow . Aspartate (left) and citrulline (right) are shown in green. ATP would bind in the
empty space in the lower left quadrant of the figure.
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Figure 25: In Silico Modeling of AS Residues with Good Accessibility for Modification
by Phosphorylation. Close up of human AS structure showing S131 (bovine T131), S134
and S328. On top of the figure is the free c-terminal helix that forms the dimer-dimer
interface. This helix partially buries these sites.
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Figure 26: Close-Up View of S131, S134 and S328. Carbon residues are labeled in gold.
S134 and 328 are on the upper left and upper right. S131 is on the lower left.
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Discussion

In this Chapter we identified the first biologically significant post-translational
modification of AS in the endothelium. The majority of AS regulation has been studied at
the level of transcription/translation [10] and very little is known about the posttranslational regulation of AS. The work described in this Chapter is the first
comprehensive investigation of one post-translational mechanism for regulating AS
function.

Although there have not been any post-translational modifications of AS
identified in endothelial cells, the post-translational modification of AS was recently
noted by Hao et. al [11]. They found that AS is nitrosylated and inactivated in vascular
smooth muscle under conditions of excess NO production via iNOS, suggesting that the
activity of AS is at least partially responsible for sensing cellular NO levels and adjusting
NO output accordingly. This addition of an NO-derived nitrosyl group to the AS protein
sequence also suggests a feedback mechanism where NO levels that exceed a certain
threshold lead to a decrease in NO output. In addition, in a phospho-proteomics study
utilized to identify phosphoproteins in HeLa cells, AS was found to be phosphorylated
(S352) [12]. However, the scope of the paper was such that the biological relevance of
AS phosphorylation was not explored. In our work, the finding that AS is an endogenous
endothelial phosphoprotein was enhanced by the identification of PKA and PKCα as AS
kinases and the regulation of this phosphorylation by VEGF.
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The importance of tight control of NO production is highlighted by vascular
endothelial cells where virtually all phenotypic properties are related to NO bioactivity.
Because of this, cardiovascular risk factors often mediate their deleterious effects by
compromising these controls which leads to endothelial dysfunction. The finding that
PKA and PKCα phosphorylate AS in addition to their known phosphorylation and
activation of eNOS [13-18] suggests that during VEGF stimulation, these kinases act
coordinately on eNOS and AS via phosphorylation to enhance NO production in
endothelial cells. The specificity of the phosphorylation of AS by PKA and PKCα is
supported by the fact that Akt, an essential kinase in regulating NO production [19-22],
did not phosphorylate AS. Additionally, the substrate-dependence of the reaction and the
multiple motifs found in the AS sequence suggest that PKA and PKCα are bona fide AS
kinases.

The specific effects of PKA and PKCα on AS function are not clear. Although the
evidence at this time compels us to believe that both kinases activate AS, this may in fact
not be the case. First, we have to consider the limitations of the tools we utilized to assess
whether PKA or PKCα-mediated AS phosphorylation was indeed enhanced by VEGF.
Second, we need to be able to test the effect of each kinase on the specific activity of AS.
Finally, we need to know specifically which sites are phosphorylated by these kinases.
All this work is currently underway.

Although there is still a substantial amount of work that needs to be done to
acquire a full understanding of PKA and PKCα-mediated AS phosphorylation, the
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literature does support our data and hypotheses. So far, the story with PKA and NO
production seems fairly clear. Under many conditions (VEGF, bradykinin, shear stress),
PKA increases eNOS phosphorylation at activating sites [13-16]. Our level of
understanding of the role of PKCα (and PKC in general) in regulating NO production is
not so clear. In many instances, PKC, and PKCα specifically, decrease NO production by
a variety of mechanisms [14, 17]. One notable mechanism involves the increase of eNOS
phosphorylation during VEGF stimulation by PKC at an inactivating site thus reducing
its activity [14]. In fact, in that particular study, PKA and PKC acted reciprocally. On the
other hand, a couple of examples link PKCα to enhanced NO production. First, in vivo
studies demonstrated that overexpression of PKCα in rat femoral arteries results in an
increase in eNOS-mediated blood flow [18]. In another instance, PKCα was shown to be
important for the maintenance of vascular integrity during chronic inflammation. This
involved the activation of VEGF by decay-accelerating factor [23]. In addition, PKCα
enhances eNOS expression [24]. Therefore, it is evident that the phosphorylation of AS
by PKCα and PKA is a very significant finding that requires careful and extensive
investigation.

There were several other kinases that were not able to phosphorylate AS in vitro
in our initial studies, but which warrant continued investigation. AMPK did demonstrate
some increase in 33P ATP incorporation, but it was not found to be significant. AMPK
has an extremely important role in regulating NO production and energy metabolism [25,
26], two functions it shares with AS. For example, AMPK activates eNOS and thus
increases NO production in response to adiponectin, shear stress insulin and VEGF
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stimulation [26-29]. Also, AMPK helps to normalize some of the endothelial defects
caused by high glucose by activating eNOS through interactions with HSP90 [30].
AMPK also protects endothelial cells against high-glucose induced apoptosis [31]. Since
AS is involved in anti-apoptotic cascades in the endothelium, part of the protection by
AMPK could be mediated by AS activation. In addition, the pathways we have linked to
AS- insulin, VEGF, TNFα, ceramide and PPARγ- have also been linked to AMPK
function [28, 32-35]. We did try two different combinations of AMPK catalytic and
regulatory subunits for the in vitro kinase screens and neither gave a significant result.
There is the possibility that something present or absent in the in vitro reaction is
preventing significant phosphorylation of AS by AMPK. We do hypothesize that if
AMPK phosphorylates AS, it is likely an activating modification.

Also, CKII and GSK3β have important roles in regulating NO production but
failed to demonstrate the ability to phosphorylate AS in vitro. For example, GSK3β is a
downstream target of Akt, a major regulator of eNOS function [36, 37]. In addition,
GSK3β regulates angiogenesis in endothelial cells [38, 39]. In one study, it was
determined that GSK3β is downstream not just of Akt signaling, but also PKA and
MAPK [39]. The mechanism by which GSK3β regulates angiogenesis involves a
downregulation of matrix attachment and migration [39]. Considering the regulation of
VEGF-mediated NO production by AS activity, it is certainly possible that GSK3β
phosphorylates AS. Thus far, eNOS has not been found to be phosphorylated by GSK3β.
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In addition, CKII has been shown to phosphorylate calmodulin and this
inactivates eNOS [40]. Furthermore, CKII phosphorylates and inactivates protein
phosphatase 2A and leads to decreased SP-1 binding to the eNOS promoter and
ultimately to decreased eNOS expression [41]. CKII has not been shown to
phosphorylate eNOS. An interesting link between CKII and NO metabolism that has not
been explored is the fact that it phosphorylates PKA and HSP90 [42, 43], two important
proteins that regulate NO production.

Often times, both GSK3β and CKII require their substrates to first be
phosphorylated by another kinase before they can phosphorylated their target [44-46].
We believe that these two kinases may indeed phosphorylate AS, but only when priming
phosphorylation occurs first. We did attempt to pre-phosphorylate AS with PKCα and
then tried the in vitro kinase reactions with CKII and GSK3β. We also obtained negative
results, suggesting that another kinase needs to pre-phosphorylate AS at sites that are
specifically adjacent to the motifs recognized by CKII and GSK3β. Considering the
negative regulation of eNOS by both GSK and CKII, it is possible that these kinases may
act to diminish AS activity.

Finally, although AS was also not a good substrate for PKG in vitro, we did
identify this kinase as a possible interacting partner with AS and eNOS in BAEC’s
(discussed in Chapter Three). PKG is associated with multiple functions of the
endothelium including vasodilation, angiogenesis, improvement of vasodilation during
recovery from heart failure and the up-regulation of the mitochondrial oxidative stress
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protection system [47-53]. In addition, PKG co-localizes with eNOS in endothelial
caveolae [54], suggesting that it is part of the functional signaling microdomain necessary
for citrulline-NO cycle function. Since we have identified AS to be part of this
microdomain ([55]; See also Chapter Three), it is quite possible that PKG has direct
effects on endothelial AS function. Although most of what is known about PKG
regulation of vascular health occurs specifically in smooth muscle, PKG does
phosphorylate eNOS at S633 and S1179 [56]. Thus, there is still a possibility that our in
vitro kinase screening results are simply false negatives and that there are in fact
mechanisms of PKG regulation of AS that occur specifically in the endothelium.

The biological importance of AS phosphorylation by identification of AS kinases
is strengthened by our identification of VEGF as one pathway for post-translational
regulation of AS. Our finding that AS activity is necessary for maximal activation of NO
production by VEGF draws a clear link between AS function and the endotheliumspecific biological roles of VEGF such as angiogenesis and vasodilation [28, 52, 57-60].
The decrease seen with the data generated at the two hour time point represented a state
where continued stimulation by VEGF allowed for sufficient activation of eNOS and
possibly the utilization of compensatory mechanisms so that NO could still be produced
at levels significantly above controls. In comparison, when this experiment was
conducted at the 10 minute time point, which represented and acute scenario of AS and
eNOS activation, MDLA alone led to a dramatic reduction in basal NO production and
abolished the VEGF-mediated increase in NO production. This represents a situation
where there is insufficient time for additional compensatory mechanisms to emerge in an
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effort to restore the cell’s capability to respond to the VEGF stimulation. This also
highlights just how critical acute activation of AS is for a suitable response to simulation.

Furthermore, the implication that VEGF stimulates AS phosphorylation is
significant due to the known mechanisms by which VEGF leads to activation of eNOS
with concomitant increases in NO production [14, 52, 61, 62]. The data showing an
increase in AS phosphorylation signal with a phospho-PKA and phospho-PKC substrate
antibodies suggests that VEGF leads to the phosphorylation of AS by PKA and PKCα.
Although not shown due to difficulty in generating a clear image, it does seem that there
are several bands that are near the AS molecular weight that are phosphorylated by PKA
and PKC in response to VGEF and other treatments. Additionally, when AS is purified
via immunoprecipitation, two bands near the AS molecular weight are noted when a gel
is coomassie stained. Therefore, it is possible that there are multiple phosphorylated AS
species.

Considering that VEGF and eNOS expression and function are diminished in
diabetes and cardiovascular disorders [63, 64], the inclusion of AS in this regulatory
scheme suggests that there are multiple unexplored roles of AS in these diseases. This
work is supported by the findings of Shen et al. demonstrating that AS activity is
essential for endothelial NO production mediated by eNOS (not iNOS) and that inhibiting
its activity with MDLA diminishes maximal NO production by the calcium ionophore
A23187 [65]. This supports both the functional importance of AS for endothelial NO
production and links AS to calcium signaling, which is part of the mechanism by which
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VEGF mediates NO production [61]. Additionally, there is reciprocal regulation between
NO and VEGF designed to restore homeostasis [66] leading to the distinct possibility that
there are mechanisms that will diminish the response of AS to VEGF. Although eNOS is
critically important for the regulation of vascular NO production, our work demonstrates
that the function of the citrulline-NO cycle as a whole is essential and warrants further
study to provide a more global understanding of such an important system.

The regulation of NO production via reversible phosphorylation is exemplified
extensively by eNOS. There are at least 5 known sites of eNOS serine/threonine
phosphorylation that either activate or inactivate its function. These sites are responsive
to a variety of stimuli [67-69]. We have noted a similar mechanism for AS. Our
molecular biology studies demonstrated time and time again, that AS is phosphorylated
basally and that this changes, qualitatively or quantitatively, upon stimulation. Our mass
spectrometry analysis identified 5 sites of serine/threonine phosphorylation and 2 of
tyrosine phosphorylation. The phosphorylation at these sites was dynamic and responsive
to stimuli. One example was the enhancement of AS phosphorylation at T131 in response
to okadaic acid, a serine/threonine phosphatase inhibitor. Specifically, okadaic acid has
been shown to diminish the activation of ceramide activated protein phosphatases [70],
which suggests a link between ceramide and AS activity in addition to its effects on AS
expression demonstrated in Chapter One, Figure 10. If indeed there is a direct
relationship between ceramide and the regulation of AS on multiple levels, this would
mimic very closely what is known about ceramide and eNOS [71, 72].

151

There were significant difficulties in obtaining reproducible and reliable data
related to quantitation of AS phosphorylation due to the low stoichiometry of
phosphorylation, the labile nature of these modifications and possibly due to the methods
used to overexpress and purify AS. At times, the precise site that was actually
phosphorylated was ambiguous due to close proximity of more than one phosphorylated
site. These types of problems are common and this is precisely why these types of
projects are known to be extremely difficult to accomplish [73]. We do know, without a
doubt, that AS is indeed phosphorylated and we will continue to optimize our methods so
that characterization of the function of each relevant phosphorylation site can be
achieved. It is possible that one way to solve these issues is to assess organelle-specific
AS phosphorylation by, for example, enriching caveolar fractions. There may be distinct
areas of the cell where phosphorylation is more prominent and assessing this in whole
cell preparations may be diluting the results. This will be further discussed in Chapter
Three. Despite the limitations, our collective findings strongly suggest that AS is
regulated by a complex interplay of phosphorylation-dephosphorylation evens that
generate a cellular barcode that defines AS function.

Based on our in silico studies, it is also likely that there are several kinases that
phosphorylate AS, mediating the differential signaling necessary to maintain tight control
over endothelial NO production. Table 6 lists possible kinases that can phosphorylate AS
at indentified phosphorylation sites. Several of them have been discussed in previous
sections: PKA (S180), AMPK (T131), GSK3β (S328), and CKII (T131, S180, S189,
S328). This section will focus on some of the other kinases identified.
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Besides CKII, CKI was also found to be a putative kinase for T131 and S134.
There have not been any direct studies of CKI in the nitric oxide system. CKI and CKII
have both overlapping and distinct substrate specificities, although they each recognize a
different motif in their targets [74]. CKI does phosphorylate glycogen synthase which
implies a role in glucose metabolism [75]. Thus, a link to nitric oxide function is possible.

Mitogen activated protein kinase (MAPK) family members were identified as
additional putative kinases for T131, S189 and S328. Members of the
MAPK/extracellular signal-regulated kinase (ERK) family are known to have multiple
roles in regulating NO production. One example is an increase in eNOS expression by
angiotensin II which is mediated by MAPK [76]. In addition, MAPK activates PPARγ in
response to NO and may represent a cardioprotective mechanism [77]. In addition,
MAPK activates eNOS by increasing phosphorylation at S1177 and decreasing
phosphorylation at T495 in response to black tea polyphenols [78]. ERK is also involved
in mediating the pro-angiogenic effects of NO [79]. Thus, it is possible that at least one
MAPK family member is involved in regulating AS activity by phosphorylation. Overall,
the combination of in vitro and in silico experiments to identify AS kinases strongly
suggested that multiple kinases control the dynamic phosphorylation of AS.

Our investigation of the mechanism of AS phosphorylation by site-directed
mutagenesis suggested that T131, S180 and S189 are all important for AS function. This
data combined with the in silico modeling of the human AS crystal structure with or
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without phosphorylation at all the serine/threonine sites identified by mass spectrometry
led to additional implications. First, T131, S134 and S328 are the sites with the highest
possibility of being phosphorylated. This certainly supports the mutagenesis data with
T131 that showed significantly diminished NO production in the phospho-null variant
and partial recovery with the phospho-mimetic variant. It will be interesting to correlate
these findings, future molecular biology experiments and the information we have on
bioinformatic database frequency. This will allow us to gauge how bioinformatic
database frequency relates to true biological significance.

In addition, the decrease in AS-mediated NO production seen with S180 and
S189 is most likely due to the direct interactions of these sites with substrates [9]. If
phosphorylation can indeed occur at these sites, then the effects we saw are likely due to
alterations in substrate binding. Alternatively, even if phosphorylation does not actually
occur at those sites, the data we obtained is likely due to the fact that the alanine mutants
are missing the hydroxyl side chain of the serine and again this would alter substrate
binding and inhibit NO production. Further, although the quaternary structure of AS
suggests that these sites are not accessible for phosphorylation, it is possible that they are
phosphorylated only in the monomeric configuration. Perhaps phosphorylation of AS
monomers is a mechanism that triggers the formation of the active tetramer and this has
mechanism has not yet been defined. In addition, even seemingly inaccessible sites may
become accessible upon conformational change due to physical interactions with kinases
or proteins that can deliver kinases to substrates such as heat shock proteins.
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Finally, an intriguing possibility related to AS phosphorylation is the proximity of
T131 and S134 to the identified nitrosylaiton of AS at C132 in vascular smooth muscle
[11]. The nitrosylation of this site in endothelium and the putative cross-talk between AS
phosphorylation and nitrosylation have not been studied. Furthermore, in endothelial
cells, eNOS has been found to be basally nitrosylated (inactive) then de-nitrosylated
(active) in response to VEGF stimulation [80]. It is a possibility that a similar mechanism
regulates AS due to the important link we made between VEGF signaling and AS
function.

There are two other types of post-translational modifications that were not
addressed experimentally in this work, but are worth mentioning. First, as discussed
further in Chapter Three, acylation is an important mechanism for the subcellular
targeting of eNOS with important functional consequences [81]. An in silico search for
acylation motifs is the AS sequence suggested that these modifications do not occur in
AS. Further, it has recently been determined that eNOS that is phosphorylated at serine
1177 and thus active, is inactivated by glycosylation at this site in diabetes [82]. A global
investigation of proteins modified by O-glycosylation found that AS can be glycosylated
[83]. Thus, it is clear that the barcode of dynamic post-translational modifications of AS
including phosphorylation, nitrosylation and glycosylation illustrate an intricate
mechanism of AS regulation that defines its tissue-specific functions and highlights the
biological relevance of this enzyme.
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In summary, this Chapter has presented the first comprehensive exploration of AS
regulation by dynamic serine/threonine phosphorylation. Although deciphering and
understanding the phosphoproteome is one of the most complex tasks in proteomics [73],
the findings we have to this point have greatly increased our understanding of AS
regulation and will open up multiple avenues of important experimentation with far
reaching implications for vascular biology.
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CHAPTER THREE
ARGININOSUCCINATE SYNTHASE SUBCELLULAR LOCALIZATION AND
PROTEIN INTERACTIONS

Overview

Argininosuccinate synthase (AS) is an essential mediator of endothelial health by
providing a dedicated source of arginine for nitric oxide (NO) production and promoting
endothelial cell viability. Our laboratory has previously demonstrated that AS is present
in endothelial caveolar fractions along with endothelial nitric oxide synthase (eNOS) and
argininosuccinate lyase (AL), the core components of the citrulline-NO cycle. The
studies in this Chapter were designed to define the subcellular localization of AS in
relationship to these components, to determine whether there are interactions that are
essential for nitric oxide metabolism and to begin characterizing additional novel
components of the nitric oxide metabolome. Utilizing immunofluorescence microscopy,
we found that AS localizes to perinuclear regions and the plasma membrane. Further,
eNOS localization overlaps AS localization suggesting functional relevance . We also
found that AS colocalizes with caveolin-1, a key regulator of eNOS function, in distinct
plasma membrane regions and the Golgi. Utilizing co-immunoprecipitation studies, we
found that AS interacts with HSP90 and caveolin-1. These two proteins are intimately
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involved in the regulation of endothelial nitric oxide production. We determined that AS
and co-localizes with HSP90 utilizing immunofluorescence. We also identified a caveolin
binding motif in the AS protein sequence that suggests a direct interaction. Finally, to
begin characterizing the nitric oxide metabolome from a more global perspective, we
utilized co-immunoprecipitations followed by mass spectrometry. We identified several
putative interacting partners that are either novel or understudied in the regulation of NO
production. Overall, our work defines a tightly coupled system for the regulation of nitric
oxide production and highlights the intricate and dynamic nature of citrulline-NO cycle
localization and interactions.

Materials and Methods

Immunofluorescence: BAEC were plated out on chamber slides. Cells were fixed
with 3.7% paraformaldehyde and permebealized with 0.05% triton X-100. After
blocking, cells were incubated with the following antibodies: AS (Everest Biotech),
eNOS, HSP90 and caveolin-1 (BD Biosciences). Cells were then incubated with
fluorescently labeled secondary antibodies (Invitrogen). Images were generated with a
Nikon Eclipse E1000 Fluorescent Microscope running Genus 2.81 software from Applied
Imaging. On all experiments, negative controls were conducted by staining one chamber
with secondary antibodies only.

Immunoprecipitation and protein identification using LC-MS/MS: Coimmunoprecipitation studies were conducted with the following antibodies: AS (Everest
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Biotech), HSP90, caveolin-1, eNOS (BD Biosciences), calmodulin I, NOSIP, PKG, AL
(Santa Cruz), AMPKα, PKCα, PKAcα, CKII, and Akt (Cell Signaling Technology)
utilizing the methods described in Chapter Two, Page 101.

For samples that were utilized for mass spec, processing occurred very rapidly
due to the labile nature of post-translational modifications and some protein-protein
interactions. In addition, RIPA buffer was utilized as the lysis and wash buffer since it is
more stringent and diminishes the possibility of non-specific interactions. Eluted protein
complexes were subject to SDS-PAGE, bands of interest were excised, then digested
proteins were subjected to liquid chromatography-tandem mass spectrometry as
described in Chapter Two, Page 108.
Bioinformatics: The AS caveolin binding motif was identified utilizing Expasy
Prosite (Scan Prosite Tool: http://www.expasy.ch/tools/scanprosite/) by searching for the
following motif in the AS protein sequence: [WFY] - X - X - X - X - [WFY] - X - X [WFY]. The motif was then identified on the 3D crystal structure of AS utilizing
ViewerLite software version 5.0 (Accelrys Corporation, San Diego, California).

Results

AS Subcellular Localization Overlaps with eNOS and Caveolin-1: The subcellular
localization of endothelial AS has not previously been characterized and we believe that
it is a key regulatory feature of the citrulline-NO cycle. We hypothesized that for optimal
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function of the citrulline-NO cycle, AS and eNOS should localize to the same regions
within the cell. Utilizing immunofluorescence microscopy, we demonstrated that AS and
eNOS colocalize and distribute in endothelial cells in a similar fashion, predominantly in
the Golgi and the cytoplasmic membrane (Figure 27). We have previously demonstrated
that caveolin-1 and AS co-fractionate in crude caveolar cell extracts, but we did not
determine whether these two proteins were in the same or independent caveolar regions.
Since eNOS and caveolin-1 colocalize and physically interact, we hypothesized that there
would be distinct regions of overlap in the localization of AS and caveolin-1. As shown
in Figure 25, AS co-localizes with caveolin-1 in distinct membrane regions and the
Golgi, much like what is seen with eNOS.
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Figure 27: AS Colocalizes with eNOS and Caveolin-1. Immunofluorescence
microscopy images demonstrating the localization of AS in the Golgi and plasma
membrane along with its colocalization with eNOS (A) and caveolin-1 (B). AS is red,
eNOS or caveolin are green and the merged image shows regions of co-localization in
yellow. The nucleus is stained in blue. Arrows point to selected areas of colocalization in
the Golgi and plasma membrane (n = 3). (C) Secondary only negative control.
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AS Protein Interactions: In order to begin deciphering key AS interacting
partners, a series of immunoprecipitations (IP) were carried out. When utilizing AS as the
IP antibody, two interactions were consistently noted: HSP90 and caveolin-1 (Figure 28).
These interactions were verified by immunoprecipitaing with HSP90 and caveolin-1 then
probing with AS (Figure 28).

Figure 28: AS Co-Immunoprecipitates with HSP90 and Caveolin-1. (A)
Representative blot (n = 3) of BAEC lysates that were immunoprecipitated with an AS
antibody (IP AS). The membrane was probed with HSP90 (IB HSP90) and caveolin-1
(IB Cav-1). (B) Representative blot (n = 2) of BAEC lysates that were
immunoprecipitated with an HSP90 antibody (IP HSP90). The membrane was probed
with AS (IB AS). (C) Representative blot (n = 2) of BAEC lysates that were
immunoprecipitated with a caveolin-1 antibody (IP Cav-1). The membrane was probed
with AS (IB AS).
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These results prompted us to assess the subcellular localization of AS and HSP90.
As shown in Figure 29, there appears to be co-localization between AS and HSP90,
although the specific regions are difficult to discern since HSP90 is widely distributed in
the cytoplasm.
Figure 29: AS Colocalizes with HSP90. (A) Immunofluorescence microscopy images
demonstrating colocalization of AS with HSP90 (n = 1). AS is red, HSP90 is green and
the merged image shows regions of co-localization in yellow. The nucleus is stained in
blue. (B) Secondary only negative control.
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Since eNOS has a caveolin binding motif, we decided to search for the same
motif in the AS protein sequence. We identified the sequence 317-FAELVYTGF-325
which fits the pattern of the caveolin binding motif found in eNOS: [WFY]-X-X-X-X[WFY]-X-X-[WFY] (Figure 30). This implies a direct interaction between AS and
caveolin.
Figure 30: AS has a Caveolin Binding Motif. Three dimensional structure of Human
AS (PDB ID 2NZ2) demonstrating the region containing the following caveolin
binding motif: [WFY]-X-X-X-X-[WFY]-X-X-[WFY]. The motif corresponds to the
sequence: 317-FAELVYTGF-325. Identified phosphorylation sites and substrates are
also shown as described in Figure 22, Chapter Two, Page 135.
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It is also important to note that the investigation of AS protein interactions via
immunoprecipitation was quite comprehensive and many other proteins were explored.
We did obtain some positive preliminary results with AS interactions with eNOS, AL,
PKA, PKCα and calmodulin. Taken together, our results demonstrate that there are key
protein interactions that potentially mediate AS function and the function of the
citrulline-NO cycle as a whole.

Proteomic Examination of the Nitric Oxide Metabolome: In order to begin
characterizing the NO metabolome, we utilized immunoprecipitation with an AS or
eNOS antibody followed by LC-MS/MS. BAEC cell lysates were collected in RIPA
buffer and immunoprecipitation was conducted. Putative interacting components were
separated by SDS-PAGE then specific bands were cut from the gel and subjected to mass
spectrometry for protein identification. This revealed several interesting interacting
partners that are relevant to known regulatory mechanisms of NO production. A list of
the most relevant interactions and their known or potential roles in NO biology is shown
in Table 8. Some interactions were specific for AS while others were identified with both
AS and eNOS antibodies. Interestingly, AS and eNOS did not seem to interact with each
other with this methodology, although the interaction has been noted previously with
other methodologies (Brenda Flam, unpublished results). Another interaction that was
missing from the list was the well documented eNOS-HSP90 interaction. The AS-HSP90
interaction was confirmed with the mass spec data. Table 9 shows all 85 proteins found to
co-IP with either AS or eNOS.
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Table 8: The Basal Nitric Oxide Metabolome. Table showing a few of the
interactions identified utilizing basal cell lysates that were immunoprecipitated with an
AS antibody. After separation via SDS-PAGE, bands were excised, digested and
subjected to liquid chromatography-tandem mass spectrometry. Table also shows role
of these interacting partners in regulating NO metabolism (n = 1).

PROTEIN

FUNCTION

IP ANTIBODY

cGMP-dependent protein
kinase

Kinase activated by soluble guanylylcyclase. Important for vasodilation and
regulates eNOS.

AS
eNOS

Dynamin

Large GTP-binding protein residing
within similar membrane compartments
as eNOS. Interacts with eNOS and
increases its activity.

AS

Golgi SNAP Receptor
Complex

Involved in transport from the ER to the
Golgi apparatus as well as in intra-Golgi
transport. Disruption of intracellular
trafficking has been associated with
cardiovascular disorders.

AS
eNOS

HSP90

Interacts with eNOS and increases its
activity.

AS

Kininogen-1 precursor

Cleaved into several products, including
bradykinin, which is an important
regulator of vasodilation. eNOS is
known to interact with the bradykinin
receptor. This interaction is inhibitory
and is released upon treatment with
bradykinin.

AS
eNOS

Prohibitin

Mitochondrial protein that protects
endothelial cells from reactive-oxygen
species damage.

AS
eNOS
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Table 9: Putative AS and eNOS Interacting Partners. Complete list of all proteins identified
via IP with an AS and/or eNOS antibody followed by mass spec as described in Table 8 above.
Actin, cytoplasmic 2 - Bos taurus (Bovine)
Trypsin precursor - Sus scrofa (Pig)
Tropomyosin alpha-1 chain - Bos taurus (Bovine)
Myosin-10 - Bos taurus (Bovine)
Myosin regulatory light chain 2, smooth muscle isoform - Bos taurus (Bovine)
Myosin-9 - Canis familiaris (Dog)
Actin-like protein 3 - Bos taurus (Bovine)
Histone H2A type 1 - Bos taurus (Bovine)
Ornithine decarboxylase antizyme - Bos taurus (Bovine)
Cationic trypsin precursor - Bos taurus (Bovine)
Actin, alpha skeletal muscle - Bos taurus (Bovine)
Myosin light polypeptide 6 - Bos taurus (Bovine)
ADP/ATP translocase 2 - Tachyglossus aculeatus aculeatus (Australian echidna)
Vimentin - Bos taurus (Bovine)
Kininogen-1 precursor - Bos taurus (Bovine)
Ribonuclease pancreatic - Hippopotamus amphibius (Hippopotamus)
Histone H2A type 2-C - Bos taurus (Bovine)
Ribonuclease pancreatic - Antilocapra americana (Pronghorn)
Dynamin-1-like protein - Bos taurus (Bovine)
Ubiquitin - Bos taurus (Bovine)
130 kDa phosphatidylinositol 4,5-biphosphate-dependent ARF1 GTPase-activating protein - Bos taurus (Bovine)
Actin-related protein 2/3 complex subunit 4 - Bos taurus (Bovine)
Myosin-Id - Bos taurus (Bovine)
Heterogeneous nuclear ribonucleoprotein A1 - Bos taurus (Bovine)
Actin-related protein 2/3 complex subunit 3 - Bos taurus (Bovine)
Serum albumin precursor - Bos taurus (Bovine)
Histone H2B type 1-K - Bos taurus (Bovine)
Golgi SNAP receptor complex member 1 - Bos taurus (Bovine)
Alpha-S1-casein precursor - Bos taurus (Bovine)
Glycoprotein GIII precursor - Bovine herpesvirus 1.1 (strain Cooper) (BoHV-1) (Infectious bovine rhinotracheitis
virus)
Prohibitin-2 - Bos taurus (Bovine)
Abnormal spindle-like microcephaly-associated protein homolog - Ovis aries (Sheep)
Alpha-enolase - Bos taurus (Bovine)
Actin-related protein 2/3 complex subunit 1B - Bos taurus (Bovine)
60S ribosomal protein L4 - Bos taurus (Bovine)
Junction plakoglobin - Bos taurus (Bovine)
Polymeric-immunoglobulin receptor precursor - Bos taurus (Bovine)
Tubulin alpha-1A chain - Sus scrofa (Pig)
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 - Bos taurus (Bovine)
Pyruvate kinase isozyme M1 - Felis silvestris catus (Cat)
von Willebrand factor precursor - Canis familiaris (Dog)
Tyrosine-protein kinase SYK - Sus scrofa (Pig)
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Table 9 (continued)
Endoplasmin precursor - Bos taurus (Bovine)
Gamma-aminobutyric-acid receptor subunit alpha-3 precursor - Bos taurus (Bovine)
Elongation factor 1-alpha 1 - Bos taurus (Bovine)
Histone H3.1 - Bos taurus (Bovine)
60S acidic ribosomal protein P0 - Bos taurus (Bovine)
cGMP-dependent protein kinase 1, alpha isozyme - Bos taurus (Bovine)
Calpain-1 catalytic subunit - Oryctolagus cuniculus (Rabbit)
Beta-casein precursor [Contains: Casoparan] - Bos taurus (Bovine)
Ribosome recycling factor, mitochondrial precursor - Bos taurus (Bovine)
Heterogeneous nuclear ribonucleoproteins A2/B1 - Bos taurus (Bovine)
Rho guanine nucleotide exchange factor 9 - Bos taurus (Bovine)
52 kDa Ro protein - Bos taurus (Bovine)
Telomerase reverse transcriptase - Canis familiaris (Dog)
Fatty acid-binding protein, adipocyte - Sus scrofa (Pig)
Nitric oxide synthase, inducible - Bos taurus (Bovine)
Desmoglein-1 precursor - Canis familiaris (Dog)
Heat shock 70 kDa protein 4 - Canis familiaris (Dog)
Alpha-S2-casein precursor [Contains: Casocidin-1 - Bos taurus (Bovine)
Serpin H1 precursor - Bos taurus (Bovine)
Coiled-coil domain-containing protein 113 - Bos taurus (Bovine)
Cofilin-2 - Bos taurus (Bovine)
Histone H1.1 - Bos taurus (Bovine)
Pro-epidermal growth factor precursor - Canis familiaris (Dog)
Glial fibrillary acidic protein - Bos taurus (Bovine)
Probable phospholipid-transporting ATPase IF - Oryctolagus cuniculus (Rabbit)
Histone H3.2 - Bos taurus (Bovine)
Heat shock protein HSP 90-alpha - Bos taurus (Bovine)
5-hydroxytryptamine 1A receptor - Equus caballus (Horse)
Tripartite motif-containing protein 9 - Bos taurus (Bovine)
Cystic fibrosis transmembrane conductance regulator - Sus scrofa (Pig)

An additional piece of data related to protein interactions was uncovered when
searching for AS phosphorylation sites via mass spec. When AS was overexpressed and
then treated with okadaic acid, T131 was identified as a phosphorylation site (Chapter
Two, Figure 19, Page 129). In addition, several other bands were cut out from the gel that
contained purified AS and any proteins that might have come down with it. One notable
protein identified was NOSIP (eNOS interacting protein). NOSIP is a known binding
partner with eNOS and is important for its subcellular localization. NOSIP promotes
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translocation of eNOS from the plasma membrane to intracellular sites, thereby
uncoupling eNOS from caveolae and inhibiting NO synthesis.

Discussion

In this Chapter, the subcellular localization of endothelial AS was defined, its colocalization with eNOS, caveolin-1 and HSP90 was described and important AS
interacting partners were identified. This is the second post-translational regulatory
mechanism addressed in this dissertation.

The subcellular localization of AS has been defined in several tissues. For
instance, in untransfected or AS-transfected VSMC, AS is detected in both cytosolic and
membrane fractions via western blot [1]. AS expression is increased in membrane
fractions upon stimulation with LPC/IFNγ, suggesting that AS is transported to
membrane regions for functionally relevant purposes [1, 2]. In addition,
immunohistochemical studies of AS-transfected cells indicates a punctuate pattern of
expression that suggests mitochondrial localization [1], much like what is seen in liver
[2]. This study supported the concept of substrate channeling [1], which would
necessitate co-localization and assembly into a functional complex. Our identification of
AS localization to the perinuclear/Golgi region and plasma membrane supports those
previous findings since NO is produced in these two subcellular compartments [3-5].
Thus, much like urea cycle enzymes, the citrulline-NO cycle enzymes form functional
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complexes in specific cellular compartments that allow efficient channeling of substrates
so that the arginine required for NO production is distinct from bulk cellular arginine.

The distinct localization pattern for AS in endothelial cells also led to an
important observation. It is possible that AS has localization-specific or organellespecific functions. These functions might be related to post-translational modifications.
Therefore, some of the difficulties in obtaining definitive mass spectrometry data may be
related to the fact that we utilized whole cell lysates to look for AS phosphorylation sites.
This may in fact have led to a dilution of the data since perhaps certain regions of the
cells have a high population of phosphorylated AS while others, perhaps most, don’t. It
will be important to determine the phosphorylation pattern in different cellular
compartments to gain a better understanding of the impact and regulation of these
modifications.

eNOS is also known to localize to the Golgi and plasma membrane [5] and we did
find that AS and eNOS co-localize. Although it is unclear how AS functions within
specific cellular compartments, there are two distinct pools of active eNOS, one in the
Golgi and one in the plasma membrane. The relative importance of these two pools of
eNOS is still under investigation, but one study demonstrated that although NO is
produced each of these regions, the plasma membrane produces significantly more NO
[3]. In that study, they generated endothelial cells that expressed wild type eNOS, Golgionly eNOS or plasma membrane-only eNOS without altering any other components of
the citrulline-NO cycle. This suggested that either the other enzymes of the cycle are also
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present in Golgi and plasma membrane or that there is another source of substrate for
eNOS. Our studies and those of others suggest that endothelial cells are dependent on
recycling of citrulline to arginine as a source of eNOS substrate [6, 7]. The fact that AS
localized to those regions supports those studies. It would be interesting to design a
similar study where both AS and eNOS localization could be manipulated. Then, the
dependence of co-localization could be definitively proven. However, the studies with
Golgi versus plasma membrane eNOS were done by first knocking out endogenous
eNOS and then re-constituting the endothelial cells with the different eNOS constructs
[3]. We have shown that moderate AS knockdown leads to significant endothelial
apoptosis [8], so the same approach might not be successful for AS. This suggests that
while the function of eNOS may be exclusively to produce NO, AS might have several
different functions, including as anti-apoptotic signaling [8], that make it even more
important for overall vascular biology.

In addition, we demonstrated that AS localized in distinct plasma membrane
regions in conjunction with caveolin-1 [7, 9]. This expands our previous work by
demonstrating that the regions where AS localizes in the plasma membrane are also
regions where caveolin-1 is present. In other words, our previous work showing that AS
and caveolin localized to similar crude caveolar fractions did not prove that the
localization was to the same specific caveolar regions [9]. The co-localization of AS and
caveolin suggests a role for caveolin-1 in assembling AS into a functional signaling
microdomain, much like its role in regulating eNOS transport and function. For example,
caveolar domains assemble at the Golgi and traffic to the plasma membrane as stable
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transport platforms [10, 11]. These platforms constitute signaling microdomains where
multiple kinases, phosphatases and regulatory enzymes assemble into functional
complexes [12, 13]. The transport mechanisms regulating the formation of the NO
metabolome at caveolae enhance NO production at the plasma membrane and involve
vesicular transport elements and cytoskeletal components [10, 11, 14-17].

In addition, interaction with other proteins plays a role in eNOS targeting. For
example, there are two eNOS-interacting proteins named NOSIP (for eNOS-interacting
protein) [18] and NOSTRIN (for eNOS-trafficking inducer) [19], which both influence
the subcellular localization of eNOS. NOSIP, targets eNOS to the cytoskeleton and
inactivates it [20]. NOSTRIN, when overexpressed, leads to translocation of eNOS from
the plasma membrane to intracellular vesicular structures [19], possibly involving an
endocytic process [21]. Utilizing AS overexpression, purification and mass-spectrometry
of associated proteins we did identify NOSIP as a putative binding partner of AS. This
leads to the intriguing possibility that there are some shared mechanisms in AS and eNOS
transport. Although these findings could not be confirmed utilizing IP/western, the
antibodies for NOSIP that we utilized were not very good, our IP techniques needed
optimization and the AS antibody available on the market at that time did not work well
for IP. With the new methods and tools we now have available, it is certainly worthwhile
to pursue this mechanism.

Another mechanism that regulates the subcellular translocation of eNOS is dual
acylation, an irreversible N-myristoylation at Gly2 and reversible thiopalmitoylation at
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C15 and C26 [16]. These lipid functional groups are responsible for targeting eNOS to
the Golgi and plasma membrane, particularly to caveolae [16, 22, 23]. Acylation deficient
eNOS variants cannot translocate to the plasma membrane and this leads to alterations in
eNOS activity [14]. It was intriguing to hypothesize that AS might be modified by
acylation. A bioinformatic search for motifs for myristoylation and palmitoylation did not
identify any such motifs in the AS sequence. It is still possible that AS is acylated via
motifs that have yet to be described. In fact, the palmitoylation motif uncovered for
eNOS is distinct from the motif found on other signaling proteins [22]. For example, the
motif identified for the Src family of proteins is MGCXXC/S while eNOS the motif for
eNOS is MGXXXS…C15(GL)5C26. The human AS sequence does have a glycine at
position 5 and a cysteine at position 19, making is possible that lipidation does indeed
occur. Although we did not examine the transport of AS in this work, the findings we
describe below do support a dynamic translocation of AS in endothelial involving several
key interacting partners.

We believe that our evidence supports a model whereby protein interactions
regulate the subcellular localization of AS. Caveolin-1 may indeed be a key factor in this
level of regulation. The fact that the AS protein sequence has a caveolin binding motif
suggests that the interaction we found via immunoprecipitation may in fact be a direct
interaction. In addition, previous unpublished data from our laboratory supports this
hypothesis since both GST and His-tag pull down experiments demonstrated that AS can
pull down caveolin-1 (Brenda Flam, unpublished results). Since this motif has been
identified, it can be utilized for the design of experiments aimed directly at disrupting the
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motif and determining not only whether the interaction is direct, but also the specific
region that is involved in the interaction. Since we have identified an AS phosphorylation
site very close to that motif, it is quite possible that phosphorylation regulates this
interaction. The eNOS caveolin binding motif is located in the peptide 348FPAAPFSGW-356 [24, 25]. To date, there have not been any eNOS phosphorylation
sites in the vicinity of the caveolin binding motif with respect to the secondary structure.
Since the entire eNOS protein has not been crystallized, it is difficult to know if perhaps
one of the eNOS phosphorylation sites is near the caveolin binding motif in the 3dimensional structure. However, it is known that phosphorylation regulates the
interaction between eNOS and caveolin-1, thus it is certainly possible that the mechanism
involves spatial proximity of phosphorylation sites. We speculate that there is an interrelated mechanism that controls the binding of caveolin to AS and eNOS.

Along with the possible regulation of AS localization and function by caveolin-1,
the finding the HSP90 also co-localizes with and interacts with AS strengthens our
hypothesis due to the reciprocal regulation of NO production by these two proteins.
HSP90 is involved in the activation of eNOS by allowing the interaction of eNOS with
calmodulin, the phosphorylation of eNOS by Akt and the dissociation of eNOS from
caveolin-1 [26-29]. It is possible that the AS-HSP90 interaction regulates AS through
similar mechanisms. Interestingly, we were able to confirm this interaction with IP/mass
spec analyses.
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Several more interactions were uncovered via IP analyses, including the
interactions of AS with AL, eNOS, calmodulin, PKA and PKCα, but the results have not
been reproduced. Previous work in our lab did indicate a direct interaction between AS,
AL and eNOS (Brenda Flam, unpublished results) and our preliminary results do support
this. In addition, the interaction of AS with PKA and PKCα supports previous studies that
demonstrate the presence of both of these kinases in caveolae [30, 31]. Considering that
our results show that AS is an in vitro substrate for these kinases, these interactions are
certainly worth pursuing. The possible interaction of AS with calmodulin suggests
regulation via calcium signaling, and our link between AS and VEGF supports this since
VEGF stimulates NO production, in part, by increasing intracellular calcium [26].
Overall, the above findings strengthen our hypothesis of a dynamic and complex set of
interacting proteins in the NO metabolome.

Up to this point, our results were obtained by rational investigation of AS
interacting partners based on preliminary data or the known role of certain proteins in
regulating NO production. Our ultimate goal, was to put together the pieces of the nitric
oxide metabolome. In order to accomplish this, we needed a more global approach to
characterize the dynamic nature of both hypothesized interactions and novel or
understudied interactions. We developed a proteomic approach to identify all proteins
that are pulled down when an AS or an eNOS antibody was used for IP analyses. We
identified 85 proteins that co-immunoprecipitated with AS and/or eNOS. From those,
there were 6 that stood out as having a possible functional role.
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First, cGMP-dependent protein kinase or protein kinase G (PKG) was found to
interact with both AS and eNOS. PKG is an important kinase in regulating the function of
nitric oxide in vascular smooth muscle. When endothelial NO is released, it acts in
smooth muscle to activate soluble guanylyl cyclase (sGC), increase cGMP and activate
PKG. This leads to vasodilation [32]. PKG has been also been found to have direct
functions in the endothelium. For example, PKG colocalizes to caveolae in both smooth
muscle and endothelium [30]. In addition, PKG is involved in the regulation of
angiogenesis in endothelial cells [33]. Considering the link between VEGF and AS that
we established in Chapters One and Two and the well established link between VEGF
and eNOS [26, 33-41], it is quite possible that this is a true functional interaction. This
interaction was not verified by IP/western, but optimization of the IP methodology or a
different methodology altogether might reveal a different result.

A second interaction revealed by IP/mass spectrometry was dynamin. Dynamin is
a large GTP-binding protein that co-localizes with and interacts with eNOS, thereby
increasing its activity [42]. It targets to Golgi membranes and also co-localizes with
caveolin in caveolae [43, 44]. In addition, NOSTRIN (eNOS trafficking inducer) interacts
with dynamin and mediates eNOS subcellular translocation [21]. In our experiments,
dynamin was not found to interact with eNOS. It is possible that the conditions and/or
methods used did not favor this interaction. The interaction between AS and dynamin fits
well with previous, unpublished data from our lab where tandem affinity purification was
utilized to pull down AS and associated proteins. These results identified a GTP-binding
protein as an AS interacting partner.
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Another AS and eNOS interacting partner identified via IP/mass spectrometry
was the Golgi SNAP receptor complex. This protein is one of several involved in
transport from the endoplasmic reticulum to the Golgi and in intra-Golgi transport [45]. It
has been demonstrated that in vascular disorders, there are disruptions of intracellular
trafficking. Specifically, hypoxia and other conditions cause disruptions in ER/Golgi
trafficking that lead to sequestration of eNOS and a reduction in plasma membrane
associated eNOS. This leads to diminished NO production [46]. The possibility of AS
interacting with this protein suggests that AS trafficking in the ER and Golgi may be an
important regulatory mechanism.

We also identified HSP90 as an AS interacting partner via IP/mass spec, which
confirms the IP/western data described earlier. The fact that we did not find the well
documented eNOS-HSP90 interaction highlights the fact that each methodology utilized
to probe for protein interactions, and the variations within individual methodologies, can
lead to false positive or false negative results.

Kininogen-1 precursor was another AS and eNOS interacting partner identified
via IP/mass spectrometry. This precursor is cleaved into several products including
bradykinin [47]. Bradykinin is a vasodilator that regulates eNOS function via several
mechanisms [48-51] and the coordinate interaction with both AS and eNOS suggests that
bradykinin also plays an important role in regulating AS function.
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The final protein in the IP/mass spectrometry analyses that has an important
functional link in the endothelium was prohibitin-1. It interacted with both AS and eNOS.
This protein was originally identified in yeast and is localized to the inner mitochondrial
membrane. It is now apparent that prohibitins have diverse roles in several disease states
such as obesity and inflammation [52]. Recently, it was determined that prohbitin-1 is
highly expressed in the vascular system [53]. Knock-down of prohhibitin-1 in endothelial
cells leads to dysfunction characterized by increased production of reactive oxygen
species in mitochondria. This suggests that prohibitin-1 is important for protecting
endothelial cells from oxidative damage [53]. Interestingly, prohibitin was recently found
to regulate the function of OPA-1, a dynamin-like protein involved in cristae
morphogenesis [54]. This regulation led to the control of cell proliferation and apoptosis
and the authors speculated a role for prohibitin in lipid rafts. Since AS has been
hypothesized to localize in mitochondria in vascular smooth muscle [1] and does localize
to mitochondria in other tissues [2], it is possible that AS is also localizes in endothelial
cell mitochondria. There is some evidence that eNOS localizes to mitochondria [55] but
the function of the citrulline-NO cycle in endothelial mitochondria has not been studied.
Furthermore, NO itself has important roles in regulating mitochondrial function and
biogenesis [56, 57]. Collectively, the identification of dynamin and prohibitin and AS
interacting partners implies important functional significance. Thus, a functional
citrulline-NO cycle in mitochondria might regulate functions that are specific to that
organelle.
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Finally, another set of prominent interactions seen via IP, IP/mass spec and
tandem affinity purification/mass spec were several cytoskeletal components including
actin, vimentin and tubulin. Although the high expression of these proteins in most cell
types leads to the initial assessment that these results are false positives, it is quite
possible that there is an intricate cytoskeletal network responsible for the trafficking of
AS within endothelial cells. Indeed, such mechanisms have been extensively
characterized for eNOS. There is a prominent role of actin polymerization that regulates
eNOS activity and transport [58]. More recently, it was uncovered that the protein αactinin-4, an actin binding protein responsible for actin cross-linking, interacts with and
inactivates eNOS by competitively inhibiting calcium-dependent activation [59].
Furthermore, the mechanisms of eNOS regulation by NOSIP and NOSTRIN involve the
actin cytoskeleton [18, 19]. Shear stress regulates dilation and remodeling of resistance
arteries via several cytoskeletal components such as vimentin, desmin and intermediate
filaments [60]. Thus, further investigation into the role of the actin cytoskeleton and other
cytoskeletal components in AS-eNOS co-translocation and function is an important area
for further exploration.

It is clear from our studies that obtaining an accurate picture of true interacting
partners is a complex process. Each technique employed can lead to false positive or false
negative results. In addition, many techniques cannot confirm whether an interaction is
direct or indirect. Despite these limitations, our studies indicate that there is a vast and
dynamic network of associating proteins that regulate the function of the nitric oxide
metabolome.
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PERSPECTIVES

Summary

The work conducted in this dissertation has uncovered significant advances in our
understanding of AS regulation as it relates to nitric oxide production and vascular health.
In Chapter One, the regulation of AS function and expression was explored. The data
revealed the important role of AS in the production of nitric oxide since overexpressing
AS led to a significant increase in endothelial NO production above the levels of the
endogenous enzymes of the citrulline-NO cycle. We were also able to show that insulin
and VEGF up-regulated AS expression and increased NO production while ceramide
diminished AS expression. In Chapter Two, we identified and characterized the first
post-translational modifications of AS in the endothelium: phosphorylation at serine,
threonine and tyrosine residues. After utilizing bioinformatics to determine that AS
phosphorylation was a possible AS regulation mechanism, we focused on biological
relevance. First, we identified PKA and PKCα as kinases that regulate AS
phosphorylation. We also showed that phosphorylation of AS by PKA and PKCα is
required for maximal VEGF-mediated NO production. We then identified 7 different
sites of phosphorylation utilizing a proteomics approach and demonstrated the potential
biological roles of T131/S134, S180, S189 and S328. In Chapter Three, the subcellular
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localization of AS was defined in endothelial cells for the first time. In addition, our
results demonstrated an overlap in localization of AS with eNOS, caveolin-1 and HSP90.
We were then able to characterize important AS interacting partners utilizing
immunoprecipitation including caveolin-1 and HSP90. We also provided the first
example of the possible relationship between AS phosphorylation and protein interactions
utilizing the proximity of S328 to the newly identified caveolin-binding motif. Finally,
utilizing proteomics, we were also able to identify 85 proteins that interact with eNOS
and/or AS in BAEC’s under basal conditions. From that list of proteins, 6 were
highlighted as having known or potential roles in regulating NO production: PKG,
dynamin, prohibitin, HSP90, the Golgi SNAP receptor complex and kininogen-1.

Significance

The work presented in this dissertation demonstrated that AS is a central player in
the regulation of NO production as evidenced by the multiple and intricate mechanisms
that regulate its function. Often times, the studies that focus strictly on eNOS function to
address the regulation of NO production only tell part of the story. Considering that most
phenotypic properties of the endothelium are mediated by NO [1], it is essential that the
scientific community focus more attention on looking at the bigger picture.

The key observation that in the endothelium, AS transient overexpression
enhances nitric oxide production further supports the fact that AS is the rate limiting step
in the process [2-5]. Such an important distinction supports our initial hypothesis that
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multiple-levels of AS regulation need to be in place in order to maintain NO levels at the
appropriate levels. The finding that AS overexpression led to a loss of endothelial cell
viability confirms the importance of AS as an anti-apoptotic signaling molecule [6] and
implies that the specific mechanisms by which AS regulates this process warrant further
investigation.

The transcriptional regulation of AS is important in many of its key target tissues
such as liver, immune cells and macrophages [7-11]. Our work demonstrating the
coordinate regulation of AS and eNOS expression by both positive and negative stimuli
extends our understanding of the importance of this mechanism in regulating the health
of the endothelium. This also opens avenues for investigation of these observations in
animal models of vascular disease. In addition, this work continues to add to the
mounting evidence that the arginine paradox can be explained by the tightly coupled
arginine regeneration system exemplified by the citrulline-NO cycle [12-14].

The link between AS and VEGF is the first demonstration of a potential role of
AS in mediating angiogenesis. The possible direct effects of AS on the angiogenic
process could have dramatic importance in understanding the global effects of AS on
vascular health. Furthermore, this link may explain some of the possible roles for AS in
cancer [15]. Additionally, our work links AS to calcium signaling thus opening up
another possible regulatory avenue.
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Post-translational regulation of AS, whether by phosphorylation or protein
interactions, is an essentially uncharacterized field of NO biology. Considering the fact
that NO is such a potent mediator of whole body metabolism [16, 17], it is certainly a
rational principle that multiple mechanisms are needed to maintain the function of the
system. Post-translational modifications allow for acute regulation of protein function. It
is absolutely essential for AS to be able to respond quickly to the ever changing cellular
need for NO, and we have shown that AS phosphorylation is one such mechanism. This
type of regulation also opens up a multitude of therapeutic avenues aimed at the kinases
and phosphatases that control the ever-changing barcode of post-translational
modifications. Considering that eNOS is so intricately regulated by dynamic association
with a number of other proteins [17], it makes sense that AS is part of this regulatory
scheme. In addition, the continuation of our work to characterize the NO metabolome
will be essential in identifying additional, novel binding partners that have not previously
been considered.

The multiple possible functions of AS in the vasculature and the complex and
numerous mechanisms that regulate its function, some presented in this dissertation and
many yet to be uncovered, lead to the prospect that many possible interventions to
regulate AS function could impact a number of disease processes. For example, there is
controversy related to the usefulness of arginine supplementation in the treatment of
vascular disorders [18]. Our work suggests that this is because of the multiple functions
of AS in vascular and non-vascular roles. Although citrulline supplementation may
indeed be a better option due to the unique metabolic fate of this amino acid as compared
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to arginine [19], it remains to be determined whether whole body supplementation will be
effective since increasing the substrate for AS might have additional, unwanted effects
such as enhanced NO production in tissues that do not require it or perhaps even
pathogenic angiogenic consequences related to tumorigenesis. Perhaps the delivery of
citrulline to the specific tissues with a deficiency in NO production is a better option.

In addition, our finding that AS is phosphorylated by kinases that are also
important for eNOS regulation improves our understanding of how drugs that target some
of those kinases might have a greater cardiovascular impact than originally intended. In
addition, targeting kinases that directly phosphorylate AS for therapeutic purposes might
have greater efficacy and fewer side effects since the target is further downstream in the
NO signaling cascade. Another therapeutic avenue involves protein interactions. If a
defect in the HSP90 interaction with AS and eNOS can be corrected therapeutically with
a drugs such as insulin sensitizers that have been shown to correct this defect [20], the
benefit to the vascular system could be prominent. The use of such specific therapies will
depend on genomic and proteomic approaches that will allow us to understand the
specific defect that is causing an individual’s disease. Whether the therapy is
pharmacological or nutritional, this type of information will allow for the implementation
of individualized patient therapies that will dramatically improve our success in the
prevention and treatment of the prominent and devastating diseases that plague global
health.
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Limitations

One of the main limitations of our work is the fact that it has almost entirely been
carried out in tissue culture. There are definite advantages to tissue culture systems since
they allow for the study of single variables without the influence of some compensatory
mechanisms and of other tissues. These studies also allow for tissue specific mechanisms
to be defined. Although tissue culture does not completely mimic an in vivo approach, it
does allow for initial hypotheses and mechanisms to be developed that can then be used
as starting points for translational work. We have begun projects to translate our work
into relevant animal models with an ultimate goal of determining the applicability of our
work in humans. However, our work and that of others fits well with the known functions
of eNOS in the vasculature which has been extensively characterized in animals and
humans. Therefore, we feel strongly that our tissue culture work will have relevance for
human health.

Another limitation of our work relates to the groundbreaking nature of our
projects. For several of the experimental avenues that were undertaken, adequate tools
were not readily available. Thus, methodologies had to be designed to make judicious use
of available tools. In addition, for the continuation of this work, new tools will have to be
generated such as site-specific AS antibodies and ultimately even tissue-specific AS
knockout mouse models so that a thorough understanding of the role of AS in human
diseases can be delineated. These tools, in conjunction with similar tools already
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available for eNOS, will allow for a thorough understanding of the importance of AS
within the citrulline-NO cycle.

Future Directions

There are several areas of work that will be important in expanding the findings of
this dissertation. In Chapter One, each pathway studied requires two main areas of
investigation to clearly delineate the role of AS expression in NO production. First, the
role of insulin, VEGF and ceramide on AS specific activity needs to be determined. That
will allow the direct connection between these biological molecules and AS function.
Although this was addressed partially with the AS inhibitor studies with VEGF, enzyme
assays are critical to make stronger conclusions. Second, the regulation of AS expression
needs to be mechanistically defined by carrying out experiments that will determine
whether message stability or specific promoter regulation accounts for the up or
downregulation of AS. It is also possible that the mechanisms involving AS regulation by
ARP (Argininosuccinate Synthase Regulatory Protein) might be tied into the
transcriptional regulation uncovered in Chapter One.

The findings Chapter Two related to AS post-translational regulation by
phosphorylation are indeed novel and could drive the field of nitric oxide biology into
multiple new and relevant areas of investigation. Ultimately, progress in this field will
depend on definitively identifying specific sites of AS phosphorylation that are necessary
for NO production and importantly, for AS specific activity. This will require continued
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optimization of proteomic approaches, the development of AS enzyme assays and the
generation of site-specific AS antibodies. Currently, experiments are underway to
identify the specific sites phosphorylated by PKCα and PKA and also to assess AS
phosphorylation in the endogenous AS enzyme via immunoprecipitation. In addition, the
possibility of other types of PTM needs to be explored such as nitrosylation,
glycosylation and acylation. It has taken many, many years to get a decent understanding
of these regulatory mechanisms for eNOS function. Even with all the progress, there are
still many areas that require further research and understanding. Certainly, it will take a
comparable amount of time and concerted effort to get a strong understanding of how
similar mechanisms regulate AS.

The regulation of AS by protein interactions is also of great significance. A more
thorough understanding will require both basic molecular and proteomic approaches.
Each individual protein interaction will have to be characterized extensively. First, the
utilization of several types of methods such as pull down approaches will be necessary to
confirm the interactions and to determine if the validated interactions are direct or
indirect. Second, to further prove whether interactions are direct or indirect, studies will
need to be designed to determine the specific regions of each protein involved in the
interaction. We already have a good start with the caveolin-AS interaction due to the
identification of a caveolin-binding motif in the AS protein sequence. The biological
significance of these interactions will need to be assessed by determining the role of each
interaction on AS specific activity. Finally, the optimization and continuation of
proteomic approaches to find additional members of the nitric oxide metabolome will be
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essential to truly understand nitric oxide metabolism from a global systems perspective.
Furthermore, these approaches will also allow us to define the role of PTM in regulating
protein interactions via the utilization of methods that can simultaneously identify protein
interactions and PTM. We have already designed these methodologies in conjunction
with the Moffitt Proteomics Core and preliminary experiments have been initiated.

Finally, the significance of our work will be strengthened by projects designed to
characterize our tissue culture findings in animal models and ultimately in humans. We
have such a project underway currently. We plan on beginning our translational work by
utilizing streptozotocin (STZ) to induce diabetes in rats. This type 1 diabetes model will
allow us to examine the impact of total insulin deficiency on the expression of AS, AL
and eNOS. This type of work will mimic our tissue culture experiments with insulin. In
addition, we will have 4 treatment groups: sham treated, STZ only, STZ plus suboptimal
insulin treatment and STZ plus optimal insulin treatment. This will allow us to study
expression patterns in conditions of normal glycemia, moderate hyperglycemia and
extreme hyperglycemia. We will also be able to measure serum NO levels, the expression
of other proteins that we have identified as essential for AS regulation (VEGF, PKA,
HSP90, etc.), and the subcellular localization of these proteins. Therefore, we can build
an in vivo model of specific dysfunction of the citrulline-NO cycle in diabetes as it relates
to AS that can eventually be utilized to carry out human studies.
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APPENDIX A: (Continued)
Abstract

Vascular endothelial nitric oxide (NO) production via the citrulline-NO cycle not
only involves the regulation of endothelial nitric oxide synthase (eNOS), but also
regulation of caveolar-localized endothelial argininosuccinate synthase (AS), which
catalyzes the rate-limiting step of the cycle. In the present study, we demonstrated that
exposure of endothelial cells to troglitazone coordinately induced AS expression and NO
production. Western blot analysis demonstrated an increase in AS protein expression.
This increased expression was due to transcriptional upregulation of AS mRNA, as
determined by quantitative real time RT-PCR and inhibition by 1-Dribofuranosylbenzimidazole (DRB), a transcriptional inhibitor. Reporter gene assays and
EMSA analyses identified a distal PPARγ response element (PPRE) (–2471 to –2458)
that mediated the troglitazone increase in AS expression. Overall, this study defines a
novel molecular mechanism through which a thiazolidinedione (TZD) like troglitazone
supports endothelial function via the transcriptional up-regulation of AS expression.
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APPENDIX A: (Continued)
Introduction
Almost all normal functions of vascular endothelial cells are dependent on or
affected by the bioactivity of nitric oxide (NO). Thus, impairment of endothelial NO
production is often a common pathogenic mechanism by which cardiovascular risk
factors such as hypercholesterolemia, hypertension, smoking, homocystinemia, vascular
inflammation, and diabetes mellitus promote their deleterious effects on the vascular wall
[1]. Endothelial NO production is supported by reactions catalyzed by endothelial nitric
oxide synthase (eNOS), argininosuccinate synthase (AS) and argininosuccinate lyase
(AL) which are core components of the citrulline-NO cycle [2-4]. The principal role of
AS and AL catalysis is in the conversion of citrulline to arginine, the substrate utilized by
eNOS to produce NO and citrulline. AS is rate-limiting to the citrulline-NO cycle [3, 4],
and as such is required to sustain endothelial function and viability [5].
PPARγ is a member of the nuclear receptor superfamily of ligand-activated
transcription factors that has been shown to regulate the transcription of genes involved
in lipid metabolism differentiation and cell growth [6]. Both naturally derived PPARγ
ligands, including a number of fatty acid metabolites such as eicosanoid derivatives [7]
and 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) [8, 9], as well as synthetic ligands such
as the thiazolidinediones (TZDs) have been described. The TZDs have insulin-sensitizing
properties [10-12] which provide cardiovascular benefits [13-17] and promote flowmediated vasodilatation, in part, by stimulating endothelial NO production via the
activation of eNOS [17, 18]. Because of these findings, we examined whether the TZD,
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troglitazone, known to promote NO production [19] and vasodilatation in diabetic
patients [20], may affect the efficiency of the citrulline-NO cycle via AS expression in
vascular endothelial cells.
Materials and Methods

Cell Culture: Bovine aortic endothelial cells (BAEC) were cultured in complete
Dulbecco’s modified Eagle’s medium (1 g/L glucose, Mediatech) containing 10% fetal
bovine serum (Hyclone Laboratories), 100 units/ml penicillin and 100 μg/ml
streptomycin (Mediatech) at 37°C in an atmosphere of 5% CO2.

Nitric Oxide Assay: BAEC were treated with troglitazone as indicated in DMEM
(minus phenol red) plus 5% fetal bovine serum. Aliquots (100 µl) of media were
removed at the indicated times and nitrite was measured as an indicator of cellular NO
produced using a fluorometric method [21]. Samples were read on a BMG Fluostar
Galaxy spectrofluorometer in a 96-well plate. Data is presented as quantity of nitrite
produced in pmols per mg protein.

Western Blot Analysis: Following treatment with troglitazone, BAEC were
harvested in 500 µl PBS, centrifuged briefly and lysed in RIPA buffer. The lysate was
incubated on ice for 30 minutes and protein concentration determined by BCA reagent
(Pierce). Ten μg of protein was electrophoresed on 4-15% polyacrylamide gels (Bio-Rad)
and transferred onto membrane (Immobilon-P). Membranes were incubated with
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antibody 1:2500 anti-AS and 1:1000 anti-GAPDH (BD Transduction Labs) in 5%
blocking solution in TBS-T (20 mM Tris-HCl, 137 mM NaCl, 0.1% Tween-20) and then
washed in TBS-T. Membranes were subsequently incubated with horseradish
peroxidase-conjugated anti-mouse antibody for 1 hour, immersed in ECL reagent (GE
Healthcare) for 1 minute and then exposed to film. Band intensities were quantitated
using ImageQuant software (Molecular Dynamics).

RNA Isolation and Quantitative RT-PCR: Total RNA was isolated using Tri
Reagent following the manufacturer’s instructions (Sigma). RNA was treated with DNase
(Ambion DNA-free). Five hundred ng of RNA was reverse transcribed using Superscript
II (Invitrogen) as described previously [22]. Real time quantitative PCR was performed
using AS specific primers ASL228 and ASR278 [22]. Results were normalized to 18S
rRNA.

Vector Construction: Luciferase reporter constructs were designed to include the
AS promoter and 5´-UTR up to the AUG start codon cloned upstream of the luciferase
gene. Luciferase reporter construct p3ASP189 was described previously [23]. Left
primers ASL-3075 (5´-GTACCTCCACTGAAATTGAA) and ASL-2616 (5´GCACTCGAGGAAAGTCAAAGGCCATGGTG) were combined with ASRluc, (5´ATAGAATGGCGCCGGGCGTTTCTTTATGTTTTTGGCGTCTTCCATCGTGACGG
GTGACCAGCGGC) to amplify a deletion series of the AS promoter with an Xho I site
on the 5´ end and an Nco I site on the 3´ end which were used to clone into the vector
210

APPENDIX A: (Continued)
pGL3Basic (Promega) and create the vectors p3ASP3075 and p3ASP2616, respectively.
Mutations were made in the PPRE sites in p3ASP2616 using a three-way PCR method
[23]. Primer PPREmut (5´-GCTGGTCTTGATCTCCTGATCTCAGGTGA) was
combined with primer ASRluc to amplify a fragment that contained the mutations. This
PCR product was then used as a right primer and paired with ASL-2616 to produce a
second product. A third round of PCR was used with the second product as a template
with primers ASL-2616 and ASRluc to enrich for the target. Amplified products were
purified and ligated into pGL3Basic to create p3ASP2616PPREmut. All constructs were
verified by sequencing.

Luciferase Assay Analysis: BAEC were cultured as described above and plated in
a 24 well plate prior to transfection. Experimental plasmids (200 ng each) and renilla
control plasmid pRL-TK (50 ng) were transiently transfected into BAEC using TransitLT1 (Mirus) in serum free media. Transfected cells were cultured for 24 hours in media
containing troglitazone and lysed in passive lysis buffer (Promega). Ten

l lysate was

assayed for luciferase and renilla activity using a Dual-Luciferase Reporter Assay System
(Promega) according to the manufacturer’s instructions.

Electrophoretic Mobility Shift Assay: Nuclear extracts, prepared from BAEC as
described previously [23, 24], were combined with or without cold oligonucleotide
competitors and incubated for 20 minutes at room temperature. Probes were labeled by
combining equimolar amounts of complementary oligonucleotides (2x10-10 moles),
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which were heated to 70°C, and allowed to cool to room temperature slowly. The oligos
were labeled using 10 μl [α-32P]dCTP (3000 Ci/mmol) and Klenow enzyme.
Unincorporated label was removed using Nuc Away spin columns (Ambion). The
reaction mixture contained binding buffer (10 mM HEPES, pH 7.9, 10% glycerol, 1 mM
DTT, 0.1 μg/μl poly(dI:dC), 0.5 μg/μl BSA and 4000 dpm/μl radiolabeled probe) and
nuclear extract (5 μg) in a total volume of 10 μl which was incubated at 30°C for 30
minutes. Samples were loaded onto a 5% non-denaturing polyacrylamide gel and run at
180 V. Gels were dried under vacuum and exposed to film. Double-stranded
oligonucleotides composed of the following sequences were used for EMSA analysis:
PPRE (5´-ACCTGAGGTCAGGAGTTCAAGACC-3´), PPREmut (5´ACCTGAGAACAGGAGAACAAGACC-3´), Sp1 site 1 (5´GCTCCAGGCGGGGGCCGGGCCCGGGGGCG-3´), Sp1 site 2 (5´GGCCGGGCCCGGGGGCGGGGTCTGTGGCGC-3´) and Sp1 site 3 (5´CCGGTCACCGGCCCTGCCCCCGGGCCCTG-3´).

Statistical Analyses: Experimental data is expressed as the mean of experiments
plus or minus the standard error of the mean. Each experiment was performed
independently at least three times.
Results

The PPARγ Ligand, Troglitazone, Increases Endothelial NO Production: To
confirm that troglitazone stimulates NO production in cultured endothelial cells,
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confluent bovine aortic endothelial cells (BAECs) were incubated for 24 hours with
increasing concentrations of this synthetic PPARγ agonist. As shown in Figure 1A, a
dose-dependent increase in NO production following treatment was observed up to 20
µM troglitazone. The dose dependent effect was consistent with previous findings
relative to the extent of NO produced [18].

Troglitazone Treatment Increases AS Expression: Since the expression of AS is
necessary to support endothelial NO production [3-5, 25], we investigated whether
troglitazone affected the increase in vascular endothelial NO production, at least in part,
through the up-regulation of AS expression, or whether the increase in NO production
was simply due to established effects on eNOS activation [17-19]. Confluent BAECs
were treated with increasing concentrations of troglitazone for 24 hours and AS protein
levels were determined by western blotting. As shown in Figure 1B & 1C, treatment with
troglitazone resulted in an increase in AS protein that closely correlated with the
troglitazone dependent increase in NO production, demonstrating that this PPARγ agonist
does indeed support an increase in NO production through up-regulation of AS
expression.
To determine whether the increase in AS expression resulted from transcriptional
upregulation, BAECs were grown to confluence and stimulated with troglitazone for 24
hours. RNA was prepared and quantitative real time RT-PCR showed that treated
endothelial cells had a 3.5-fold increase with 20 µM troglitazone (Figure 2). This
increase in AS mRNA could be inhibited by treatment with the transcriptional inhibitor
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1-D-ribofuranosyl-benzimidazole (DRB) suggesting that the increase in steady-state AS
mRNA levels was due to an increase in transcription rather than decreased AS mRNA
turnover. These results also suggested that the increase in AS protein could be accounted
for at the level of transcriptional regulation.

Identification of a Putative PPRE in the Promoter of the AS Gene: In order to
account for the transcriptional regulation of AS expression by troglitazone, the AS
promoter was examined using luciferase reporter gene constructs to identify regions
regulated by this PPARγ agonist. Previous work by others [26] and by us [27] has shown
that three Sp1/3 elements in the proximal AS promoter are required for AS expression.
Since PPARγ agonists are known to mediate transcriptional effects through Sp1 elements
[28, 29], we initially examined the involvement of the proximal promoter using a
construct, p3ASP189, containing these three Sp1/3 elements in the first 189 bp of the AS
promoter. However, transfection of the p3ASP189 construct into BAEC followed by
treatment with troglitazone did not result in an increase in promoter activity (Figure 3A).
Thus, the up-regulation of AS expression by troglitazone was not mediated by these Sp1
elements or other sequence elements located in the proximal promoter.
Based on these findings, the search to identify the element(s) involved in PPARγ
regulation was extended using a series of constructs containing increasing lengths of the
AS promoter. Cells transfected with AS promoter constructs containing up to 2088 bp
again showed no change in reporter gene activity in response to troglitazone treatment
(data not shown). However, when a construct containing 2616 bp of the AS promoter was
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transfected into BAEC, a significant increase in reporter gene expression was observed in
response to treatment with troglitazone. The construct containing 2616 bp of the
promoter was activated 2.7-fold by 20 μM troglitazone (Figure 3A). This comparative
analysis of luciferase activity between treated and untreated transfections of the construct
p3ASP2616 mapped the PPARγ responsive region from -2616 to -2088 bp upstream of
the transcriptional start.

DNA sequence analysis identified a near consensus PPARγ response element
(PPRE) from –2471 to –2458 bp (AGGTCAGGAGTTCA) in the p3ASP2616 construct.
To verify the involvement of this element, comparative transient transfection assays were
performed using a construct mutated (non-functional) in the putative PPRE and the wildtype construct. As shown in Figure 3B, mutation of the putative PPRE site in
p3ASP2616 completely abolished the activating effects of troglitazone supporting the
involvement of this PPRE (-2471 to -2458 bp) in the distal region of the AS promoter.

PPARγ Binds to the AS PPRE: To further confirm the involvement of the PPRE in
AS promoter function, we investigated whether PPARγ binds to the putative AS PPRE.
Electrophoretic mobility shift assays (EMSAs) were performed with oligonucleotides
containing the putative sequence. Nuclear extracts from troglitazone and untreated BAEC
were mixed with [32P]-labeled AS PPRE oligonucleotides. As shown in Figure 4,
troglitazone enhanced binding to the PPRE.
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To demonstrate specificity, excess unlabeled PPREwt oligonucleotides were
shown to compete, diminishing the signal of the shifted band. In contrast, addition of
excess, unlabeled PPREmut oligonucleotide, with a mutation that should not allow
binding and therefore should not compete with [32P]-labeled AS PPRE oligonucleotides,
did not diminish the specific signal. These results were taken to further support the
involvement of this distal PPRE in the AS promoter as the element that mediates the
transcriptional upregulation by troglitazone.
Discussion
One mechanism by which PPARγ agonists provide cardiovascular benefits is by
enhancing endothelial NO production [17]. Endothelium-derived NO is a potent chemical
mediator with antiatherogenic properties, such as stimulation of vasorelaxation and
repression of endothelial leukocyte adhesion molecules, platelet aggregation and smooth
muscle cell proliferation [30-32]. Although troglitazone demonstrates vasodilator
activities to lower blood pressure in diabetic patients, its precise mechanism is not well
defined [20, 33, 34]. However, these studies suggest that troglitazone mediated direct
effects on the vascular wall.
Until now, troglitazone was thought to promote endothelial NO production
through up-regulation of eNOS protein expression [19] or activity [18], although the
mechanism was not established. This report is the first demonstration that the PPARγ
agonist, troglitazone, facilitates the production of vascular endothelial NO through the
up-regulation of AS expression, the rate-limiting enzyme of the citrulline-NO cycle. The
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increase in AS protein levels paralleled AS mRNA levels and the increased NO
production. Since DRB, a transcriptional inhibitor, blocked the induction of AS
expression by troglitazone, our results indicated that the increase in AS expression
resulted from transcriptional regulation by this PPARγ agonist. Therefore, we identified a
distal PPRE in the AS promoter that mediated the transcriptional effects of troglitazone
on AS expression. To our knowledge, this is the first identification of a functional PPRE
in the AS promoter.
These results further support our view that the coordinate regulation of endothelial AS
expression and NO production is essential [5], and that physiologic or pharmacologic
stimuli that promote or diminish endothelial function do so not only by affecting eNOS
activity or expression, but also by affecting AS expression [5]. Moreover, the results in
this report contribute new and additional insight as to how PPARγ agonists promote
endothelial NO production through diverse mechanisms [18, 19, 35]. For example, 15dPGJ2, a naturally occurring PPARγ ligand, increases hsp90 expression which promotes
eNOS activation, while ciglitazone and rosiglitazone do not, yet still increase NO
production [35]. In addition, 15d-PGJ2 and rosiglitazone increase binding of hsp90 to
eNOS to promote NO production, while ciglitazone does not. Finally, both 15d-PGJ2 and
rosiglitazone, but not ciglitazone, increase phosphorylation of eNOS at ser1177, which is
linked to enhanced enzyme activity [35] and increased NO production. In this report,
troglitazone was found to promote NO production through the up-regulation of AS
expression. This would be in addition to its reported effect on eNOS where troglitazone
was shown to up-regulate eNOS expression through a mechanism independent of PPARγ
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activation [19], or where changes in eNOS phosphorylation correlated with an increase in
eNOS activity rather than expression [18].
Overall, the findings of this report demonstrate that argininosuccinate synthase
represents an additional and physiologically important step in the citrulline-NO cycle by
which the TZD, troglitazone, promotes vascular endothelial function. Although
troglitazone was withdrawn from the market because of its hepatic toxicity, the multiple
mechanisms through which TZDs can improve insulin sensitivity, as well as NOdependent vasodilatation, suggests that further studies with new TZD drugs may be
warranted.
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Figure Legends

Figure 1: The PPARγ agonist, troglitazone, stimulates endothelial NO production
and AS protein expression. BAEC were treated with increasing concentrations of
troglitazone as indicated for 24 hours. (A) NO was measured as nitrite produced/mg
protein. (Nitrite is a stable reaction product of NO and molecular oxygen.) Results are
expressed as relative levels of NO produced in control (no treatment) versus treated cells,
and error bars represent the standard error of the mean. (B-C) Ten μg of whole cell lysate
was loaded onto an SDS polyacrylamide gel and standard western blotting performed.
Anti-AS (1:2500) was used to detect the amount of AS protein present. A representative
western blot is shown in B, and relative spot density for AS protein, normalized against
GAPDH and quantitated, is represented in C. These results are representative of three
independent experiments and error bars represent the standard error of the mean.

Figure 2: Troglitazone induces transcription of AS mRNA. BAEC were untreated
(U) or treated with 20 µM troglitazone plus or minus the transcriptional inhibitor DRB
(50 µM) (T and T+D, respectively) for 24 hours. Total RNA was isolated, and AS mRNA
was detected using real time quantitative RT-PCR. Results were normalized to 18S rRNA
and represent the average ± the standard error of the mean.

Figure 3: Troglitazone induces a distal element in the AS promoter. (A) BAEC
were transiently transfected with the proximal AS promoter construct, p3ASP189, or an
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extended AS promoter construct, p3ASP2616, and treated with 20 µM troglitazone
(Trog) for 24 hours. (B) BAEC were transiently transfected with the AS promoter
constructs with wild type p3ASP2616 (W) or p3ASP2616PPREmut (M, represents
mutated PPRE) and treated with 20 µM troglitazone (Trog) for 24 hours. All results are
presented as relative luciferase activity units and represent the average ± the standard
error of the mean of at least four experiments conducted in triplicate.

Figure 4: Troglitazone increases binding to the AS PPRE. (A) Electrophoretic mobility
shift assays were performed using BAEC nuclear extracts prepared from untreated and
troglitazone treated cells for 6 hours. Extracts were combined with an oligonucleotide
probe containing the putative PPRE sequence of the AS promoter, and competed with
either a 100-fold excess of cold wild-type or mutated oligonucleotide probe where
indicated. Labeled arrow indicates position of PPARγ specific bands. (B) Relative
density of PPARγ specific bands.
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Figure A-1
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Figure A-2
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Figure A-3
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Figure A-4
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